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ABSTRACT 
High-throughput screening (HTS) has played an integral role in the discovery of lead 
molecules that eventually are transformed into the therapies of tomorrow.  Contributing towards 
the success of any screening campaign is the target choice, chemical library size and diversity, as 
well as the technology utilized in screening.  Photonic crystal (PC) biosensors are a relatively 
new technology whose potential is only beginning to be realized.  PC biosensors are a “label-
free” technology compatible with standard high-throughput techniques.  Macromolecular 
interactions including protein—small molecule, protein—nucleic acid, protein—protein, and 
whole cell interactions can be measured using PC biosensors.  Presented herein is the first 
application of PC biosensors to a protein—nucleic acid interaction and a simplified protein—
protein interaction platform.  The protein—nucleic acid interaction targeted is the apoptosis 
inducing factor (AIF)—DNA interaction, which is critical for the mediation of caspase-
independent cell death in neurodegenerative disease and stroke.  Protein—protein interactions 
were targeted by modifying the PC biosensor surface for detection of the His6 tag, which is 
widely employed in protein purification. 
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CHAPTER 1: THE ROLE OF PHOTONIC CRYSTAL (PC) BIOSENSORS 
IN HIGH-THROUGHPUT SCREENING AND AN INTRODUCTION TO 
APOPTOSIS INDUCING FACTOR (AIF) MEDIATED CELL DEATH IN 
NEURODEGENERATIVE DISEASE 
 
The information and contents for this chapter were partially taken from the following article with 
permission from the publishers: James T. Heeres and Paul J. Hergenrother “Poly(ADP-ribose) 
makes a date with death.” Curr. Opin. Chem. Biol. 2007, 11, 644-53.   
 
1.1 High Throughput Screening (HTS) for Modulators of Macromolecular 
Interactions 
The advent of high-throughput screening (HTS) in the early 1990s has lead the field of 
chemical biology into a time of unparalleled excitement.  HT techniques allow for the rapid 
identification of small molecule modulators of macromolecular function, and in turn cellular 
function, from large compound libraries.  Typical drug discovery involves the identification of a 
lead compound from 1) an isolated natural product 2) structure-based design or 3) a small 
molecule library.  Natural products lack the synthetic tractability of smaller molecular weight 
entities, while structure-based design inherently requires a certain amount of structural 
knowledge about the macromolecular target.  Small molecule libraries, meanwhile, offer an 
unbiased pool of compounds that can be used for screening targets without structural information, 
and derivatization of resulting hit compounds is much more feasible than with natural products. 
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Small molecule screening campaigns have identified a host of lead compounds.1  Natural 
products have dominated the field of anti-cancer and anti-microbial development because of the 
typical compound formats screened at the time.2  While most natural products contain an 
inherent level of complexity unattainable in most all screening libraries, they are typically less 
amenable to derivatization due to the effort required for the synthesis of the natural product in a 
laboratory setting.  In addition, natural products have been shown to have anti-cancer and anti-
microbial properties,3-6 but their broad-based application in complex diseases where cell death is 
not the ultimate endpoint is less certain.  Described in a comprehensive review7 of new chemical 
entities (NCEs) approved from 1981 to 2006, small molecules represent 30% of the total entity 
set, the other 70% includes natural products and biologicals.  However, the large majority of this 
30% are enzyme inhibitors, derived from natural products, or derived from existing drug 
scaffolds (so-called “me-too” drugs).  In addition, the authors report only one compound out of 
310 small molecule NCEs that was identified via a de novo HTS.  In recent years the number of 
new molecular entities (NMEs) identified through HTS has been accelerating (Table 1.1 and 
Figure 1.1).  This data was collected by analyzing FDA approvals and approvals around the 
world of drugs within the last 5 years and investigating their origin and mechanism of action.   
Nine new drugs have been approved in the last five years using HTS including Erlotininb,8 
Sorafenib,9 Tipranavir,10, 11 Rimonabant,12, 13 Ambrisentan,14 Lapatinib,15 Maraviroc,16 
Rivaroxaban,17 and Pazopanib.18  Although natural products and synthetic scaffolds discovered 
without screening still populate the list in Table 1.1, small molecule screening remains relevant 
in the discovery of therapeutics for the treatment of many different diseases.  At the core of many 
disease states lies not only the commonly targeted ligand—receptor interactions and  
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Table 1.1.  FDA-approved drugs (non-biologicals) on the market from 2004-2009.  Molecules discovered utilizing high-throughput screening at some point 
in the development of the molecule are highlighted in red.  SM: small molecule; NP-derived: natural product derived; S: synthetic molecule not developed 
through screening, focused-libraries, or structure-based design and does not show any apparent similarity to naturally occurring molecules; S*: synthetic 
molecule developed by modifying naturally occurring scaffolds; FL: molecule developed through focused-library synthesis of existing scaffolds; FL*: 
molecule developed through focused-library synthesis based off of naturally occurring scaffolds; SBD: structure-based design; HTS: high-throughput 
screening; β2R: β2-adrenergic receptor; COX: cyclooxygenase; CRBN: cereblon; D2R: dopamine receptor 2; DHFR: dihydrofolate reductase; EGFR: 
epidermal growth factor receptor; GABA: γ-aminobutryic acid; GARFT: glycinamide ribonucleotide transformylase; GR: glucocorticoid receptor; HBV: 
hepatitis B virus; HIV: human immunodeficiency virus; 5-HT: 5-hydroxytryptamine (serotonin); NMDAR: N-methyl-D-aspartate receptor; PDGFR: 
platelet derived growth factor receptor; R: receptor; RNAP: RNA polymerase; TS: thymidylate synthase; VEGFR: vascular endothelial growth factor 
receptor; ALL: acute lymphoblastic leukemia; COPD: chronic obstructive pulmonary disease; NSCLC: non-small cell lung cancer; PAH: pulmonary 
arterial hypertension; T-ALL: T-cell acute lymphoblastic leukemia. 
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Table 1.1. (continued)  FDA-approved drugs (non-biologicals) on the market from 2004-2009.  Molecules discovered utilizing high-throughput screening 
at some point in the development of the molecule are highlighted in red.  SM: small molecule; NP-derived: natural product derived; S: synthetic molecule 
not developed through screening, focused-libraries, or structure-based design and does not show any apparent similarity to naturally occurring molecules; 
S*: synthetic molecule developed by modifying naturally occurring scaffolds; FL: molecule developed through focused-library synthesis of existing 
scaffolds; FL*: molecule developed through focused-library synthesis based off of naturally occurring scaffolds; SBD: structure-based design; HTS: high-
throughput screening; CCR5: C-C chemokine receptor 5; c-KIT: CD117; DA: dopamine; DPP-4: dipeptidyl peptidase-4; DR: dopamine receptor; ETAR: 
endothelin receptor type A; EGFR: epidermal growth factor receptor; HDAC: histone deacetylase; HER2: human epidermal growth factor receptor 2; 
hNET: human norepinephrine transporter; hSERT: human serotonin transporter; INa: sodium current; MAO: monoamine oxidase; mTOR: mammalian 
target of rapamycin; NA: norepinephrine; PAH: phenylalanine hydroxylase; PBP: penicillin-binding protein; PPARγ: peroxisome proliferator-activated 
receptor γ; ROS: reactive oxygen species; ADHD: attention deficit hyperactivity disorder; CCL: chronic lymphocytic leukemia; CML: chronic 
myelogenous leukemia; CTCL: cutaneous T-cell lymphoma; GIST: gastrointestinal stromal tumor; MDD: major depressive disorder; RCC: renal cell 
carcinoma;  
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Table 1.1. (continued)  FDA-approved drugs (non-biologicals) on the market from 2004-2009.  Molecules discovered utilizing high-throughput screening 
at some point in the development of the molecule are highlighted in red.  SM: small molecule; NP-derived: natural product derived; S: synthetic molecule 
not developed through screening, focused-libraries, or structure-based design and does not show any apparent similarity to naturally occurring molecules; 
S*: synthetic molecule developed by modifying naturally occurring scaffolds; FL: molecule developed through focused-library synthesis of existing 
scaffolds; FL*: molecule developed through focused-library synthesis based off of naturally occurring scaffolds; SBD: structure-based design; HTS: high-
throughput screening; CRMP2: collapsin response mediator protein 2; CXCR4: chemokine (C-X-C motif) receptor 4; DHFR: dihydrofolate reductase; 
HMG: 3-hydroxy-3-methyl-glutaryl; NK-1R: neurokinin-1 receptor; P2Y12ADPR: P2Y12 ADP receptor; RT: reverse transcriptase; TPOR: thrombopoietin 
receptor; VMAT2: vesicular monoamine transporter 2; CINV: chemotherapy-induced nausea and vomiting; CTL: cutaneous T-cell lymphoma. 
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Table 1.1. (continued)  A partial list of non-FDA-approved drugs (non-biologicals) on the market around the world from 2004-2009.  Molecules discovered 
utilizing high-throughput screening at some point in the development of the molecule are highlighted in red.  SM: small molecule; NP-derived: natural 
product derived; S: synthetic molecule not developed through screening, focused-libraries, or structure-based design and does not show any apparent 
similarity to naturally occurring molecules; S*: synthetic molecule developed by modifying naturally occurring scaffolds; FL: molecule developed through 
focused-library synthesis of existing scaffolds; FL*: molecule developed through focused-library synthesis based off of naturally occurring scaffolds; SBD: 
structure-based design; HTS: high-throughput screening; CB1R: cannabinoid-1-receptor; f-channels: funny channels; FXa: factor Xa; MAPK: mitogen-
activated protein kinase; PDE: phosphodiesterase; RAR: retinoic acid receptor; SUR1: sulfonylurea receptor-1; APL: acute promyelocytic leukemia; IPF: 
idiopathic pulmonary fibrosis; SCL: small cell lung; STS: soft tissue sarcoma.  ***: Rimonabant was withdrawn from the market in early 2009. 
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Figure 1.1.  Chemical structures of drugs from Table 1.1. 
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Figure 1.1. (continued) 
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Figure 1.1. (continued) 
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Figure 1.1. (continued) 
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Figure 1.1. (continued) 
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Figure 1.1. (continued) 
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Figure 1.1. (continued) 
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phosphorylation events, but the protein—protein and protein—nucleic acid interactions critical 
for mediation of the disease. 
The inhibition of macromolecular interactions is a large focus of modern chemical 
biology.  Although protein—protein interactions received the most attention, protein—nucleic 
acid interactions are still very relevant to disease.19, 20  One reason protein—protein interactions 
have been more extensively targeted is the relative “druggability” of protein—protein targets.21-25 
While most protein—protein interactions lack the classical hydrophobic pockets present in many 
enzyme classes, the possibility for hydrophobic interactions between proteins and small 
molecules is greater than with protein—nucleic acid interactions because the nature of the 
protein—nucleic acid interface is largely dependent on initial electrostatic recognition.26, 27  This 
has made targeting the protein—nucleic acid interface inherently difficult, though allosteric 
modulation or disruption of protein dimerization (e.g. transcription factors) are both feasible 
alternatives.19, 28   
While inhibitiors of protein—protein interactions are highly sought, the enhancement of 
protein—protein interactions is of equal value, though the identification of such compounds is 
rare and usually requires multimerization of a single binding module to facilitate protein 
multimerization.29   The most notable example of protein—protein interaction enhancement is 
the recruitment of FK506 binding protein of 12 kDa (FKBP12) to mammalian target of 
rapamycin (mTOR) or calcineurin by the natural products rapamycin30 and  FK50631 respectively.  
To date, no small molecule enhancer of protein—protein interactions has ever been reported 
from a screening library, and design-based strategies have had far more success.29   In contrast, 
several successes in the inhibition of protein—protein interactions have been reported recently, 
including the inhibition of XIAP—caspase, Bcl-XL—Bak, and p53—MDM2 (Figure 1.2).   
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X-linked inhibitor of apoptosis protein (XIAP) is a key negative regulator of apoptosis.32  
XIAP inhibits apoptosis by binding to and preventing the activity of active caspases (cysteine-
dependent aspartate-specific proteases).33-36   The upregulation of anti-apoptotic proteins such as 
IAPs in cancers is common and serves to aid in the evasion of apoptosis and resistance to 
therapeutics.37-40  XIAP inhibits caspases through its baculoviral IAP repeat (BIR) domains, with 
BIR2 inhibiting caspases-3/733, 34, 36 and BIR3 inhibiting caspase-9.35, 41  An endogenous 
inhibitor of XIAP is second mitochondrial derived activator of caspases (Smac) which is able to 
displace XIAP from active caspases.42-44  SM-164 was developed as a bispecific inhibitor of the 
XIAP—caspase-3/7 and XIAP—caspase-9 interactions45 and was synthesized via the 
dimerization of a single BIR3 binding Smac peptidomimetic (SM-122).42, 44  SM-164 was able to 
directly bind to BIR2 and BIR3 containing XIAP fragments, disrupt preformed complexes of 
XIAP and peptides derived from Smac, and induce apoptosis directly in cell culture. 
Bcl-2 family members are also key negative regulators of apoptosis that function by 
inhibiting events that lead to mitochondrial outer membrane permeabilization (MOMP) and the 
intrinsic apoptotic pathway.46-48  Bcl-XL is a Bcl-2 family member that blocks the proapoptotic 
Figure 1.2.  Recently reported inhibitors of protein—protein interactions. 
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action of Bak49 and Bax,50, 51 by binding to and sequestering their oligomerization which causes 
pore formation on mitochondria.52  Antiapoptotic Bcl-2 family members are frequently 
upregulated in lymphomas,53, 54 and their upregulation has been tied to the oncogene c-Myc.  The 
small molecule ABT-737 was developed as a Bak mimetic capable of disruption of Bcl-XL—
Bak complexes.55  ABT-737 was discovered through fragment-based drug discovery, where 
weakly interacting small molecules are detected (in this case by nuclear magnetic resonance 
(NMR)) at separate sites on a macromolecular target, and then linked to provide a molecule with 
enhanced affinity.56, 57  ABT-737 was able to disrupt Bcl-XL—Bak complexes, induce cell death 
in cell culture, and induce tumor regression in vivo. 
The transcription factor p53 has been coined the “gatekeeper” of cell death in that it 
controls the expression of many different proapoptotic genes.58, 59  p53 is the most commonly 
inactivated gene in all cancers,60-63 and those that still retain a genetic copy of p53 may have a 
premature degradation of this protein.64, 65  Mouse double minute 2 (MDM2, HDM2 in humans) 
is a E3 ubiquitin ligase that recognizes p53 and prepares it for ubiquitin-mediated degradation.66  
Nutlin-3 and its derivatives were discovered as inhibitors of the p53—MDM2 interaction by an 
unreported screening method,67 though they were validated using standard surface plasmon 
resonance (SPR) techniques.  Nutlin-3 was able to disrupt p53—MDM2 complexes, induce 
downstream expression of p53-responsive genes, induce cell death in cell culture, and induce 
tumor regression in vivo. 
As described above, there have been successes in discovering inhibitors of protein—
protein interactions.  While not featured specifically in the molecules described above, HTS is 
still essential to the initial stages of drug discovery.  The success of HTS in the future depends on 
several factors; 1) the choice of target; 2) the size and diversity of the chemical library screened; 
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and 3) the availability of technologies suitable for HTS.  New technologies for HTS will expand 
the chemical biologist’s toolbox for the discovery of small molecule leads.  The following 
sections discuss the utility of several popular technologies in HTS, problems associated with in 
vitro HTS, as well as photonic crystal (PC) biosensors, a newer technology employed in HTS.  
Also included is a discussion of Apoptosis Inducing Factor (AIF), the first DNA-binding protein 
targeted using PC biosensors. 
 
1.1.1 Fluorescence Polarization (FP) in HTS 
Fluorescence polarization (FP) is the difference in polarization of light emitted from a 
fluorophore and the plane polarized light the fluorophore is excited with.68  This phenomenon 
was first described in 1926 by Perrin69 and has since been used heavily for the study of 
macromolecular interactions70 as well as a primary screening method.68  FP is based upon the 
relative rates of rotation in solution of a fluorescently-tagged macromolecule and the 
macromolecular complex formed upon cognate binding partner addition.  Plane-polarized light is 
used to excite a fluorophore, and if that fluorophore is able to rotate in solution prior to emission, 
the intensity of the light emitted with the same polarization as the incident light will be low.  
However, larger macromolecular complexes will rotate more slowly in solution allowing enough 
time for the emission of light with the same polarization of the incident light.  As this technique 
requires no macromolecular immobilization, it can be performed in standard 96-, 384-, and 1536-
well plates and data can be collected using commercially available fluorescence readers.  In 
addition, fluorophore-tagged nucleic acids are commercially available making this assay ideal for 
protein—nucleic acid screens; fluorophore-tagged proteins or fluorescent protein fusions for 
probing protein—protein interactions require additional steps to be utilized in FP.  An inherent 
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limitation of this technique is the ability of the macromolecular complex to change the 
polarization of the emitted light.   The degree of change in polarization is naturally dependent on 
the affinity between the two macromolecules, but also their complexation must result in a 
sufficient overall change in mass to affect the rotation of the fluorophore itself.  With a 
recommended mass difference of ~ 10-fold,71 FP may be better suited to fluorescently-tagged 
oligonucleotides or peptides with much larger cognate binding proteins.   
Small molecule inhibitors of protein—protein interactions have been readily identified 
from various screening libraries using FP; selected compounds are displayed in Figure 1.3.  
Included in this group of compounds are inhibitors of the dimerization of the transcription factors 
c-Myc and Max, which are oncogenic when misregulated;72 inhibitors of the interaction between 
thyroid hormone receptor (TR) and multiple coregulators;73 inhibitors of DNA polymerase 
subunits in two different viruses;74, 75 inhibitors of the Bcl-xL—Bak interaction, inducing cell 
death as described above;76 inhibitors of the ZipA—FtsZ interaction, an interaction critical for 
bacterial cell division;77, 78 inhibitors of the JNK—JIP interaction, which is involved in signal 
transduction in cancer;79 inhibitors of the PLK1—PBD intramolecular protein—protein 
interaction, which is required for mitotic progression in cancer;80 inhibitors of the calcineurin—
NFAT interaction, which contributes to autoimmune disease;81 and inhibitors of eukaryotic 
translation initiation factors eIF4E—eIF4G, which are overexpressed in cancer.82 
The compounds displayed in Figure 1.3 represent the inhibitors of protein—protein 
interactions discovered through high-throughput screening of diverse chemical libraries, where 
FP was used as a primary screening method.  Many more compounds have been developed 
though the use of focused libraries from design-based strategies83-86 where FP was used to screen 
smaller libraries of compounds. 
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Figure 1.3.  Small molecule (SM) inhibitors of protein—protein interactions discovered through 
fluorescence polarization high-throughput screens.  TR: thyroid hormone receptor; CoR: coregulator; 
UL44,54: cytomegalovirus DNA polymerase subunits; UL42, 30: herpes simplex virus DNA polymerase 
subunits; JNK: c-Jun N-terminal kinase; JIP: JNK interacting protein; PLK1: polo-like kinase 1; PBD: 
polo box domain; NFAT: nuclear factor of activated T-cells; eIF4E,G: eukaryotic translation initiation 
factor 4E, G. 
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Fluorescence polarization has been used extensively in HTS over the past two decades.  
A key advantage of FP is the minimal modification of the macromolecular interface other than 
the required fluorophore.  Immobilization of one of the macromolecular binding partners is less 
desirable due to the constrained molecular motion inherent to the technique.  Nonetheless, 
technologies employing protein or nucleic acid immobilization, such as enzyme-linked 
immunosorbent assays (ELISAs), have also been used extensively in drug discovery. 
 
1.1.2 Enzyme-Linked Immunosorbent Assays (ELISAs) in HTS 
 ELISA is based upon the detection of a molecular binding event by recognition of one or 
more of the binding partners by antibodies.  ELISA was first developed in 1971,87, 88 and was 
rapidly expanded into multi-well plates.  Typical ELISAs are performed by coating multi-well 
plates with one of the binding partners, either by non-specific adhesion or affinity recognition 
(e.g. biotin—streptavidin), and adding the second binding partner.  Detection of the binding 
event is achieved by washing the wells and then treating with an antibody specific for the second 
binding partner, and then detection usually using an enzyme-conjugated secondary antibody.89  
As mentioned above, FP measures macromolecular interactions most effectively when there is a 
sufficient difference in size of the complex versus that of the labeled binding partner.  ELISA 
does not require a significant change in the size of the complex, only that the epitope for 
antibody recognition is not obscured by complex formation.  The disadvantages of ELISA 
include the requirement of an antibody which is not always available for a particular target, and 
the development and generation of sufficient quantities of antibody is not trivial. 
 Small molecule inhibitors of protein—protein interactions have been discovered using 
ELISA-based strategies (Figure 1.4).  Included in this group are inhibitors of the TCF4—β- 
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catenin interaction, which controls expression of c-Myc in colorectal cancer;90 inhibitors of the 
HIF-1α—p300 interaction, which controls the expression of multiple cancer-related genes such 
as vascular endothelial growth factor receptor (VEGFR);91 inhibitors of the RNAP—σ 
interaction, which is critical for bacterial RNA polymerase assembly;92 inhibitors of the LFA-
1—ICAM interaction, which is involved in leukocyte cell-cell adhesion in immunological 
disorders;93 and inhibitors of the JNK1—JIP1 interaction, which is involved in signal 
transduction in cancer as mentioned earlier.94 
 FP and ELISA are the two most common in vitro techniques used in HTS of 
macromolecular interactions.  Cell-based HTS has usually focused on attaining a particular 
phenotypic result (e.g. cell death, differentiation, expression/repression of target gene).95-98  
Figure 1.4.  Small molecule (SM) inhibitors of protein—protein interactions discovered through ELISA-
based high-throughput screens.  TCF4: T-cell factor 4; HIF-1α: hypoxia inducible factor-1α; RNAP: 
RNA polymerase; LFA-1: lymphocyte function associated antigen-1; ICAM-1: intercellular adhesion 
molecule 1; JNK1: c-Jun N-terminal kinase 1; JIP: JNK interacting protein. 
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Yeast and mammalian two-hybrid systems are growing in popularity for the screening for small 
molecule modulators of macromolecular interactions in a cellular setting. 
 
1.1.3  Two-Hybrid Systems in HTS 
 Two-hybrid systems use plasmid constructs expressing fusion or “hybrid” proteins that 
are fused to DNA-binding and activation domains of a split transcription factor.99  The 
association of the two proteins unrelated to the transcription factor allows for the formation of a 
complex capable of inducing downstream expression of reporter gene such as luciferase or GFP.  
Depending on whether protein—protein interaction inhibition or enhancement is sought, small 
molecules capable of interacting with the fusion proteins will enhance or repress reporter gene 
transcription.  The key advantage of two-hybrid systems over other in vitro screening methods is 
that hit compounds have a higher likelihood of being cell permeable and capable of inhibiting the 
targeted protein—protein interaction in a cellular context.  However, considerable effort is 
required in the construction of vectors harboring fusion proteins, and this process must be 
repeated with each protein—protein interaction targeted. 
 While two-hybrid systems have been used extensively as probes for pathway elucidation 
in protein signaling cascades,100, 101 small molecule screening using two-hybrid systems has been 
slower to develop.  Nevertheless, small molecule inhibitors of protein—protein interactions have 
been discovered using two-hybrid systems (Figure 1.5), including inhibitors of the c-Myc—Max 
interaction, which is important for oncogenic transformation as mentioned above;102 inhibitors of 
the interaction between the α1B—β2 subunits of N-type calcium channels, which are important 
for neurotransmitter release;103 inhibitors of the TGFβR—FKBP12 interaction, which  
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is important for calcineurin-mediated signaling;104 and inhibitors of the EGFR—PI3K interaction, 
which is important for signal transduction in cancer.105 
 The FP, ELISA, and two-hybrid screening platforms discussed above have been 
successful in the identification of small molecule modulators of macromolecular interactions.  
While the above sections have concentrated on HTS and the technologies involved in HTS, a 
particular lower throughput technology has been instrumental in the investigation of 
macromolecular interactions, surface plasmon resonance (SPR).   
 
1.1.4 Surface Plasmon Resonance (SPR) in HTS 
 Surface plasmon resonance was first described in 1983 and is now considered a standard 
“label-free” technique for the analysis of macromolecular interactions.106  “Label-free” is a 
Figure 1.5.  Small molecule (SM) inhibitors of protein—protein interactions discovered through two-
hybrid high-throughput screens.  TGFβR: transforming growth factor β receptor; FKBP12: FK506 
binding protein 12; EGFR: epidermal growth factor receptor; PI3K: phosphoinosotide 3-kinase. 
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general term that refers to a technology where the method of detection of macromolecular 
interactions is uncoupled from the interaction itself.  Whereas fluorescence polarization requires 
one of the binding partners to be labeled with a fluorophore, no such label is required for SPR.  
SPR is based upon the observation that materials with differing refractive indices reflect light at 
different angles and intensities depending on the local electromagnetic field near the sensor.107, 
108
  Typical SPR configurations involve the illumination of a prism below a gold biosensor chip 
that is in direct contact with the liquid medium.109  The difference in refractive indices of the 
gold surface and the liquid media allows for the generation of an evanescent field that can couple 
with the longitudinal surface plasmon waves; both of which are generated upon sensor 
illumination.  Binding is detected by measuring the angle at which the reflected light is at a 
minimum, and this minimum is influenced by the presence of biomolecules at the gold surface, 
that in turn interact with the evanescent field generated upon illumination.  SPR has been used 
extensively since its introduction commercially in 1991 (see review107). 
 The utility of SPR in high-throughput screening remains to be seen, as SPR is currently 
limited by its microfluidic chip-based format that only allows for the analysis of 4 to 20 samples 
at a time depending on the instrument (http://www.biacore.com/lifesciences/index.html).  The 
most advanced microfluidic chip-based SPR technology is the Biacore A100, which allows for 
the analysis of samples from 96 and 384-well plates.  However, this improvement only allows 
for the analysis of ~ 3,000 interactions per day, which is far fewer than would be needed to 
qualify as high-throughput.  SPR imaging (SPRI) has been developed in the past decade as an 
array-based technology capable of measuring many macromolecular binding events in 
parallel.110  Unfortunately, SPRI has only been applied to HTS for inhibitors of protein—protein 
interactions in a proof-of-concept study involving the interaction between HPV E7—Rb.111  The 
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authors demonstrate the measurement of 1500 binding events in a single array, and are able to 
detect the presence or absence of inhibitory peptides based off of HPV E7.  Though no high-
throughput screens of small molecule libraries have been reported using SPRI, the technology 
holds great promise for the future.  
Given the advantages of label-free technologies, several other technologies, including 
photonic crystal (PC) biosensors, have been developed in an effort to merge the sensitivity of 
SPR with the throughput of classical HTS techniques. 
 
1.2 Photonic Crystal (PC) Biosensors 
Photonic crystal biosensors have been developed within the last decade as a label-free 
screening technology capable of assaying many different macromolecular interactions.  The 
theory and application of PC biosensors to HTS is discussed below. 
 
1.2.1 From Wood’s Anomaly to HTS: A Short History of PC Biosensors 
 Robert W. Wood first observed in 1902 the optical phenomenon that would become the 
basis of photonic crystal biosensors and other optical devices.112, 113  “Wood’s anomalies” are the 
observation of unique reflection patterns and intensities when a diffraction grating is illuminated 
with white light of varying incidence and polarization.  Several investigators attempted to 
explain these phenomena by the optical theory developed at the time,114, 115 but it was not 
resolved until 1965 when the “guided wave” theory was described.113  Guided-mode resonant 
filters (GMRFs) have been developed using the principles of Wood’s anomalies to produce 
devices capable of reflecting narrow wavelengths of light when illuminated with white light.116  
The principle of the reflection observed in GMRFs is that the illumination generates cut-off or 
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evanescent diffracted waves that couple with “leaky” diffraction modes which are then reradiated 
as resonant reflectance peaks.116  Photonic crystal (PC) technology further tunes the wavelengths 
of light reflected in GMRFs.117, 118  Essentially, a low refractive index diffraction grating (e.g. 
glass, polycarbonate or other plastics) is coated with a thin layer of high refractive index material 
(e.g. TiO2, Ta2O5), which gives rise to a photonic crystal (Figure 1.6).  Illumination of the PC 
with wavelengths of light longer than the periodicity of the grating generates a standing wave 
that is reflected as a narrow band of light.  The standing wave is sensitive to the local 
electromagnetic field in contact with the TiO2 surface, and changes in this field result in changes 
in the wavelength of reflected light.118  Macromolecular interaction with the PC induces a change 
in the wavelength at which maximal reflection is observed or the peak wavelength value (PWV).  
PCs can be produced in large plastic sheets and attached to the bottom of 96, 384, and 1536-well 
plates that are compatible with standard liquid handling techniques.  Discussed below are the 
multitude of applications of PC biosensors to macromolecular interactions and HTS. 
 
1.2.2 Measurement of Macromolecular Interactions Using PC Biosensors 
 PC biosensors have been applied to the detection of antibody—antigen and small 
molecule—protein interactions, as well as cell-based assays.  Unfortunately, no screening efforts 
using PC biosensors have been reported, only secondary assays and proof-of-concept 
experiments.  Two commercially available technologies take advantage of resonant waveguide 
gratings (SRU Biosystems BINDTM system and Corning EpicTM system)(Figure 1.7).  Novel 
applications of PC biosensors to protein—DNA and protein—protein interactions will be 
discussed in Chapters 3 and 4 respectively. 
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1.2.2a Biomolecular Interaction Detection System (BINDTM) 
 Photonic crystals utilized in the BINDTM system are composed of an epoxy-cured 
polycarbonate diffraction grating that is coated with a thin layer of TiO2.118  Surface 
modifications available include glutaraldehyde-conjugated sensors for amine-mediated 
macromolecular attachment; streptavidin-conjugated sensors for biotin binding; and sensors 
modified to be compatible with mammalian cell culture.  BINDTM has been applied to 
antibody—antigen interactions including the recognition of protein A with different isotypes of 
immunoglobulin G,118-120 and biotin—anti-biotin recognition followed by secondary antibody 
recognition.120  This technology has been applied to small molecule—protein interactions  
Figure 1.6.  Photonic crystal biosensors.  Illumination of a low refractive index (RI) diffraction grating coated 
with a high refractive index material (TiO2 or Ta2O5) with a broadband light results in a sharp reflectance peak.  
The wavelength of maximum reflectance shifts in the presence of biomaterial near the sensor surface. 
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including the binding of carbonic anhydrase inhibitors to carbonic anhydrase II;121, 122 the 
binding of warfarin to human serum albumin (HSA);121 and the binding of biotin to 
streptavidin.120  Lastly, the BINDTM system has been applied to cell-based assays involving CHO 
and MCF-7 proliferation assays,118, 123 and cell type recognition by coating sensor plates with 
antibodies.118  
 
 
Figure 1.7.  Applications of different label-free detection systems.  A) Surface plasmon resonance (SPR) B) 
Biomolecular interaction detection system (BINDTM), and C) EpicTM detection systems.  SPR systems use 
microfluidic techniques to monitor association and dissociation of binding partners.  BINDTM and EpicTM are 
both colorimetric resonant reflection techniques that increase throughput by using microplates.  Images from 
www.biacore.com, www.srubiosystems.com, www.corning.com.   
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1.2.2b The EpicTM System 
 The resonant waveguide grating (RWG) device using in the EpicTM system is composed 
of a glass diffraction grating coated with a thin layer of Ta2O5.124  The proprietary surface 
modifications available are not described in detail, though in vitro and cell culture assays in the 
literature hint at similar surface modifications to the BINDTM system.  The EpicTM system has 
been applied to protein—protein and small molecule—protein interactions including the binding 
of 14-3-3 proteins to phosphorylated peptides;125 trypsin cleavage of immobilized protein 
substrates;126 and biotin—streptavidin interaction studies.124  The EpicTM system has been used 
primarily for cell-based studies using dynamic mass redistribution (DMR).  DMR is the 
observation of changes in cellular attachment or morphology in response to signals stimulating 
extracellular receptors or signaling cascades that result in a change in interaction with the sensor 
surface.  DMR has been applied to cell-based studies including ligand—G-protein coupled 
receptor (GPCR) interactions;127-132 bradykinin—B2 receptor interactions;133, 134 ligand—
epidermal growth factor receptor interactions;133, 135 ligand—β2 adrenoreceptor interactions;136 
prostaglandin D2—chemoattractant receptor homologous molecule on T helper type 2 cells 
(CRTH2) interactions;137 ligand—free fatty acid receptor 1 (FFA1) interactions;138 and small 
molecule modulators of cytoskeletal structure.139 
 
1.3 Non-Specific Mechanisms of Action of Hit Compounds in HTS 
All high-throughput screening campaigns are subject to false positive hit compounds, 
though these compounds are generally eliminated upon retesting.  Compounds that are 
determined to be dose-dependent and repeatable are subjected to a series of secondary assays to 
confirm the activity of the compound.  However, research within the last decade has addressed 
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the problem of dose-dependent and repeatable compounds having nonspecific mechanisms of 
action.  Known nonspecific mechanisms of action include aggregation, detergent-like behavior, 
and covalent modification. 
 
1.3.1 Aggregation-Based Inhibition 
Some small organic molecules are capable of forming soluble and insoluble aggregates 
that inhibit macromolecular interactions.  High-throughput screening is plagued by these 
aggregates, as significant effort can be wasted if non-specific mechanisms of action are not 
identified early in the drug discovery process.  Small molecule aggregators are defined by 
several features including detergent-sensitive inhibition, promiscuous inhibition, incubation time 
dependence, enzyme concentration dependence, and the formation of large light scattering 
colloidal particles in solution.140 
 There are a few precautions one can take in order to prevent the identification of 
aggregators in primary screening, and there are standard secondary assays for aggregation-based 
inhibition after screening.  Aggregation-based inhibition is largely preventable with the simple 
addition of detergent (~ 0.01% Triton-X-100) to the screening buffer of a given HTS.  However, 
it was recently reported the existence of “super-aggregators” that can tolerate up to and above 0.1% 
Triton-X-100,141 though these compounds are relatively rare compared to the detergent-sensitive 
aggregators.  Promiscuous inhibition is a concern in any screening effort whether or not 
aggregation is suspected.  Testing of inhibitory compounds against multiple well-studied 
enzymes (β-lactamase,142-146 chymotrypsin,146 cruzain,147 malate dehydrogenase146) is a standard 
practice to assay promiscuity of hit compounds.  Further, the addition of an unrelated protein (e.g. 
BSA) to the screening buffer may abrogate the inhibitory properties of aggregating 
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compounds.140  Time and enzyme concentration dependence of inhibition is more relevant to 
enzyme inhibitor screens, though dramatic shifts in inhibitory qualities (e.g. IC50) with time or 
enzyme concentration can be telling.140  Dynamic light scattering (DLS) and electron microscopy 
have been used to confirm the formation of large aggregates in solution.140   
 It should be noted that all of the above assays should be taken as evidence for 
aggregation-based inhibition, though no single assay is conclusive to the point of elimination of 
lead compounds.  In addition, promiscuous aggregation was found to be highly dependent on 
buffer conditions,141 and certain assay conditions may be more amenable to aggregation than 
others.  However, testing of unrelated enzymes for promiscuous inhibition should be considered 
the most important assay as it can identify non-aggregating promiscuous inhibitors as well as 
aggregators, which are generally promiscuous. 
 
1.3.2 Detergent-Based Activation 
 As mentioned above, detergents can be used to disrupt inhibitory small molecule 
aggregates.  In addition, detergent-like molecules have been reported to non-specifically raise the 
activity of enzymes in vitro.148  Though screens for enhancers of enzyme function are fewer in 
number than enzyme inhibition screens, small molecule enhancers of enzyme function would 
still have value including small molecule enhancers of glucokinase,149 guanylate cyclase,150 
RNase L,151 and SIRT1.152  Detergent-based activation of enzyme function in vitro occurs by 
stabilization of the active enzyme, alteration of the active-site, or by modifying the surface 
adsorption of enzymes during the course of the assay.148   
 Unfortunately, precautions for primary screening do not exist for non-specific enhancers 
of enzyme activity.  Promiscuous activation of enzymes can only be ascertained by testing hit 
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compounds against multiple well-studied enzymes148 as mentioned above for aggregation-based 
inhibition. 
 
1.3.3 Covalent Modification 
 Covalent modification of macromolecules by small molecules in screening collections is 
also a large problem.  Reactive functional groups on putative small molecule inhibitors can 
covalently modify macromolecules specifically or non-specifically depending on the design and 
reactivity of the lead compound.  “Suicide” enzyme inhibitors depend on noncovalent 
interactions prior to covalent modification to generate macromolecular specificity.153-155  In 
contrast, covalent modifiers presumably lack specific noncovalent interactions and act primarily 
through their reactive functional groups.156, 157 
 High-throughput screening has been instrumental in the identification of classes of 
reactive compounds, in that compounds that are common across multiple assays and targets are 
assumed to have a non-specific mechanism of action.  Some efforts have focused on the 
identification and elimination of reactive compounds from screening libraries,158 though their 
complete eradication is not likely because of the expanding list of reactive compounds.157-159  
Several reviews157, 159 have attempted to catalogue reactive compound classes which include acyl 
and alkyl halides, anhydrides, aldehydes, imines, epoxides, aziridines, α,β unsaturated ketones 
(Michael acceptors), thioesters, sulfonate and phosphonate esters.   
 Compound reactivity is near impossible to predict because the reactivity is dependent on 
the compound structure as well as the assay conditions.  Promiscuous inhibition or activity 
against unrelated enzymes could be indicative of covalent modification, but only if the initial 
target and unrelated enzyme contain residues necessary for activity that are both modified by the 
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reactive compound.  Mass spectrometry should be conclusive for compounds that form covalent 
adducts that are stable to the ionization mode employed. 
 
1.4 Apoptosis Inducing Factor (AIF) and Neurodegenerative Disease 
 As the population within the US and around the world gets older, a larger focus must be 
placed on the treatment of age-related diseases such as neurodegeneration.  Neuronal cell death 
can occur in multiple cell types and by multiple mechanisms.160  It is critical to understand the 
mechanisms of cell death involved in chronic and acute neuronal injury as this will inform future 
treatment strategies for each disease.  Neurodegenerative disease pathology as well as neuronal 
cell death mechanisms including 1) classical apoptosis, 2) caspase-independent cell death 
(CICD), and 3) AIF-mediated cell death are discussed below. 
 
1.4.1 Neurodegenerative Disease 
 Neurodegenerative diseases can be chronic or acute, but they all involve neuronal cell 
death and subsequent loss of cognitive and/or motor function.  Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, and amyotrophic lateral sclerosis are all chronic 
neurodegenerative diseases involving some type of protein aggregation.  Stroke is an acute 
disease where the loss of oxygenation (ischemia) followed by reoxygenation (reperfusion) causes 
large scale neuronal cell death at and around the site of blockage. 
1.4.1a Alzheimer’s Disease 
 Alzheimer’s disease (AD) is a late-onset illness characterized by dementia and the loss of 
neurons in the basal forebrain and hippocampus.161  AD is the most prevalent neurodegenerative 
disease, affecting 2-3% of those aged 65 years, accelerating to ~ 50% by age 85.162  AD is caused 
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by two distinct protein aggregation events whose connection remains a mystery, the formation of 
extracellular plaques of the Aβ peptide and the intracellular formation of neurofibrillary tangles 
(NFTs) composed mostly of the microtubule-associated protein tau.  Aβ plaques arise from the 
processing of amyloid precursor protein (APP),163 while the mechanism of tau aggregation is 
linked to hyperphosphorylation.164  Familial AD is connected with mutations in APP and the 
presenilins.  These proteins are the individual components of γ-secretase, the enzyme responsible 
for the cleavage of APP.165-167  Only apolipoprotein E has been validated as a genetic indicator of 
sporadic AD.168  Caspases are directly implicated in the mediation of AD in that Aβ plaques and 
active caspase-3 accumulate in the hippocampus.169  However, studies involving Aβ peptide 
treatment suggest an alternative cell death program.170, 171  Interestingly, animal models of AD 
have shown that only the overexpression of mutant APP is required for synaptic dysfunction, 
though this is insufficient for neuronal cell death.162, 172, 173  The combination of mutant APP and 
mutant tau is required for neurodegeneration.162, 174 
1.4.1b Parkinson’s Disease 
 Second only to AD, Parkinson’s disease (PD) is one of the most common 
neurodegenerative diseases, affecting 0.1% of the population over 40 years of age.175  Symptoms 
of PD include tremor, rigidity, and impairment of mobility.  Characteristics at the cellular level 
include Lewy bodies (α-synuclein aggregates), decreased dopamine levels, and the eventual 
death of dopaminergic neurons in the substantia nigra pars compacta (SNpc).176  Familial PD can 
arise from mutations in the α-synuclein, DJ-1, parkin, or UchL1 encoding genes.176  Alpha-
synuclein is a 140 amino acid protein that adopts an α-helical structure when associated with 
membrane structures, but forms fibrils upon oxidative stress or modification.  The A53T and 
A30P mutants of α-synuclein are implicated in PD and PD-like neurodegeneration.176  Mutations 
 35
in DJ-1, UchL1, or parkin result in proteosomal malfunction and cell death.160, 176, 177  A 
condition resembling sporadic PD can be brought on by the intravenous injection 1-Methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a byproduct of heroin analog synthesis.178  MPTP 
crosses the blood-brain-barrier (BBB), is oxidized by monamine oxidase I into 1-Methyl-4-
phenylpyridinium (MPP+, the active metabolite of MPTP), and then is selectively taken up by 
dopamine transporters (DATs) on the surface of dopaminergic neurons in the SNpc.179  The 
mechanism of MPP+ is through mitochondrial electron transport chain complex I inhibition and 
the subsequent generation of reactive oxygen species (ROS).  MPP+ also contributes to 
excitotoxic cell death by causing the overstimulation of N-methyl-D-aspartate (NMDA) receptors, 
leading to an increase in intracellular Ca2+ levels that activates Ca2+ dependent proteases and 
neuronal nitric oxide synthase (nNOS).179, 180  MPTP and rotenone (another complex I inhibitor) 
are both used in cell culture and mice to mimic the effects of PD in humans.179, 181  
1.4.1c Huntington’s Disease 
 Huntington’s disease (HD) is an autosomal-dominant inherited disorder that affects 
roughly 0.01% of the population in the US.182  HD is mediated though age-dependent expansion 
of CAG repeats in the protein huntingtin (Htt).183  Increases in oxidative stress burden on the 
brain with age causes the activation of 7,8-dihydro-8-oxoguanine-DNA glycosylase 1 (OGG1), 
the protein directly responsible for CAG expansion in Htt.184  Expression of mutant Htt results in 
selective degeneration of γ-aminobutyric acid (GABA) producing neurons in the striatum.182  
Neuronal cell death is mediated by the aggregation of mutant Htt and subsequent cellular toxicity 
that is poorly understood.182, 185  Both NMDA receptor mediated excitotoxicity186, 187 and 
caspase-dependent cell death188 have been implicated in neuronal cell death in HD.  HD can be 
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models in cell culture and animal models by expression of CAG-expanded Htt; the phenotypes 
exhibited are consistent with HD in humans.189 
1.4.1d Amyotrophic Lateral Sclerosis 
 Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is the selective degeneration 
of motor neurons in the spinal cord and brain.  The majority (90%) of ALS cases are sporadic, 
and all forms of ALS affect roughly 0.01% of the population in the US.190  The discovery of 
familial ALS was critical in developing experimental models of ALS, in that 1 in 5 of patients 
with familial ALS contain a mutation in Cu,Zn superoxide dismutase 1 (SOD1).191, 192  The 
mechanism of cell death in ALS is largely unknown, though ROS and excitotoxicity 
accompanied by protein aggregates are again implicated in the mediation of the disease.190, 193-195  
Given that SOD1 is a ROS scavenging enzyme, it was initially thought that mutant SOD1 had 
reduced activity compared to WT.  However, SOD1 knockout mice did not develop ALS 
although they were shown to be more sensitive to spinal cord injury.190  Alternatively, SOD1 
mutations could result in a toxic gain-of-function activity that could produce different reactive 
species.190  Lastly, expression of mutant SOD1 results in protein aggregates, which have been 
shown to contain mutant SOD1 along with a number of other proteins.190 
1.4.1e Stroke 
 Stroke is the third leading cause of death in the USA, killing > 135,000 people in 2006 
(http://www.americanheart.org/).  Stroke can be ischemic (blockage of blood flow to the brain) 
or hemorrhagic (excessive bleeding in the brain).  Ischemia/reperfusion (I/R) injury accounts for 
85% of all stroke cases,162 and consequently receives the greatest research attention.  Currently, 
it is thought that necrotic cell death occurs at the site of the blockage (umbra), while cells in the 
penumbra die through multiple modes; the involvement of caspases is debated.196  The mediators 
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of neuronal cell death following I/R are many, though ROS seems to play a large role in the 
expression of inflammatory cytokines and glutamate excitotoxicity as mentioned above.197  
Models of stroke include middle cerebral artery occlusion (MCAo) in whole animals, and 
oxygen-glucose deprivation in cell culture.197-199    
 
1.4.2 Classical Apoptosis 
Apoptosis or programmed cell death (PCD) is a highly regulated form of cell death that is 
operational in all stages of life.200-202  Although typically associated with caspase activation 
(Figure 1.8), apoptosis can actually be divided into two classes: caspase-dependent and caspase-
independent cell death.  Caspases are the cysteine-dependent-aspartate-specific proteases that 
both initiate and execute the classical form of apoptosis.203  Caspases exist as low-activity 
zymogens called procaspases, which are activated either by proximity induced cleavage, or 
cleavage by an already activated caspase (e.g. procaspase-7 cleavage by active caspase-8).  The 
initiation of caspase-dependent apoptosis can either be cellular stress or an extracellular signal 
(e.g. Tumor Necrosis Factor-α mediated cell death).  Either event will lead to the activation of 
pro-apoptotic Bcl family proteins, which act on the mitochondria to release pro-apoptotic 
proteins contained in the intermembrane space.47, 204  Cytochrome c, a well-studied protein in the 
electron transport chain, was found to be an inducer of cell death when released into the 
cytoplasm,202  where it binds to the scaffolding protein apoptotic protease activating factor-1 
(Apaf-1).  The resulting  “apoptosome,” recruits and activates caspase-9, which in turn activates 
caspase-3.202  Caspase-3 has over 100 cellular substrates,  including caspase activated DNase 
(CAD), which mediates internucleosomal cleavage of chromatin.205  Other hallmarks of classical  
  
 38
  
Figure 1.8.  Classical apoptosis.  The extrinsic pathway is initiated by extracellular death receptor activation 
(top) followed by caspase-8 activation and caspase-7 activation.  The intrinsic pathway is initiated by many 
different cellular stresses including DNA damage (bottom).  DNA damage is followed by cytochrome c release 
from the mitochondria and Apaf-1 oligomerization into the apoptosome.  Apoptosome formation activates 
caspase-9 which activates caspase-3.  Caspase-3,-6,-7 are executioner caspases that cleave many different 
cellular substrates.  Considerable crosstalk is involved in the execution of the extrinsic and intrinsic pathways.  
For example, caspase-8 mediated cleavage of Bid can induce the dimerization of Bax and direct release of 
cytochrome c into the cytoplasm. 
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apoptosis include marked pyknosis, phosphatidylserine exposure, and cleavage of the nuclear 
enzyme poly(ADP-ribose) polymerase 1(PARP-1).200, 201 
By definition, classical apoptosis features the activation of caspases as stated above.  In a 
neuronal context, a myriad of morphologies are observed, ranging from caspase-dependent 
apoptosis to necrosis, depending on the disease condition.206-210  The cytochrome c mediated 
“intrinsic” pathway of apoptosis in neuronal cell death is largely required,210 though “extrinsic” 
death receptor mediated neuronal apoptosis has been reported.210  The requirement of 
cytochrome c211 and the proapoptotic Bcl family member Bax,212-216 has been extensively studied 
in growth factor withdrawal.  However, the involvement of classical caspase-dependent 
apoptosis in neuronal cell death is still contested, and it is likely that multiple mechanisms of cell 
death are active during neurodegenerative disease or stroke.210   
  
1.4.3 Caspase-Independent Cell Death 
 Caspase-independent cell death (CICD) is defined as cell death that occurs in the absence 
of significant caspase activation.217, 218  CICD includes necrosis,200 autophagic cell death,219 
necroptosis,220 paraptosis,217 and AIF-mediated cell death.  AIF-mediated cell death is initiated 
by reactive oxygen or nitrogen species production and DNA damage.221    The common 
neurotransmitter nitric oxide (NO) has been implicated in the initiation of AIF-dependent cell 
death in the nervous system.222, 223  In healthy cells, NO is absorbed by heme-containing proteins, 
or oxidized to nitrate.222  In cells suffering oxidative stress or cells that have a mitochondrial 
complex I dysfunction, superoxide radical anions are produced.170  Normally, most of the 
superoxide produced is converted to molecular oxygen and hydrogen peroxide by SOD1.222  
Oxidative stress results in an increase in the intracellular level of NO, which can combine with 
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superoxide to form peroxynitrite (ONOO-), a potent DNA damaging agent.222  Peroxynitrite 
causes DNA damage by base oxidation, which results in abasic sites as well as single strand 
breaks by cleavage of the phosphate backbone.223  These single strand breaks can be recognized 
by the nuclear enzyme PARP-1.  By poly(ADP-ribosyl)ating itself and target proteins, PARP-1 
helps to recruit DNA repair proteins to the site of DNA damage.224  However, the overactivation 
of PARP-1 leads to the production of poly(ADP-ribose) polymers and energy depletion, both of 
which contribute to AIF-mediated cell death.  
  
1.4.4 Poly(ADP-ribose) Polymers in Caspase-Independent Cell Death 
 Poly(ADP-ribose) (PAR) polymers have been under scrutiny for many decades, as they 
are influential in mitotic progression, DNA repair mechanisms, transcriptional control, and 
caspase-independent cell death.  Traditionally, PAR is thought to be produced in response to 
DNA damage, but its role in cell death suggests that alterations to the synthesis or metabolism of 
PAR could provide intriguing therapeutic options for a variety of disease states.   
1.4.4a Biosynthesis and Biological Functions of PAR 
 Poly(ADP-ribose) polymerase-1 (PARP-1) is the main enzyme responsible for producing 
PAR polymers, accounting for >99% of PAR synthesis in the cell during genotoxic stress.225, 226  
PAR is synthesized directly from NAD+ (thus indirectly from ATP), initially generating free 
nicotinamide and protein bound mono(ADP-ribose).  Elongation of the polymeric chain occurs at 
the 2’–OH of the mono(ADP-ribose) and subsequent branching of the polymer occurs at the 3’–
OH of the ribose moiety (Figure 1.9).  PARP-1 is potently activated by single and double 
stranded DNA breaks, leading to a 10-500 fold increase in PAR levels.227  PAR is degraded by 
the enzyme poly(ADP-ribose) glycohydrolase (PARG) in an endo- and exoglycosidic manner,  
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Figure 1.9.  The biosynthesis and degradation of poly(ADP-ribose).  1) NAD+ is consumed in the 
mono(ADP-ribos)ylation of a PAR acceptor protein, typically on a glutamic acid residue.  2) Elongation 
of the chain occurs at the 3’—OH of the ribose moiety.  3) Branching occurs at the 2’—OH of the ribose 
moiety.  PAR polymers average 1 branch every 20-50 ADP-ribose units.  4) PARGs endoglycosidic 
(debranching) activity removes large branches from complex polymers first.  5) PARGs exoglycosidic 
activity removes single ADP-ribose units from the end of the chain.  6) Mono(ADP-ribose) hydrolase 
(MARH) or Mono(ADP-ribose) protein lyase activity removes the final ADP-ribose unit from the PAR 
acceptor protein. 
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with KM values of 0.1-0.4 µM and ~ 10 µM for branched and short unbranched polymers, 
respectively.228  This KM difference of PARG for its substrate will become more important later 
as the discussion shifts to the inhibition of PARG in different disease states.  PAR polymers can 
reach lengths of hundreds of ADP-ribose units in vivo, with a half-life on the order of 1-10 min 
depending on the extent and type of DNA damage.226   
The nuclear accumulation of PAR leads to the recruitment of DNA repair proteins such 
as XRCC1, DNA ligase III, and the Ku70 subunit of the DNA-dependent protein kinase.229, 230  It 
has been reported that in response to DNA damage, PARP-1 can modulate transcription by 
poly(ADP-ribosyl)ating core histones and transcription factors, and recruiting PAR-binding 
proteins to ribosylated proteins; PARP-1 itself can also act as a cofactor in transactivation.231 
The importance of PAR in mitosis was reported initially by Mitchison and co-workers.232  
In these experiments, the microinjection of exogenous PARG into Xenopus eggs rapidly lead to 
misalignment of chromosomes and disruption of bipolar spindle assembly.  The requirement of 
PAR for proper mitosis is further supported by the involvement of tankyrase-1 in metaphase 
progression.233, 234  Tankyrase-1 is a member of the PARP family that can bind to and poly(ADP-
ribosyl)ate NuMA, whose function is to crosslink microtubules to spindle poles during 
mitosis.235  The siRNA mediated knockdown of tankyrase-1 leads to metaphase arrest due to the 
inhibition of sister telomere separation.233  Interestingly, tankyrase-1 also positively regulates 
telomere length through its poly(ADP-ribosyl)ation and subsequent inhibition of TRF1 DNA-
binding.236   
1.4.4b Death Signaling by PAR  
 As mentioned above, mild DNA damage leads to the stimulation of PARP-1 activity and 
the nuclear accumulation of PAR, allowing for the recruitment of DNA repair proteins and 
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conferring cytoprotection against genotoxic stress.  However, under conditions of excessive 
DNA damage, PARP-1 overactivation can be detrimental to cell viability.   Proposed by Berger 
and co-workers in 1983,237 the “suicide hypothesis” connects PARP activity to necrotic cell 
death by suggesting that the PARP-dependent depletion of cellular NAD+/ATP pools biases the 
cell towards necrosis.238  This hypothesis is supported by the observed protective effects of the 
genetic ablation of PARP-1, and the use of PARP-1 inhibitors to hinder cell death mediated by 
DNA alkylation (MMNG), oxidative insult (H2O2, peroxynitrite), excitotoxic injury (NMDA, 
glutamate), complex I inhibition (MPTP/MPP+), and ischemia/reperfusion.239-241   
Evidence in the literature suggests that PAR itself could contribute to cell death induced 
by PARP-1 activation.  To investigate whether free PAR itself is toxic, Dawson and co-workers 
published a study242 where the PARP-1 dependent decrease in cellular NAD+ and ATP levels 
was uncoupled from the production of PAR.  They used a lipid-based delivery system to 
transport in vitro synthesized PAR into living cells.  The cell death observed after PAR delivery 
was strongly dependent on the size and dose of PAR; it was also caspase-independent, as cell 
death was not abrogated by the use of the pan-caspase inhibitor zVAD-fmk.  As expected, 
pretreatment of the PAR polymer with PARG or phosphodiesterase 1 (PD1) prior to delivery 
prevented cell death, as the more toxic long chain polymers were degraded. 
 To analyze the involvement of PAR in a cellular disease model, mouse cortical neurons 
were treated with the excitatory toxin N-methyl-D-aspartate (NMDA).242  NMDA over-
stimulates NMDA receptors leading to a large increase in intracellular calcium, which leads to 
the production of reactive oxygen species (ROS).  Intracellular ROS production and the 
subsequent DNA damage results in PARP-1-dependent cell death.  Using an ELISA-based assay, 
the authors found that in response to NMDA treatment (1 hr) the levels of PAR reached ~80 nM 
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causing ~60% cell death.  This concentration and toxicity was similar to the results obtained 
when PAR was in vitro injected into HeLa cells.  Due to the embryonic lethality of PARG-/- mice, 
mice heterozygous for PARG were used in a middle cerebral artery occlusion (MCAo) study, in 
which NMDA receptor overstimulation is thought to mediate cell death after ischemia.243  The 
authors found that the infarct volume was increased significantly in PARG+/- mice, and decreased 
in transgenic mice overexpressing PARG.  Given the enhancement of infarct volume observed in 
PARG+/- mice, it would be interesting to study the ablation of different PARG isoforms 
(discussed below) and their involvement in MCAo.  These studies indicate that PAR-dependent 
cell death may be due to the direct toxicity of PAR. 
1.4.4c The Duality of PAR 
 PAR polymer is thus a central player in both the life and death of the cell.  PAR is 
required for proper mitosis, and PAR synthesis helps to stimulate the DNA-damage repair 
response.  Conversely, too much PAR synthesis may deplete NAD+/ATP stores and kill the cell, 
and long chain PAR itself is a key player in caspase-independent cell death (Figure 1.10).  
Depending on the therapeutic goal, enhancement or reduction in cell death could be 
accomplished by modulating PAR levels, and the most logical target would be the inhibition of 
PARG, as it is the key enzyme involved in the degradation of PAR.  Keeping with this life/death 
duality of PAR, genetic evidence (presented below) indicates that under certain conditions 
PARG inhibition could be cytoprotective, and under other conditions it could be cytotoxic. 
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1.4.4.d Modulating PAR Levels: Knockdowns, Knockouts, and Small Molecule Inhibition of 
PARG 
PARG isoforms present in mammalian cells are the full length PARG110 (nuclear), 
PARG103 and PARG99 (cytoplasmic), PARG60 (cytoplasmic/mitochondrial), and PARG85 and 
PARG74 (cytoplasmic, catalytically active fragments produced upon caspase-3 cleavage).  While  
most of the PARG activity in healthy cells is contained in the cytoplasm, DNA damage causes 
the nuclear translocation of cytoplasmic PARG isoforms.244, 245 
In recent years, much work has been performed to identify the role of PARG in response 
to genotoxic stress and ischemia; most studies employ either total PARG depletion by RNAi, or 
the genetic deletion of exons 2 and 3 which leaves only the 60 kDa isoform.  RNAi-mediated 
reduction of PARG results in sensitivity to radiation in C. elegans,246 as well as accumulation of 
PAR and increased infarct volume after MCAo in mice.247  Interestingly, conflicting results have 
been reported addressing the role of PARG in DNA repair.  Genetic deletion of PARG exons 2 
and 3 caused decreased XRCC1 foci formation, but an increase in DNA repair was observed.248  
In contrast, RNAi-mediated knockdown of PARG resulted in increased XRCC1 foci formation 
and duration, yet a decrease in DNA repair was observed.249  It should be noted that two separate 
studies have reported the early embryonic lethality of PARG-/- mice250 or Drosophila.251  PAR 
accumulation was observed in both studies, likely due to the inability to hydrolyze PAR.  
Phenotypically, PARG-/- mouse trophoblast stem cell lines established prior to embryonic failure 
required the PARP inhibitor benzamide (0.5 mM) for growth and were more sensitive to the 
toxic action of MNNG and menadione.250  Surviving mutant PARG-/- Drosophila embryos had to 
be grown at a permissive temperature for proper embryo eclosion, and exhibited progressive 
neurodegeneration during their brief adult life.251 
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In PARG’s absence, PAR accumulates; at the same time PARP-1 automodification is 
increased, causing PARP-1 to dissociate from DNA, assuming an inactive state.  In this way the 
inhibition of PARG results in the indirect inhibition of PARP-1, at least in an acute insult or 
DNA repair scenario.  As previously mentioned, the inhibition of PARP or PARG in DNA repair 
Figure 1.10.  The biological functions of PARP-1 signaling in response to DNA damage.  Nuclear 
accumulation of PAR allows for the recruitment of DNA repair complexes, loosening of chromatin to 
allow transcription, and death signaling for AIF release from the mitochondria. 
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scenarios generally results in the increased sensitivity of the cell to additional insults, hence the 
interest in combining PARP/PARG inhibitors with DNA damaging agents for treating cancer.241, 
252, 253
  In contrast to basal DNA repair in cancer, an alternative scenario emerges when the DNA 
damage is overwhelming, causing the overactivation of PARP-1 and a large and immediate 
reduction in the cytosolic pool of NAD+.  Inhibition of PARP or PARG in this scenario will halt 
the production of PAR and the consumption of NAD+, offering cytoprotective effects in models 
such as ischemia/reperfusion254, 255 and heart attack.256  Additionally, Blenn and co-workers257 
reported that RNAi-mediated silencing of PARG results in the accumulation of PAR, but confers 
resistance to oxidative stress.   
It thus appears that the absence of PARG can either sensitize cells to oxidative damage, 
or protect them from injury during times of extreme stress. Thus, from a therapeutic perspective, 
modulating PAR levels could be an attractive strategy for either induction or prevention of cell 
death, depending on the disease.  The obvious choice for altering cellular PAR levels would be 
through the inhibition of PARP or PARG. In vitro inhibition of PARG is possible with the 
substrate mimic ADP-HPD,258 but this compound is not useful in cell culture or in vivo as it is 
not cell permeable.  Ethacridine and other DNA intercalating agents inhibit PARG by binding to 
DNA and thus are not useful in studying PARG specifically.259  A large body of work has been 
performed on the cytoprotective effects of tannins, however their inhibition of PARG may be 
nonspecific and their protective effect may be due to ROS scavenging abilities.260  The most 
recent class of synthetic PARG inhibitors, typified by GPI 16552, initially did not show much in 
vitro PARG inhibition, but some recently reported in vivo effects against ischemia/reperfusion 
injury may warrant further investigation.261  With few potent specific inhibitors of PARG, the 
modulation of PAR synthesis would seem to largely depend on PARP-1 inhibition.  However, 
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there is an additional protein that is strongly connected to PAR signaling and could be targeted 
by small molecules, apoptosis inducing factor (AIF). 
 
1.4.5 Apoptosis Inducing Factor (AIF) 
 First described in mammalian cells by Susin and co-workers in 1999, translocation of 
AIF from the mitochondria to the nucleus was found to induce initial early stage chromatin 
condensation, large scale (~50 kb) DNA fragmentation, and cell death.262  AIF is a flavoprotein 
normally anchored to the inner mitochondrial membrane where it acts as an NADH oxidase, and 
purportedly contributes to the maintenance of complex I.263  AIF is released from the 
mitochondria in response to a wide range of caspase-dependent and caspase-independent 
insults.264  Once in the cytoplasm, AIF translocates to the nucleus where it is involved in 
chromatin condensation (although it itself is not a nuclease) and recruits nucleases such as 
cyclophilin A,265 and endonuclease G.266  The exact mechanism of AIF release remains a 
question, though the requirement of Bax oligomerization and pore formation on the surface of 
the mitochondria, or mitochondrial outer membrane permeabilization (MOMP), has been well 
studied in the release of other mitochondrial proapoptotic factors.267  The discovery of AIF 
helped bring into focus the process of caspase-independent cell death (Figure 1.11).  AIF is 
required for embryonic development, as the only viable system for its study is the Hq mutation 
which results in a 80% reduction in AIF expression;268 complete ablation of the AIF gene is 
embryonic lethal.269    
The connection between PARP-1 and AIF was first described in 2002,239 wherein 
embryonic fibroblasts from PARP-1 KO mice failed to release AIF from mitochondria and 
cytoprotection was conferred against DNA damaging agents.  Published simultaneously with the  
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discovery of free PAR as a cytotoxin was another report by Dawson and co-workers describing 
AIF as the mediator of cell death in response to PAR delivery.270  Interestingly, AIF was released 
from isolated mitochondria in response to PAR-containing nuclear supernatants, as well as in 
response to purified PAR in a size and dose-dependent manner.  Treatment of nuclear 
supernatants with proteinase K failed to prevent AIF release, suggesting that the factor critical 
Figure 1.11.  Model for cell death induced by PAR.  Cytosolic PAR accumulates at the surface of the 
mitochondria and releases AIF by an unknown mechanism.  Bax and Calpain are also required for AIF 
release, though the mechanism of Bax-mediated permeabilization of the outer mitochondrial membrane is 
unknown.  Once in the cytoplasm, AIF translocates to the nucleus via its NLS, where it can then bind 
DNA, condense chromatin, and elicit large scale (~ 50 kb) chromatin fragmentation by recruiting other 
nucleases such as cyclophilin A (cypA). 
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for the release of AIF may be non-proteinaceous in nature, consistent with the involvement of 
PAR.  Indeed, purified PAR does induce release of AIF, but the possibility of a carrier protein 
not confined to the nucleus cannot be ruled out.  Analogous to the cytoprotective effect of 
pretreating PAR polymers with PARG or PD1, AIF release was reduced when PAR polymer was 
degraded prior to addition to isolated mitochondria.  Additionally, AIF nuclear translocation and 
chromatin condensation was induced by PAR delivery into living cells, and this effect was 
prevented by pretreatment with PARG or PD1.  The cell death associated with PAR was shown 
to be AIF dependent as cortical neurons harvested from Hq mice were resistant to both PAR and 
NMDA toxicity.  However, the mechanism of AIF release by PAR is still unclear.  Although 
PAR can elicit AIF release from isolated mitochondria in vitro, other factors may be involved in 
a cellular context.   
In a recent report, Moubarak and co-workers identify PARP-1, calpains, and Bax as 
requirements for AIF release and cell death in response to MNNG.271  Using a series of 
knockouts, they identify PARP-1 upstream of calpains, though a possible mechanism for calpain 
activation after PARP-1 activation is not proposed.  Furthermore, active Bax was significantly 
reduced in calpain knockouts, suggesting that calpain may activate Bax in addition to the well 
studied mechanism of caspase-8 dependent, tBid-mediated activation of Bax.  Calpains have also 
been implicated as the enzyme responsible for AIF cleavage and release from the inner 
mitochondrial membrane.272 
1.4.5a AIF and PARG: Potential for Small Molecule Inhibition? 
Given the broad scope of diseases associated with aberrant PAR metabolism, it is not 
surprising that there is significant interest in the development of potent and cell permeable 
inhibitors of PARP, PARG, and AIF (Figure 1.12).  In addition to stroke and cancer, PARP-1  
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inhibitors have been shown to be efficacious in chronic neurodegenerative models such as the 
Parkinson’s Disease (PD) model drug 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) and 
its active metabolite 1-methyl-4-phenylpyridinium (MPP+);273 a more comprehensive description 
of the benefits of PARP inhibitors has been compiled elsewhere.241  PARG inhibitors have been 
shown to be beneficial in the potentiation of the alkylating agent temozolomide,274 and against 
ischemia/reperfusion injury.261  Currently, no small molecule inhibitors of AIF exist, so the 
evidence remains purely genetic in nature; reduction of AIF levels has been shown to be 
beneficial in models of neurodegenerative disease275 and stroke.276 
The data from Dawson and co-workers242, 270 indicate that PARG activity is likely 
cytoprotective in many contexts.  These findings imply that the inhibition of PARG would 
enhance the effect of PAR-induced toxicity.  Other reports discussed present the reduction in 
Figure 1.12.  Modulation of PARP-1, PARG, and AIF activity as a therapeutic strategy. The current applications 
of chemical and genetic inhibition of PARP-1, PARG, and AIF are shown. The reduction in PARP-1 activity 
(through inhibition, genetic knockout, or RNAi) has shown promise in all three disease states.240, 241  Both 
genetic and chemical studies have shown that PARG inhibition could sensitize cells to certain anticancer agents, 
and could be protective in stroke.252-257, 277  Studies utilizing RNAi or Hq mice (and cells derived from those 
mice) indicate that the reduction in AIF would be protective in neurodegenerative models and stroke.264, 275, 276, 
278, 279  Genetic and chemical inhibition of PARG activity in neurodegeneration, as well as chemical inhibition of 
AIF, remains to be explored. 
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PARG expression as a sensitizer to oxidative injury, which certainly would not be beneficial for 
neurons under constant oxidative assault.   
PARP-1 inhibitors are beneficial in PD models of cell death, but recent evidence of PAR 
toxicity indicates that PARG inhibition would be detrimental.  However, if the longest PAR 
polymers are the most toxic, and there is at least a 40-fold difference in KM values for PARG 
against long branched polymers versus short chain polymers, it may be possible to primarily 
inhibit the slow reaction, thus allowing for the PARG mediated degradation of long chain PAR 
(Figure 1.13).  If in fact this were a currently attainable scenario, questions still exist: 1) Will the 
automodified PARP-1 still retain its ability to recruit DNA repair proteins without long complex 
PAR polymers attached to it? 2) Are there benefits to inhibiting PARG versus AIF or PARP-1 if 
potent and specific inhibitors were developed for those proteins?  3) How will inhibitors of the 
endoglycosidic activity of PARG be identified?  As mentioned previously, caveats exist with 
most if not all of the PARG inhibitors identified so far,277 and genetic evidence points to AIF as a 
viable target for small molecule inhibition in neurodegeneration. 
 AIF has been implicated in many different disease states,264, 275, 276, 278, 279 and given the 
connections recently made among PARP-1, PAR, and AIF, it would seem that inhibitors of the 
AIF—DNA interaction would be cytoprotective.  Although orignally identified as being more 
sensitive to oxidative stress,268 the Hq mouse (with an 80% reduction in levels of AIF) has 
proved a useful tool in studying the role of AIF in neuronal cell death.   When cortical neurons 
from the Hq mouse are treated with camptothecin or excitatory toxins (glutamate, NMDA, 
AMPA, kainic acid), they show increased viability relative to WT neurons.280  Recently, mice 
carrying the Hq mutation also displayed a reduced infarct volume after hypoxia/ischemia.281  
Additionally, siRNA-mediated knockdown of AIF attenuated MPTP/MPP+ toxicity in  
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Figure 1.13.  Potential consequences of PARG inhibition.  A) The PARP-PARG cycle.  PARP-1 binds to 
damaged DNA, catalyzes the addition of PAR onto itself and acceptor proteins, dissociates from DNA, and then 
has PAR removed from it by PARG and MARH activities, freeing it to bind to damaged DNA again.  While the 
accumulation of PAR leads to beneficial consequences such as DNA repair, AIF translocation and NAD+ 
depletion also occurs.  B) Addition of a PARG inhibitor that would block the exoglycosidic activity of PARG.   
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dopaminergic neurons.275  All of these studies imply that inhibition of AIF could be 
cytoprotective. 
Unlike PARP-1 and PARG, AIF does not have an enzymatic activity directly associated 
with mediating cell death, thus complicating the search for AIF-specific inhibitors.  However, 
key residues have been identified for AIF—DNA binding, and the ablation of these residues 
results in decreased DNA binding, decreased chromatin condensation, and improved viability 
versus overexpressed AIF alone.282  These points offer hope that small molecule inhibitors of the 
AIF—DNA interaction can be identified. 
The following chapters will describe the screening of small molecule libraries for 
inhibitors of the AIF—DNA interaction.  A gel-based approach was first employed (Chapter 2), 
followed by the development of photonic crystal (PC) biosensor technology for DNA-binding 
proteins and the second screen for inhibitors of the AIF—DNA interaction from a much larger 
small molecule library (Chapter 3).  PC biosensor technology was further extended to protein—
protein interactions (Chapter 4) and further screens for modulators of protein—protein 
interactions are forthcoming. 
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CHAPTER 2: THE DISCOVERY OF INHIBITORS OF THE AIF—DNA 
INTERACTION VIA GEL-BASED SCREENING 
 
The information and contents for this chapter were partially taken from the following articles 
with permission from the publishers: Leo L. Chan, Maria Pineda, James T. Heeres, Paul J. 
Hergenrother, and Brian T. Cunningham “A General Method for Discovering Inhibitors of 
Protein—DNA Interactions Using Photonic Crystal Biosensors” ACS Chem. Biol. 2008, 3, 437-
48.  Leo L. Chan, Erich. A. Lidstone, Kristin E. Finch, James T. Heeres, Paul J. Hergenrother, 
and Brian T. Cunningham “A Method for Identifying Small-Molecule Aggregators Using 
Photonic Crystal Biosensor Microplates.” J. Assoc. Lab Autom. 2009, 14, 348-59.  This work 
could not have been accomplished without the aid of Kristin Finch and Leo Chan.  Kristin Finch 
performed the synthesis of compounds 2.7 and 2.10 derivatives, while Leo Chan performed the 
photonic crystal (PC) biosensor assays on compound 2.7 and its derivatives. 
 
2.1      Background 
As discussed in Chapter 1, apoptosis inducing factor (AIF) is an intriguing target for the 
development of potentially neuroprotective compounds.  Reduction in AIF levels has been 
shown to be neuroprotective in several models of cell death including Parkinson’s disease (PD) 
and stroke.  Inhibitors of the AIF—DNA interaction would be useful tools in studying AIF-
dependent cell death, and could have therapeutic use against neurodegenerative disease and 
stroke.  Initial studies focused on the development of a screening platform for the identification 
of inhibitors of the AIF—DNA interaction.  Discussed below are the results of the first gel-based 
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screen for small molecule inhibitors of the AIF—DNA interaction, as well as mechanism of 
action studies of hit compounds. 
 
2.2 Development of a Gel-Based Assay in Screening for Inhibitors of the 
AIF—DNA Interaction  
 During the development of photonic crystal (PC) biosensors as an assay for the detection 
of DNA-binding proteins and their inhibition, an alternative route was sought for screening for 
inhibitors of the AIF—DNA interaction.  As discussed in Section 2.3, fluorescence polarization 
(FP) was initially pursued where a fluorescein isothiocyanate (FITC) or Texas Red labeled DNA 
oligomer was used.  Unfortunately, incubation with increasing concentrations of AIF failed to 
elicit any change in anisotropy of the fluorophore.1  It has been previously reported that AIF 
preferentially binds to larger oligomers of DNA, presumably due to its cooperative mode of 
binding.2  Thus, a screen was developed using a linearized 2.7 kb plasmid, pUC19.  AIF was able 
to bind to linearized pUC19 efficiently as shown by agarose gel electrophoresis, and this assay 
was expanded for a high-throughput assay where ~22,000 compounds were screened yielding 
several inhibitors of the AIF—DNA interaction. 
 
2.2.1 Initial AIF—DNA Binding Studies 
 AIF(∆1-128) was cloned into pET28a as described in Section 2.8.1b.  Briefly, primers 
corresponding to the 5’ and 3’ end of AIF(∆1-128) with appended restriction sites were designed 
and used to amplify AIF(∆1-128) by polymerase chain reaction (PCR) from a previously 
constructed plasmid.  This PCR product was digested, purified, and incubated with digested and 
purified pET28a (Novagen) in the presence of T4 DNA Ligase (Invitrogen).  Transformation of 
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pET28a-AIF(∆1-128) in to BL21 E. coli cells (Invitrogen) and induction of expression did not 
yield any protein at the appropriate molecular weight.  AIF(∆1-128) contains 11% rare codons, 
including 23 arginine rare codons.  Given the lack of expression in BL21 cells, and the fact that 
surface lysines and arginines mediate DNA binding by AIF(∆1-128), an expression system 
where rare codons were adequately represented was sought.  Upon transformation of pET28a-
AIF(∆1-128) into Rosetta2 chemically competent E. coli (Invitrogen), AIF expressed at a high 
level (5-10 mg/L) and was relatively pure after a single step of Ni-NTA affinity chromatography 
(Figure 2.1A).  The most notable feature of AIF(∆1-128) expression and purification was the 
yellow/green color of the clarified lysate and purified protein that arises from the bound flavin 
adenine dinucleotide (FAD) in the active site of AIF.  The broad  
Figure 2.1.  Purification and DNA-binding activity of AIF(∆1-128).  A) Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) of AIF(∆1-128) Ni-NTA purification fractions reveals the major band at ~57 
kDa.  L: 10 µL of molecular weight standard (Rainbow ladder (Amersham)); FT: 10 µL sample of flowthrough 
during purification; W: 10 µL sample of wash step during purification; 1-7: 10 µL samples of elution fractions.  
B) AIF inhibits the migration of a DNA ladder through an agarose gel.  500 ng of 1 kb ladder (Promega) was 
incubated with AIF(∆1-128) or bovine serum albumin (BSA) for 15 min at 25 ºC, loading dye was added, and 
samples were loaded onto a 1% agarose gel supplemented with 1 µg/mL ethidium bromide.  Vertical labels on A 
and B refer to kDa and kb respectively. 
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fluorescence emission spectra of the bound FAD may have precluded gross fluorescence binding 
assays. This motivated the mutagenesis of AIF(∆1-128) in an effort to generate apo-AIF(∆1-128) 
which in theory would retain DNA-binding but lack bound FAD.  Incubation of purified AIF(∆1-
128) with DNA ladder showed a dose-dependent inhibition of the migration of the ladder 
through a 1% agarose gel (Figure 2.1B).  Purified AIF(∆1-128) was shown to bind several 
different size DNA oligomers (Figure 2.2), though this binding was far from the binary signal 
desired in a high-throughput assay.  Further studies in Section 2.3 will describe the use of 
linearized pUC19 in screening assays. 
 
 
 
 
Figure 2.2.  AIF(∆1-128) inhibits the migration of different sizes of DNA through an agarose gel.  DNA 
fragments were isolated from electrophoresed 1 kb and 100 bp ladders (Invitrogen).  100 ng of DNA was 
incubated in the presence or absence of AIF (5.6 µM) for 15 min at 25 ºC, loading dye was added, and the 
mixtures were loaded onto a 1% agarose gel + 1 µg/mL ethidium bromide.  In addition, 400 ng of a 32 bp 
complementary primer set was subjected to increasing concentrations of AIF (0, 1, 5.6, 28 µM).  Black lines 
obscuring the 300 bp, 400 bp, and 3 kb fragments are the bromophenol blue and xylene cyanol in the 
loading dye, and were omitted from following experiments.  Vertical labels for the ladders represent bp. 
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2.2.2 DNA- and FAD-Binding Mutants of AIF 
 AIF DNA-binding and FAD-binding mutants have been previously described in the 
literature.3, 4  A DNA-binding mutant would be utilized as an appropriate positive control during 
screening for inhibitors of the AIF—DNA interaction, while the utility of a FAD-binding mutant 
would be to generate apo-AIF(∆1-128), a protein that could be used in gross fluorescence change 
assays.  The DNA-binding double mutant (K508A, K516A) and FAD-binding double mutant 
(K176A, E313A) were produced as described in Section 2.8.1c; it is important to note that the 
residue numbers assigned to the AIF(∆1-128) mutants are in reference to residue 1, not residue 
128.  Each double mutant was expressed and purified analogously to wild-type AIF(∆1-128), and 
displayed similar yields and purity (Figure 2.3A).  Unfortunately, no significant change in DNA-
binding was observed with AIF(∆1-128, K508A, K516A) (Figure 2.3B), and AIF(∆1-128,  
K176A, E313A) required >6M urea to remove the FAD cofactor as judged by the loss coloration, 
and refolding conditions never yielded stable protein for use in DNA-binding studies.  AIF(∆1-
128, K508A, K516A) was previously shown to have severely reduced DNA-binding capability,3 
though the concentration of AIF(∆1-128) used in those studies was much lower, and a single 
DNA oligomer is used compared to the DNA ladder shown in Figure 2.3B.  While differences in 
DNA-binding may be observed in smaller DNA oligomers, AIF(∆1-128) preferentially binds to 
larger pieces of DNA.5  Testing AIF(∆1-128, K508A, K516A) against smaller substrates may 
show similar differences in DNA-binding capability compared to WT AIF(∆1-128). 
 
2.3 Screening for Inhibitors of the AIF—DNA Interaction 
 As described in Chapter 1, fluorescence polarization (FP) is a highly utilized method in 
high-throughput screening.  FP is ideally suited for DNA-binding assays because fluorophore-  
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labeled nucleic acid oligomers are commercially available (IDTDNA).  AIF—DNA binding 
assays were attempted using fluorescein isothiocyanate (FITC) and Texas Red labeled DNA 
oligomers of 30 and 20 bp respectively (Figure 2.4).  No increase in polarization was observed 
upon the addition of increasing concentrations of AIF(∆1-128) to either oligomer.  Possible 
reasons for the lack of change in polarization include the supposed low affinity of AIF for DNA.  
While the affinity of the AIF—DNA interaction has never been measured, in vitro studies 
typically require 5,000-10,000-fold more AIF than the DNA substrate.3, 5  Another reason could  
Figure 2.3.  Purification of AIF(∆1-128) mutants using Ni-NTA affinity chromatography and DNA binding 
capability of the DNA binding mutant.  A) AIF(∆1-128) mutants purified from E. coli.  L: 10 µL of 
molecule weight standard (Rainbow ladder (Amersham)); FT: 10 µL sample of flowthrough from 
purification; W: 10 µL sample of wash step from purification; 1-10: 10 µL samples of elution fractions.  B) 
DNA binding is not significantly inhibited by mutation of K508A and K516A.  AIF (WT and DNA binding 
mutant) was incubated with 500 ng of 1 kb ladder (Promega) and 100 bp ladder (Invitrogen) for 15 min at 
25 ºC.  Loading dye was added, and the mixtures were loaded onto a 1% agarose gel + 1 µg/mL ethidium 
bromide and electrophoresed for 1 h.  Vertical labels in A and B refer to kDa and kb respectively. 
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be the relatively large size of the DNA oligomer (~ 18 and 12 kDa for the FITC and Texas Red 
labeled oligomers respectively) versus that of AIF(∆1-128) (57 kDa).  The 3 to 5-fold mass 
difference used in the assays in Figure 2.4 is well below the 10-fold mass difference that is 
recommended in the literature.6, 7  Having attempted a fluorescence polarization assay for AIF—
DNA binding, a gel-based assay was developed.   
In initial DNA-binding studies with AIF(∆1-128), complete disappearance of the DNA 
band was never observed (Figure 2.2).  A HTS assay would require more robust difference in 
signal so that inhibitors of AIF—DNA binding could be easily identified.  One reason complete 
disappearance of the DNA band was never observed was because the AIF:DNA ratio may have 
been too low compared to ratios reported in the literature.3  Increasing the concentration of AIF 
would have made the screen cost/time prohibitive, so the DNA concentration was reduced.  First, 
a single large piece of DNA was selected for AIF—DNA binding studies.  The widely used high  
Figure 2.4.  Fluorescence polarization experiments with AIF(∆1-128) and fluorescently labeled DNA 
oligomers.  A) Varying concentrations of AIF(∆1-128) were incubated with 100 nM fluorescein 
isothiocyanate (FITC) labeled DNA oligomer (20 bp) for 30 min in 50 mM Tris, 100 mM NaCl, pH 8.0.  B) 
Varying concentrations of AIF(∆1-128) were incubated with 100 Texas Red labeled DNA oligomer (30 bp) 
for 30 min in 50 mM Tris, 100 mM NaCl, pH 8.0.  Polarization (mP) was measured using an Analyst HT 
fluorescence reader (Molecular Devices).  Randomized DNA sequences were used for A) and B), and are 
described in Table 2.5.  Error bars represent the s.d. from the mean (n = 3). 
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copy vector pUC19 (2.7 kb) was chosen because of its ease of production.  pUC19 was 
propagated in E. coli and purified as described in Section 2.8.2.  Next, pUC19 was linearized by 
restriction digest (NdeI (New England Biolabs)) and repurified in order to simplify data analysis 
after incubation with AIF(∆1-128).  Linearization of pUC19 allowed the visualization of a single 
DNA band (Figure 2.5A), eliminating the supercoiled and concatenated forms that may have 
obscured AIF—DNA complexes.  Lastly, the concentration of DNA was reduced to 2.4 ng/µL 
Figure 2.5.  High-throughput gel-based screen for inhibitors of the AIF—DNA interaction.  A) AIF(∆1-
128) inhibits the migration of linearized pUC19 through an agarose gel.  Increasing concentrations of AIF 
were incubated with 60 ng of pUC19 for 15 min at 25 ºC.  Loading dye was added, and 12.8 µL of the 30 
µL final reaction volume (25 ng of pUC19) was loaded onto a 1% agarose gel, electrophoresed for 1 h, and 
stained overnight with SYBR Green I.  13 µM of AIF(∆1-128) per 60 ng of linearized pUC19 was used for 
screening.  B) A representative primary screening and deconvolution gel.  Top panel, 13 µM AIF(∆1-128) 
was incubated with 10 compounds per well (each at ~ 200 µM) for 30 min at 25 ºC.  60 ng of linearized 
pUC19 was added and further incubated for 15 min at 25 ºC.  Loading dye was added and the mixture was 
loaded onto a 1% agarose gel, electrophoresed for 1 h, and stained overnight with SYBR Green I.  The left 
most lane contains 1.5 µL of 1 kb ladder (100 ng/µL, Invitrogen).  The next lane to the right contains pUC19 
+ DMSO (outlined in white), and the following lane contains pUC19 + AIF(∆1-128) + DMSO.  All other 
lanes contain pUC19 + AIF(∆1-128) + compounds.  Bottom panel, initial hits from the primary screen were 
deconvoluted by repeating the same 10 compound mixture from the primary screen (outlined in red), and 
also screening the compounds in that mixture individually to identify the inhibitor (compound 2.1, outlined 
in yellow).  C) The structure of compound 2.1.  M1-10-F18; plate and well identifiers. 
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while the concentration of AIF(∆1-128) stayed roughly the same (0.6 µg/µL).  As shown in 
Figure 2.5A, the migration of linearized pUC19 through an agarose gel was efficiently inhibited 
by AIF in a dose-dependent manner.  To detect such a small amount of DNA, overnight staining 
in SYBR Green I was required, while all previous gels were stained with ethidium bromide 
which has a detection limit of ~100 ng.  The detection limit of SYBR Green I is 1-2 ng when 
post-staining agarose gels overnight. 
 Scaling up the assay shown in Figure 2.5A was achieved by using custom made agarose 
gel combs that enabled the electrophoresis of 168 samples at once.  AIF(∆1-128) was 
preincubated with 10 compounds per well and hit wells were deconvoluted afterwards.  Briefly, 
18 µg of AIF(∆1-128) was preincubated with 10 compounds (final [DMSO] = 5%) per well at 
200 µM each.  AIF(∆1-128) and compounds were incubated for 30 min at 25 ºC prior to the 
addition of 60 ng linearized pUC19 and further incubation for 15 min at 25 ºC.  Loading dye was 
added and the samples were electrophoresed for 1 h and stained with SYBR Green I overnight.  
A total of 22,000 compounds from an in-house library were screened using this assay and hits 
were deconvoluted in subsequent gel assays (Figure 2.5B, and Figure 2.6). 
 
2.3.1 Hit Deconvolution and Validation 
 Primary hits were identified as wells that showed complete inhibition of AIF—DNA 
binding at 200 µM; individual compounds were “cherry-picked” from frozen library plates and 
incubated with AIF(∆1-128) as described above.  An example of the deconvolution process is 
shown in Figure 2.5B.  Complete deconvolution of hits is displayed in Figure 2.6.  Out of 16 
primary hits, 12 were commercially available (2.1: Aldrich; all others: Chembridge Corp.).  
These compounds were repurchased and tested for their dose-dependent inhibition of AIF— 
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Figure 2.6.  Deconvolution of primary hits from the gel-assay screen.  Assays were performed as in Figure 
2.5, where primary hits (10 compound mixtures, outlined in red) or individual compounds (outlined in 
yellow) were incubated with AIF(∆1-128) to identify individual inhibitory compounds.  Compounds 2.2-
2.16 were identified in this manner.  pUC19 + DMSO is outlined in white.   
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Figure 2.7.  Dose-dependence of reordered hit compounds.  AIF(∆1-128) was incubated with increasing 
concentrations of compound (0.002, 0.02, 0.2, 2, 20, 100, 200, 400 µM)  for 30 min at 25 ºC.  60 ng of 
linearized pUC19 was added and further incubated for 15 min at 25 ºC.  Loading dye was added and the 
mixture, loaded onto a 1% agarose gel, electrophoresed for 1 h, and stained overnight with SYBR Green I. 
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DNA binding (Figure 2.7).  The most potent dose-dependent inhibitors of the AIF—DNA 
interaction (compounds 2.1, 2.4, 2.7, 2.9, and 2.10) were then selected for general toxicity 
studies.  Compound 2.14 was included because it was found to be more potent upon storage of 
the 10 mM stock in DMSO at 4 °C (Figure 2.9 and Section 2.3.3). 
 
2.3.2 Toxicity of Hit Compounds 
 HL-60 leukemia cells were seeded into 96-well plates at 50,000 cells/well and incubated 
with 0, 1, 10, 100 µM compound for 24 hr.  Cell death was quantified by MTS Assay (Promega) 
as detailed in Section 2.8.3.  The MTS Assay quantifies cell viability by monitoring the 
Figure 2.8.  Toxicity of hit compounds to HL-60 cells using an MTS assay.  HL-60 cells (50,000 cells/well) 
were seeded into a 96-well plate and incubated with 0, 1, 10, 100 µM compound for 24 h and cell death was 
quantified by the MTS assay.  A decrease in the absorbance at 490 nm is indicative of cell death; each 
compound set is normalized to DMSO treated cells.  Error bars represent the s.d. from the mean (n = 3). 
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conversion of [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) into a formazan product with a peak absorbance at 490 nm.  As shown in 
Figure 2.8, compounds 2.4, 2.9, and 2.10 exhibited significant toxicity in this assay. 
 
2.3.3 Lead Compound Selection 
 Full effective concentration (EC50) curves were obtained for the remaining 3 compounds 
after toxicity screening.  The EC50 is the concentration at which 50% of the desired effect has 
occurred, in this case the desired effect is the reappearance of linearized pUC19 at its correct 
location (2.7 kb) on an agarose gel.  As shown in Figure 2.9, compound 2.7 is the most potent of 
the three that were tested.  Retesting of reordered compound 2.14 revealed that freeze-thaw 
cycles of the DMSO stock were required for inhibitory activity, and the synthesis of large 
quantities of compound 2.14 for identification of the inhibitory species was not successful.  The 
following sections describe the utility of compound 2.1 (aurin tricarboxylic acid (ATA)) and 
compound 2.7 as inhibitors of the AIF—DNA interaction.  Also included is a revisitation of 
compound 2.10 which was originally eliminated due to its toxicity to HL-60 cells.  
 
2.4 Investigation of Aurin Tricarboxilic Acid (ATA) as an Inhibitor of the 
AIF—DNA Interaction 
 The structure of compound 2.1 (ATA) does not lend itself to derivatization and thus no 
derivatives were synthesized.  The only analogue of ATA that was tested was p-rosolic acid, a 
compound lacking the three carboxylic acid moieties (2.17 in Figure 2.10B).  The deletion of the 
carboxylic acids ablated all inhibitory activity as shown in an AIF gel-shift assay (see Chapter 3). 
 
 104
 
2.4.1 Isothermal Titration Calorimetry Studies with ATA 
Isothermal titration calorimetry (ITC) has been widely utilized for the determination of 
binding constants (KD) for protein—protein, protein—nucleic acid, and small molecule—
protein/nucleic acid interactions8-13.  ITC experiments were then attempted for ATA, 2.7 and 
2.14.  Unfortunately, only ATA possessed the aqueous solubility required for ITC.  As described 
in the Section 2.8.4, AIF(∆1-128) and compound were first dialyzed in to the same buffer (50 
mM Tris, 100 mM NaCl, pH 8.0).  The ITC syringe was loaded with a high concentration of  
Figure 2.9.  Potency of 2.1, 2.7, and 2.14 in the gel-shift assay.  Experiments were performed as in Figure 
2.4.  AIF(∆1-128) was preincubated with 0, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, and 200 
µM compound for 30 min at 25 ºC.  60 ng of linearized pUC19 was added and further incubated for 15 min 
at 25 ºC.  Loading dye was added and the mixture, loaded onto a 1% agarose gel, electrophoresed for 1 h, 
and stained overnight with SYBR Green I.  Percent inhibition was calculated using ImageJ densitometry 
software.  Curve fits were performed using TableCurve.  The effective concentration (EC50) values of the 
compounds in this assay are: 2.1 = 90 µM; 2.7 = 54 µM; 2.14 = 62 µM.  D = pUC19 + DMSO; A = pUC19 
+ AIF(∆1-128) + DMSO. 
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compound (100-500 µM), while the ITC cell contained AIF at a much lower concentration (0.5-
10 µM).  As shown in Figure 2.10A, only ATA showed any affinity for AIF(∆1-128).  Curve 
fitting analysis of a single-site model determined the KD = 19 ± 5 µM.  p-Rosolic acid showed no 
affinity for AIF(∆1-128) using this method (Figure 2.10B). 
 
2.4.2 ATA as a Cytoprotective Agent 
Although ATA has been previously reported as a cytoprotective agent, the mechanism of 
this cytoprotection is clouded.14-16  Given the fact that ATA was identified as an inhibitor of the 
Figure 2.10.  ITC studies with ATA (2.1) and p-rosolic acid (2.7).  A) ATA binds to AIF(∆1-128) with a KD 
= 19 ± 5 µM.  B) p-rosolic acid shows little affinity for AIF(∆1-128).  For the above experiments the 
concentrations of AIF(∆1-128) and compound was 5 and 500 µM respectively in 50 mM Tris, 100 mM 
NaCl, pH 8.0.   
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AIF—DNA interaction, and was shown to bind to AIF directly, ATA may mediate 
cytoprotection by blocking the AIF—DNA interaction in cell culture.  HL-60 cells were again 
used in toxicity/cytoprotection assays; employing flow cytometry and propidium iodide (PI) 
staining to quantify cell death.  PI is a cell impermeable dye that becomes fluorescent upon 
intercalation into cellular DNA, and thus measures plasma membrane integrity.  Briefly, HL-60  
cells were seeded in 24-well plates at 1 x 106 cells/well and treated with varying concentrations 
of ATA for 1 h prior to the addition of seven different cytotoxins; N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), a DNA alkylator;17, 18 etoposide, a topoisomerase II inhibitor;19, 20 
4150, a novel small molecule of unknown mechanism discovered in the Hergenrother lab; PAC-
1, a Zn chelating caspase-3 activating compound discovered in the Hergenrother lab;21-23 
Figure 2.11.  ATA is cytoprotective against a range of cytotoxins.  HL-60 cells were preincubated with 
ATA for 1 h  and then treated with cytotoxin for 15 min (MNNG) or 24 hr.  Cell death was assessed by PI 
staining and flow cytometry.  Error bars represent the s.e. (n = 2). 
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rotenone, a mitochondrial complex I inhibitor;24, 25 doxorubicin, a topoisomerase II inhibitor;26 
camptothecin, a topoisomerase I inhibitor.27  As shown in Figure 2.11, ATA is protective to 
different degrees against many different cytotoxins, some of which have mechanisms of action 
largely independent of AIF.  The concentrations of cytotoxin in Figure 2.11 were determined by 
treating HL-60 cells with varying concentrations of cytotoxin and selecting the concentration that 
elicited 50-80% cell death over 24 h. 
 
2.4.3 ATA as a Promiscuous Inhibitor 
 As mentioned above, ATA has been previously reported as a cytoprotective compound; it 
has also been reported to have many different inhibitory activities against different proteins.  In 
vitro assays have shown ATA to be a general inhibitor of nucleases28 and of topoisomerase  
II.29, 30  Cell culture assays revealed ATA to act on extracellular targets such as von Willenbrand 
factor,31 gp120 and interferon-α.32  Interestingly, in aqueous buffer ATA has been proposed to 
form a polymeric species by a radical-based mechanism.33  Taken together, the negatively-
charged polymeric species of ATA inhibiting DNA-binding proteins in vitro, and the fact that all 
other reported targets are extracellular, suggests that ATA may not be a cell permeable 
compound.  Indeed, other negatively-charged polymers such as DNA and RNA require cationic 
lipid formulations to pass the plasma membrane.34, 35  This also suggests that the mechanism of 
cytoprotection of ATA may most likely be based upon an extracellular interaction, and not the 
inhibition of AIF—DNA binding.  Another possibility is that ATA is cell permeable and inhibits 
cell death by the inhibition of multiple nucleases.15  Accordingly, ATA was eliminated as a 
selective inhibitor of the AIF—DNA interaction, and compound 2.7 was focused upon next. 
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2.5 Investigation of Compound 2.7 and its Derivatives as Inhibitors of the 
AIF—DNA Interaction 
 
2.5.1 Synthesis of Compound 2.7 Derivatives 
 2.7 and similar compounds were synthesized as shown in Scheme 2.1.  All derivatives 
were synthesized by Kristin Finch in the Hergenrother lab. 
 
2.5.2 Compound 2.7 Derivative Testing in AIF Gel-Shift Assay 
All derivatives of compound 2.7 were tested in the AIF gel-shift assay as previously 
described.  AIF (∆1-128) was preincubated with increasing concentrations (0.5-200 µM) of 
compound for 30 min at 25 ºC.  60 ng of linearized pUC19 was then added and further incubated 
for 15 min at 25 ºC.  Loading dye was added, and the mixture was electrophoresed for 1 h and 
stained overnight with SYBR Green I.  A representative result for the inhibitory action of 
compound 2.7 is shown in Figure 2.9.  All derivatives of compound 2.7 and their inhibitory 
activities (in +/- notation) are shown in Table 2.1.  No compounds showed greater inhibitory 
activity than 2.7 itself, and while the trihydroxybenzaldehyde was shown to be sufficient for 
moderate activity, many other groups were tolerated after formation of the N-acyl hydrazone.   
 
Scheme 2.1.  Synthetic scheme for compound 2.7 derivatives.  Derivatives containing the trihydroxy moiety 
are exemplified here, though other derivatives (Table 2.1) were synthesized analogously.  All derivatives 
synthesized by Kristin Finch.  MW: microwave.  
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Table 2.1.  Activity of 2.7 derivatives.  +++: similar inhibitory activity to 2.7; +: lower inhibitory activity 
than 2.7; -: no inhibitory activity.  All compounds were synthesized by Kristin Finch.  
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Full IC50 enhancement characterization of derivatives of compound 2.7 was not achieved due to 
later events that implied nonspecific inhibition of AIF—DNA binding. 
 
2.5.3 Evidence for Aggregation-Based Inhibition 
 As discussed in Chapter 1, aggregation-based or promiscuous inhibition is a major 
problem in HTS, particularly in enzyme inhibition screens.36  While no individual experiment is  
diagnostic of aggregation-based inhibition, if a compound is positive in multiple assays designed 
to elucidate aggregation-based inhibition it can be particularly troubling.  Assays for aggregation 
include the addition of detergents/surfactants (Triton-X-100, Tween 20) or bovine serum 
albumin (BSA) to the assay buffer.  Aggregation-based mechanisms of inhibition often are also  
promiscuous in nature, and testing inhibitory compounds against unrelated enzymes 
(chymotrypsin, β-lactamase) is a standard practice. 
 As shown in Figure 2.12, inhibition of the AIF—DNA interaction by 2.7 is sensitive to 
the commonly used surfactant Tween 20 while the inhibitory action of ATA and 2.4 are not.  
Briefly, 200 µM compounds were diluted in assay buffer containing increasing concentrations of 
Tween 20, and AIF(∆1-128) was immediately added and the mixture was incubated for 30 min at 
25 ºC.  60 ng of linearized pUC19 was then added and further incubated for 15 min at 25 ºC.  
Loading dye was added, and the mixture was electrophoresed for 1 h and stained overnight with 
SYBR Green I.  This assay was not diagnostic for aggregation, as the typical range of 
detergent/surfactant concentrations used in these assays is 0.01-0.05%,37 though it is important to 
note that compound 2.7 was the only compound of those tested to show any sensitivity to 
detergent.  The possibility remains for aggregation-based inhibition as detergent-resistant  
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aggregators, which maintain their inhibitory properties even in the presence of 0.1% detergent, 
have recently been discovered.38  
 The inhibition of the AIF—DNA interaction by compound 2.7 was also sensitive to 
bovine serum albumin (BSA) as shown in Figure 2.13.  Assays in Figure 2.13 were performed in 
a similar fashion to those in Figure 2.12, except now with increasing concentrations of BSA 
instead of Tween 20.  BSA did not adversely affect the migration of linearized pUC19 or the 
inhibition of migration by AIF.  The relevant concentration of BSA can be variable between  
Figure 2.12.  The inhibitory activity of 2.7 is affected by Tween 20.  AIF(∆1-128) was preincubated with 
DMSO or 200 µM compound + 0.01-5% Tween 20 for 30 min at 25 ºC.  60 ng linearized pUC19 was added 
and further incubated for 15 min at 25 ºC.  Loading dye was added and the mixture was electrophoresed for 
1 h followed by overnight staining in SYBR Green I.  D: pUC19 + DMSO; A: pUC19 + AIF(∆1-128) + 
DMSO; 200: pUC19 + AIF(∆1-128) + 200 µM compound.  All other samples contained the same as “200” 
with varying concentrations of Tween 20. 
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different assays, but should generally revolve around the concentration of target protein.  In 
Figure 2.13, the inhibition of AIF—DNA binding by compound 2.7 was almost completely 
absent at a concentration of 0.4 mg/mL BSA while the concentration of AIF(∆1-128) was 0.72 
mg/mL. 
 Compound 2.7 was also shown to exhibit dose-dependent inhibition of chymotrypsin in a 
simple colorimetric assay (Figure 2.14A).  Chymotrypsin assay conditions are described in 
Section 2.8.6.  Briefly, chymotrypsin was incubated with increasing concentrations of 5650817 
for 30 min at 25 ºC.  Substrate (Suc-AAPF-pNA) was added so that the final concentration was 
200 µM and the absorbance was monitored at 405 nm for 15 min.  Supporting the results in 
Figure 2.12, ATA was shown not to inhibit chymotrypsin (Figure 2.14B). 
Finally, derivatives of compound 2.7 were subjected to a novel assay using photonic 
crystal (PC) biosensors (see Chapter 1) that was capable of identifying aggregating compounds 
simply by the detection of large aggregates on the biosensor surface itself.39  As shown in Figure  
Figure 2.13.  The inhibitory activity of compound 2.7 is affected by BSA.  AIF(∆1-128) was preincubated 
with DMSO or 200 µM cmpd + 0.04, 0.08, 0.2, 0.4, 0.8, 1.2, 1.6, 2 mg/mL BSA for 30 min at 25 ºC.  60 ng 
linearized pUC19 was added and further incubated for 15 min at 25 ºC.  Loading dye was added and the 
mixture was electrophoresed for 1 h followed by overnight staining in SYBR Green I.  D: pUC19 + DMSO; 
A: pUC19 + AIF(∆1-128) + DMSO. 
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Figure 2.14.  Compound 2.7 inhibits chymotrypsin activity while ATA does not.  Chymotrypsin (20 ng/mL) 
was incubated in the presence of increasing concentrations of A) 2.7 or B) ATA in 100 mM Tris, 10 mM 
CaCl2, pH 7.8 for 30 min at 25 ºC.  Substrate was added to a final concentration of 200 µM and the 
absorbance at 405 nm was monitored for 15 min.  The production of p-nitroaniline (pNA) in nmol was 
determined by a calibration curve with pNA alone after the assay was completed.  Compound/DMSO + 
chymotrypsin controls were performed along side each data series, and were subtracted from the wells 
containing substrate. 
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Figure 2.15.  2.7 (Compound 9) derivatives display abnormally high PWV shifts.  Compounds were 
incubated with streptavidin-coated PC biosensors at a final concentration of 25 µM in PBS for 1 h at 25 ºC 
and the PWV shift was observed.  Data was adapted from Chan et. al.39  The compound numbers highlighted 
in red refer to those in Table 2.1. 
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2.15, incubation of derivatives of compound 2.7 with the biosensor surface show a non-specific 
increase of the peak wavelength value (PWV) similar to the validated aggregator and 
promiscuous inhibitor Congo Red.40-42  Full experimental details can be found in Section 2.8.7.  
Briefly, compounds were diluted to 50 µM in phosphate buffered saline (PBS) pH 7.4, and were 
incubated for 60 min at 25 ºC prior to the addition to the streptavidin (SA)-coated PC biosensor 
plate for a final concentration of 25 µM.  The corresponding shifts in PWV were observed for 1 
h.  The data shown in Figure 2.15 correlates reasonably well with the relative activities of the  
compounds in Table 2.1, further implicating aggregation as the mechanism of inhibition of the 
AIF—DNA interaction by compound 2.7 and its derivatives.  Interestingly, trihydroxy moiety 
containing compounds have appeared as hits in several in vitro assays against MurD-F ligases.43, 
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Having shown that the inhibitory action of compound 2.7 can be negated by the addition 
of Tween 20 or BSA, and 2.7 exhibits nonspecific inhibition against chymotrypsin, compound 
2.7 and its derivatives were abandoned.  Further studies focused on compound 2.10 which was 
initially discarded due to its toxicity to HL-60 cells. 
 
2.6 Investigation of Compound 2.10 and its Derivatives as Inhibitors of the 
AIF—DNA Interaction 
 
2.6.1 Synthesis of Compound 2.10 Derivatives 
Compound 2.10 and derivatives were synthesized as shown in Scheme 2.2.  All 
derivatives were synthesized by Kristin Finch. 
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2.6.2 Compound 2.10 Derivative Testing in AIF Gel-Shift Assay 
 All derivatives of compound 2.10 were tested in the AIF gel-shift assay described 
previously.  AIF (∆1-128) was preincubated with increasing concentrations (0.5-200 µM) of 
compound for 30 min at 25 ºC.  60 ng of linearized pUC19 was then added and further incubated 
for 15 min at 25 ºC.  Loading dye was added, and the mixture was electrophoresed for 1 h and 
stained overnight with SYBR Green I.  A representative result for the inhibitory action of  
compound 2.10 is shown in Figure 2.16.  All derivatives of 2.10 and their corresponding IC50  
Scheme 2.2.  Synthetic scheme for compound 2.10 derivatives.  Derivatives containing the 3,5-diiodosalicyl 
moiety are exemplified here, though other derivatives (Table 2.2) were synthesized analogously.  All 
derivatives synthesized by Kristin Finch.  MW: microwave.  
Figure 2.16.  Potency of 2.10 in the gel-shift assay.  Experiments were performed as in Figure 2.5.  AIF(∆1-
128) was preincubated with 0, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, and 200 µM 
compound for 30 min at 25 ºC.  60 ng of linearized pUC19 was added and further incubated for 15 min at 25 
ºC.  Loading dye was added and the mixture, loaded onto a 1% agarose gel, electrophoresed for 1 h, and 
stained overnight with SYBR Green I.  Percent inhibition was calculated using ImageJ densitometry 
software.  Curve fits were performed using TableCurve.  The effective concentration (EC50) value of 
compound 2.10 in this assay is 55 µM.  D = pUC19 + DMSO; A = pUC19 + AIF(∆1-128) + DMSO. 
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values from the gel-shift assay are shown in Table 2.2.  Immediately apparent was the increased 
potency of the 3,5-diiodosalicyl group linked by an imine bond to the primary amino group.  
Substitution of the iodo groups for other halides generally led to decreased or no activity, while 
deletion of the halides completely ablated all activity.  Different primary amines linked to 3,5-
diiodosalicylaldehyde had little bearing on the potency of the molecule.  The core imine bond 
was required for inhibitory activity, as the amine linkage was completely inactive.  Requirement 
of the imine bond led to the testing of 3,5-diiodosalicylaldehyde alone, and this moeity was 
sufficient for inhibition.  Different benzaldehydes tested correlate well with the predicted activity 
based on the SAR from derivatives of compound 2.10.  The ortho-hydroxyl group of the 
different aldehydes tested was shown to be dispensable, though formation of the methyl ether 
resulted in no inhibitory activity. 
 
2.6.3 Toxicity of Compound 2.10 Derivatives 
 Given the known toxicity of compound 2.10 to HL-60 cells, derivatives of 2.10 were 
tested for their toxicity to HL-60 cells in search of less toxic derivatives.  Figure 2.17 displays 
the toxicity of derivatives of compound 2.10 to HL-60 cells as measured by propidum iodide (PI) 
staining and flow cytometry.  Briefly, derivatives of compound 2.10 (50 µM) were incubated 
with HL-60 cells for 24 h, stained with PI, and cell death was quantified by % PI positive cells.  
In general, toxicity correlated with activity, therefore most of the compounds containing the 3,5-
diiodosalicylaldehyde moiety were toxic to cells, while the less active derivatives containing the 
3,5-dichlorosalicylaldehyde moiety were non-toxic. Compounds 2.58 and 2.72 are exceptions to 
this trend, as 2.58 is a inactive toxic compound, and 2.72 is a relatively non-toxic active 
derivative.  Further studies of compound 2.72, a non-toxic derivative containing the 3,5- 
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Table 2.2.  Potency of compound 2.10 derivatives in the AIF gel-shift assay.  > 200 µM: less than 50% 
inhibition at 200 µM.  --: no inhibition at 200 µM. 
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Table 2.2. (continued)   
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diiodosalicylaldehyde moiety, attempted to show cytoprotection against the DNA alkylator N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG) in HL-60 cells, but results either showed no 
protection or were inconsistent (data not shown).  Given the general toxicity of the 3,5-
diiodosalicylaldehyde moiety, the fact that the most active derivatives of compound 2.10 contain 
the 3,5-diiodosalicylaldehyde moiety, and that the aldehyde precursors of compound 2.10 
derivatives largely mirror that activity, the next hypothesis tested was that derivatives of 
compound 2.10 were hydrolyzing in aqueous solution to generate a reactive aldehyde that was 
toxic to cells and was possibly forming transient imines with AIF and other proteins. 
 
Figure 2.17.  Toxicity of selected compound 2.10 derivatives to HL-60 cells.  Cells were treated with 50 
µM compound DMSO for 24 h, and cell death was assessed by PI staining and flow cytometry.  Yellow bars 
highlight compounds that contain the 3,5-diiodosalicyl moiety.  The least toxic compounds (2.69 and 2.72) 
was selected for further testing.  Error bars for DMSO treated wells represent the s.d. from the mean (n = 4).   
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2.6.4 Evidence for Imine Formation 
 Transient imines formed upon the reaction of free amines in peptides or proteins with 
aldehydes can be reduced to a covalent amine linkage in the presence of a reductant (e.g. NaBH3, 
NaCNBH3).  Mass spectrometry was chosen for analysis of protein samples that were incubated 
with different aldehyde precursors of derivatives of compound 2.10, and subsequently reduced in 
the presence of NaCNBH3.  All samples were prepared as detailed in Section 2.8.9, and 
submitted to Dr. Peter Yau at the Protein Sciences Facility (UIUC) for trichloroacetic acid (TCA) 
precipitation of protein and electrospray ionization mass spectrometry (ESI-MS) studies.  Initial 
studies replicating the screening conditions (200 µM compound, 15 µg AIF(∆1-128), 30 min 
incubation at 25 ºC) revealed that both 2.10 and 2.74 were able to modify AIF(∆1-128), while 
the inactive compound 2.54 was not (Figure 2.18).  In addition, 2.77 and 2.78 were able to 
modify AIF(∆1-128) and showed the associated mass shifts (Figure 2.19).  Though 3,5-dichloro 
and 3,5-dibromo derivatives were much less potent inhibitors of the AIF—DNA interaction the 
gel-shift assays, their aldehyde precursors are still able to modify AIF(∆1-128) in the mass 
spectrometry assay.  Compound 2.74 and analogues were also able to modify myoglobin (Figure 
2.20).  Initially it was thought that NaCNBH3 may be facilitating a non-specific linkage of 
compound 2.74 or derivatives to myoglobin and AIF(∆1-128), and that NaCNBH3 may be 
required for modification of myoglobin, but not to AIF(∆1-128).  Compound 2.74 requires 
NaCNBH3 in order to modify AIF(∆1-128) or myoglobin (Figure 2.21).  This NaCNBH3 
dependence also depends on the inhibitory activity of the compound, as the inactive aldehyde 
(Compound was unable to modify AIF(∆1-128) or myoglobin in the presence or absence of 
NaCNBH3.  The non-specific modification of proteins with reactive aldehydes such as 
compound 2.74 was repeated with the analogous compound pyridoxal-5’-phosphate (PLP). 
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Figure 2.18.  3,5-diiodosalicylaldehyde (compound 2.74) is sufficient for modification of AIF(∆1-128).  AIF(∆1-128) was preincubated with A) DMSO or 
B-D compounds for 30 min at 25 ºC then reduced with 1 mg/mL NaCNBH3.  Proteins were analyzed by TCA precipitation and ESI-MS in positive mode.  
All modifications of the correct molecular weight are highlighted.  Incubation with compound 2.10 displays at least one mass shift of ~357 Da, while 
compound 2.74 shows at least 3 such modifications.  Compound 2.54 or DMSO did not elicit any shifts in mass. 
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Figure 2.19.  Halide-decorated salicylaldehydes modify AIF(∆1-128).  AIF(∆1-128) was preincubated with A) DMSO or B-D compounds for 30 min at 25 
ºC then reduced with 1 mg/mL NaCNBH3.  Proteins were analyzed by TCA precipitation and ESI-MS in positive mode.  Incubation with compound 2.77 
displays at least two mass shifts of ~173 Da, incubation with compound 2.78 displays at least two mass shifts of  ~263 Da, and incubation with compound 
2.74 displays at least two mass shifts of ~357 Da. 
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Figure 2.20.  Halide-decorated salicylaldehydes modify myoglobin.  40 µg myoglobin was preincubated 
with A) DMSO or B-D compounds for 30 min at 25 ºC then reduced with 1 mg/mL NaCNBH3.  Proteins 
were analyzed by TCA precipitation and ESI-MS in positive mode.  Incubation with compound 2.77 
displays at least two mass shifts of ~173 Da, incubation with compound 2.78 displays at least one mass shift 
of  ~263 Da, and incubation with compound 2.74 displays at least one mass shift of ~357 Da. 
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Figure 2.21.  Modification of myoglobin is dependent on compound activity and NaCNBH3.  40 µg 
myoglobin was preincubated compound 2.74 for 30 min at 25 ºC and then for 10 min in the A) absence or 
B) presence of  NaCNBH3.  Myoglobin was also preincubated with compound 2.83 analogously, and then 
for 10 min in the C) absence or D) presence of  NaCNBH3.  Proteins were analyzed by TCA precipitation 
and ESI-MS in positive mode.  Incubation with compound 2.74 in the presence of NaCNBH3 displays at 
least one mass shift of ~357 Da. 
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The previously reported aldehyde PLP has been used in the identification and labeling of reactive 
lysine residues on proteins.45-48  PLP is the active form of vitamin B6 and is a natural cofactor of 
many aminotransferases.49, 50  PLP forms transient imines (Schiff bases) with lysine residues 
during amino acid transfer.  When this cofactor is used outside of its natural enzyme, it behaves 
in a similar fashion, by nonspecifically labeling reactive lysine residues on enzymes and other 
proteins.  In addition, this is a technique for determining whether a given enzyme contains a 
lysine residue necessary for activity.51-56  Given the structure of PLP, and the fact that PLP 
labeling of reactive lysines also requires the presence of a reductant, it was hypothesized that 
compound 2.74 and its derivatives act in a similar fashion, through modification of the ε-amine 
of lysine.  Indeed, PLP and compound 2.74 were able to modify lysozyme (Figure 2.22), which 
was used for future studies because of superior purity and quality of signal.  Many more 
modifications were observed in the presence of compound 2.74 compared to PLP, suggesting 
either greater reactivity over PLP or a greater promiscuity.  When equimolar concentrations of 
PLP and compound 2.74 are incubated together with lysozyme, both modifications are still 
present (Figure 2.22D), suggesting similar reactivities.  The time-dependence of modification by 
compound 2.74 and PLP was investigated next.  For this the reaction had to be quenched with 
excess carbobenzyloxy-protected lysine (Cbz-Lys-OH) that will react with any remaining 
compound 2.74 or PLP upon reduction.  Compound 2.74 showed significant modification of 
lysozyme after 1 min, with the later time points displaying more modification (Figure 2.23).  
PLP was also able to show modification within 1 min, though to a much lower degree (Figure 
2.24).  Further studies will be needed in order to definitively identify the more reactive aldehyde 
by quantitative methods, as well as MS/MS studies to identify the modified residues in both PLP 
and compound 2.74 treated proteins. 
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Figure 2.22.  Modification of lysozyme with compound 2.74 and PLP.  80 µg lysozyme was preincubated 
with A) DMSO, B) compound 2.74, or C) PLP for 1 h at 25 ºC and then for 10 min with NaCNBH3.  D) 
Lysozyme was also preincubated with both compounds (400 µM) simultaneously.  Proteins were analyzed 
by TCA precipitation and ESI-MS in positive mode.  Incubation with compound 2.74 displays at least four 
mass shifts of ~357 Da.  Incubation with PLP displays at least two mass shifts of ~231 Da.  Incubation with 
both compounds displays at least one mass shifts of ~357 Da, one mass shift of ~231 Da, and one mass shift 
corresponding to the combined mass of compound 2.74 and PLP. 
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Figure 2.23.  Time dependent modification of lysozyme with compound 2.74.  80 µg lysozyme was preincubated with 400 µΜ compound 2.74 for A) 1 min, 
B) 10 min, C) 30 min, or D) 60 min at 25 ºC, then 1 mM Cbz-Lysine-OH was added and incubated for 10 min, followed by a 10 min incubation with 
NaCNBH3 and flash frozen in liquid nitrogen.  The 1 min incubation with 2.74 sample received Cbz-Lys-OH and NaCNBH3 simultaneously and was 
incubated for 1 min prior to freezing.  Modifications are indicated by a mass shift of ~357 Da. 
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Figure 2.24.  Time dependent modification of lysozyme with PLP.  80 µg lysozyme was preincubated with 400 µΜ PLP for A) 1 min, B) 10 min, C) 30 min, 
or D) 60 min at 25 ºC, then 1 mM Cbz-Lysine-OH was added and incubated for 10 min, followed by a 10 min incubation with NaCNBH3 and flash frozen in 
liquid nitrogen.  The 1 min incubation with PLP sample received Cbz-Lys-OH and NaCNBH3 simultaneously and was incubated for 1 min prior to freezing.  
Modifications are indicated by a mass shift of ~231 Da. 
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2.7 Summary and Future Directions 
 In an initial effort to discover inhibitors of the AIF—DNA interaction, a gel-based 
screening method was developed.  An in-house library of 22,000 compounds was screened, and 
three classes of compounds were studied further.  ATA was shown to be a potent inhibitor of the 
AIF—DNA interaction, even showing moderate binding to AIF itself as measured by ITC.  Due 
to its documented promiscuity, proposed polymeric nature, and potential cell impermeability, 
ATA was not pursued further.  The novel compounds 2.7 and 2.10 showed dose-dependent 
inhibition of the AIF—DNA interaction in the gel-shift assay.  Many derivatives of each 
compound were synthesized, but ultimately had to be eliminated due to promiscuous 
inhibition/interaction with unrelated proteins.  The 2.7 series of compounds were eliminated due 
to the formation of aggregates that were detergent and BSA sensitive, and these aggregates were 
able to inhibit the unrelated enzyme chymotrypsin.  The 2.10 series of compounds were 
eliminated due to nonspecific transient interactions with proteins unrelated to AIF, and these 
interactions could be made permanent in the presence of a reductant. 
 Further studies on compound 2.74 include the use of tandem mass spectrometry to 
identify the site of covalent linkage, and liquid chromatographic (LC) studies to quantify the 
level of modification occurring on simple substrates such as Cbz-protected lysine.  
Derivatization of compound 2.74 for the further addition of biotin and fluorescent dyes (Figure 
2.25) would be useful for the field of protein modification, and this seems feasible as derivatives 
of PLP have been synthesized that retain their ability to covalently link to reactive lysine 
residues.57  Furthermore, current biotinylation agents such as biotin-NHS ester result in amide 
bond formation after reaction with surface lysines, neutralizing the charged nature of the side  
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chain.  A derivative of compound 2.74 such as the one displayed in Figure 2.25 would result in 
amine bond formation after reduction and would thus retain the positive charge of the lysine. 
 As discussed in the following chapters, a novel technique employing photonic crystal 
biosensors was tapped in the continued screening for inhibitors of the AIF—DNA interaction. 
 
2.8 Materials and Methods 
 
2.8.1 AIF(1-128) 
2.8.1a Cloning of AIF(1-128) into pET28a 
 The cDNA encoding AIF(∆1-128) was obtained by Dr. Karson Putt (formerly of the 
Hergenrother lab).  The original storage vector is unknown, and AIF(∆1-128) was received in a 
pET24d vector (Novagen) which was unable to express AIF(∆1-128) in E. coli.  Primers (IDT) 
were designed for the cloning of AIF(∆1-128) into pET28a using a 5’ NdeI restriction site and a 
3’ EcoRI restriction site (Table 2.3).  PCR amplification of AIF(∆1-128) with these primers 
yielded a product that, along with empty pET28a, was digested with NdeI and EcoRI, gel 
purified, and both insert and vector were incubated in the presence of T4 DNA ligase (Invitrogen) 
following the manufacturers’ instructions.  Portions of the ligation reactions were transformed  
Figure 2.25.  Tools for the in vitro biotinylation of proteins. 
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into chemically-competent DH5α E.coli (Invitrogen), plated onto LB/agar plates containing 50 
µg/mL kanamycin A, incubated overnight at 37 ºC.  Colonies were selected and the plasmid-
harboring bacteria were grown overnight at 37 ºC in LB + 50 µg/mL kanamycin A.  Plasmid 
preps were performed using a mini-prep kit (Qiagen).  The presence of AIF(∆1-128) in pET28a 
was confirmed by redigestion with NdeI and EcoRI, and DNA sequencing. 
2.8.1b Expression/Purification of AIF(1-128) in E. coli 
 pET28a-AIF(∆1-128) was transformed into electrocompetent Rosetta2 E. coli 
(Invitrogen), plated onto LB/agar + 50 µg/mL kanamycin A, 50 µg/mL chloramphenicol, and a 
single colony was inoculated into a 20 mL culture of LB + 50 µg/mL kanamycin A, 50 µg/mL 
chloramphenicol and grown overnight at 37 ºC.  2 L of LB + 50 µg/mL kanamycin A, 50 µg/mL 
chloramphenicol was inoculated with the overnight culture and grown at 37 ºC for ~3 h until the 
OD600 = 0.6.  Expression of AIF(∆1-128) was induced by the addition of 1 mM isopropyl-β-D-1-
thiogalactoside (IPTG) for 4 h at 37 ºC.  Cells were harvested by centrifugation at 5,000 x g and 
stored at -20 ºC for as long as 6 months. 
 Purification of AIF(∆1-128) for use in gel-shift assays required only a single affinity 
chromatography step, while mass spectrometric studies required cation exchange 
chromatography (CEX) following affinity chromatography.  Cell pellets were thawed to 25 ºC by 
the addition of 10-15 mL of modified Ni-NTA binding buffer (50 mM Tris, 300 mM NaCl, 10 
Table 2.3.  Cloning primers for AIF(∆1-128). 
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mM imidazole, pH 8.0) and vortexing.  Resuspended cells were lysed by continuous sonication 
for 60 s on ice.  Lysates were clarified by centrifugation at 35,000 x g, the supernatant was 
removed and placed in a separate 50 mL conical tube, and 1-2 mL of Ni-NTA Agarose (Qiagen) 
slurry was added and incubated with agitation at 4 ºC for 1 h, with all following steps proceeding 
at 4 ºC.  Clarified lysate and slurry were poured into a disposable column and was flowed 
through by gravity.  Resin was then washed with addition of 20 mL cold modified Ni-NTA 
binding buffer, followed by the addition of 20 mL cold modified Ni-NTA wash buffer (50 mM 
Tris, 300 mM NaCl, 20 mM imidazole, pH 8.0).  AIF(∆1-128) was eluted with 10 mL of cold 
modified Ni-NTA elution buffer (50 mM Tris, 300 mM NaCl, 500 mM imidazole, pH 8.0).  
Purified protein was transferred to a 10,000 molecular weight cut off (MWCO) dialysis cassette 
(Pierce) and dialyzed overnight against 50 mM Tris, 100 mM NaCl, pH 8.0, with at least three 
buffer changes.  AIF(∆1-128) was concentrated using a spin concentrator (Amicon) and protein 
concentration was determined using the BCA assay (Pierce Biotechnologies). 
 For CEX purification, dialyzed AIF(∆1-128) was concentrated and diluted into start 
buffer (20 mM NaHPO4, pH 6.0).  Sepharose SP (GE Life Sciences) was equilibrated with start 
buffer, and diluted AIF(∆1-128) was loaded onto the column.  After a full column volume of 
start buffer had passed through, a gradient of increasing NaCl concentrations was performed, 
ending at 20 mM NaHPO4, 500 mM NaCl, pH 6.0.  Protein elution was monitored by the 
absorbance at 280 nm.  Pure fractions were ascertained by SDS-PAGE, pooled, concentrated, 
and dialyzed against the desired buffer, typically 50 mM Tris, 100 mM NaCl, pH 8.0. 
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2.8.1c Mutagenesis of AIF(1-128) 
 Primers were ordered (IDT) corresponding to the following mutations: K508A, K516A, 
K176A, and E313A (Table 2.4).   Mutagenesis was performed as per the manufacturer’s 
(Stratagene) instructions, using PfuTurbo in all reactions.  Portions of mutagenesis reactions 
were transformed into electrocompetent DH5α E. coli, plated onto LB/Agar + 50 µg/mL 
kanamycin A incubated overnight at 37 ºC.  Colonies were picked, grown up overnight, and 
potential pET28a-AIF(∆1-128) mutant plasmids were harvested via mini-prep kits followed by 
DNA sequencing. 
 
2.8.2 AIF—DNA Binding Assays and High-Throughput Screen 
2.8.2a Fluorescence Polarization Assays 
 Varying concentrations of AIF(∆1-128) were incubated with 100 nM labeled DNA 
oligomers (Table 2.5) for 30 min in 50 mM Tris, 100 mM NaCl, pH 8.0.  Polarization (mP) was 
measured using an Analyst HT fluorescence reader (Molecular Devices).   
 
 
Table 2.4.  Mutagenic primers for AIF(∆1-128). 
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2.8.2b Gel-Shift Assays 
Linearized pUC19 was generated by digesting pUC19 with NdeI for 4 h, followed by 
repurification with a mini-prep kit (Qiagen); linearization was confirmed by agarose gel 
electrophoresis.  15-30 µg (depending on the DNA-binding activity) of purified AIF(∆1-128) 
was incubated in the presence of DMSO or compound for 30 min at 25 ºC in AIF assay buffer 
(50 mM Tris, 100 mM NaCl, pH 8.0).  60 ng of linearized pUC19 in mini-prep elution buffer (10 
mM Tris, pH 8.3) was added, bringing the final volume to 25 µL, and incubated for 15 min at 25 
ºC.  5 µL of Blue/Orange Loading Dye (Promega) was added, and 12.8 µL of the mixture was 
loaded onto a 1% agarose gel, and electrophoresed for 1 h.  Completed gels were stained with 
SYBR Green I (Cambrex) overnight as per the manufacturer’s instructions.  Stained gels were 
imaged via a gel imager (BioRad), and densitometric analysis was performed using ImageJ. 
 
2.8.2c High-Throughput Screen  
Screening conditions mirror those above, except with 10 x 0.5 µL compound in each well, 
delivered by a 384-well pin transfer device.  Compounds screened were from the “Marvel” 
library, an in-house collection of donated, synthesized, and purchased compounds currently 
housed at the High-throughput Screening Facility (HTSF, http://scs.illinois.edu/htsf/) at the 
Table 2.5.  Fluorescent DNA oligomers used in fluorescent polarization assays. 
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University of Illinois at Urbana-Champaign (UIUC).  All compounds were stored at either 10 
mM or 5 mg/mL in DMSO depending on the source of the compound.  ATA was repurchased 
from Sigma-Aldrich, while compounds 5650817 and 5761863 were repurchased from the 
Chembridge Corporation prior to resynthesis. 
 
2.8.3 Toxicity Assays 
2.8.3a MTS Assays 
 MTS assays were performed as per the manufacturer’s instructions.  HL-60 cells were 
obtained from ATCC, and propagated in RPMI 1640 + 10% fetal bovine serum (FBS) + 100 
µg/mL penicillin/streptomycin.  Cells were seeded into 96-well plates at 50,000 cells/well and 
incubated with varying concentrations of compound for 24 h.  20 µL of a prepared PMS/MTS 
solution was added to 100 µL HL-60 cells, and incubated for 2 h at 37 ºC.  Cell death was 
assessed by measuring the absorbance at 490 nm and normalizing to DMSO treated and cell-free 
wells. 
2.8.3b Flow Cytometry 
 Flow cytometry assays were performed using a BD Biosciences LSR II flow cytometer.  
HL-60 cells were seeded in 24-well plates at 1 x 106 cells/well and incubated with compound for 
24 h.  Cells were washed with PBS two times prior to staining with PI (1 µg/mL in PBS).  Cell 
death was assessed by cells exhibiting a high PI fluorescence in comparison to the DMSO treated 
cells. 
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2.8.4 Isothermal Titration Calorimetry 
 ITC studies were performed on a MicroCal calorimeter at the Microanalysis Lab at UIUC.  
CEX-purified AIF(∆1-128) was diluted to 0.5-5 µM in AIF assay buffer and injected into the 
calorimeter cell.  The ITC injection needle was filled with the compound of interest diluted in 
AIF assay buffer in the absence of DMSO to avoid the large heat of solvation associated with 
DMSO.  Compound concentrations in the injection needle were varied depending on the 
solubility of the compound, but generally adhered to 100 times the concentration of AIF(∆1-128) 
in the cell.  KD values were calculated from a single-site model fit using OriginLab calorimetry 
software. 
 
2.8.5 Synthesis of Compound 2.7 Derivatives 
 As described in Section 2.5.1, complete compound syntheses will be reported in future 
theses or publications.  All compounds were stored in DMSO at a concentration of 10 mM or 
lower depending on the dilution series required. 
 
2.8.6 Chymotrypsin Assays 
 Chymotrypsin and its substrate, succinyl-Ala-Ala-Pro-pNA, were purchased from Sigma-
Aldrich (C4129, S7388 respectively).  Chymotrypsin was diluted to 2 mg/mL in assay buffer 
(100 mM Tris, 10 mM CaCl2, pH 7.8), and the substrate was diluted and stored in DMSO 
protected from light.  While different assays required different concentrations of chymotrypsin, 
the assays reported above keep the final concentration at 20 ng/mL; this concentration was 
determined by a calibration curve to determine the concentration of chymotrypsin that gave a 
linear increase in absorbance over 15 min.  In a standard, clear bottom 96-well plate, 10 µL of 
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chymotrypsin (200 ng/mL in assay buffer) was allowed to incubate with 2 µL of compound for 
30 min at 25 ºC in 78 µL of assay buffer.  10 µL of substrate (2 mM in assay buffer, diluted from 
20 mM stock in DMSO) was added (200 µM final concentrations) and immediately placed on a 
plate reader (SpectraMax Plus 384, Molecular Devices) and the absorbance at 405 nm was 
recorded over 15 min.  
 
2.8.7 Photonic Crystal Biosensor Assays 
 Compounds were diluted to 50 µM in PBS from 10 mM DMSO stocks, and added to 
streptavidin coated (SA2) PC biosensor plates (SRU Biosystems) so that the final concentration 
was 25 µM.  PWV shifts were recorded on the BIND Reader (SRU Biosystems) after a 1 h 
incubation at 25 ºC.  Aggregation was characterized by an abnormally high PWV shift in 
comparison to negative controls such as DMSO or D-biotin. 
 
2.8.8 Synthesis of Compound 2.10 Derivatives 
As described in Section 2.6.2, complete compound syntheses will be reported in future 
theses or publications.  All compounds were stored in DMSO at 10 mM or lower depending on 
the dilution series required. 
 
2.8.9 Mass Spectrometry 
 All assays were performed in AIF assay buffer or PBS.  Compounds were incubated with 
AIF(∆1-128), myoglobin (Aldrich M8007), or lysozyme (Aldrich L6876) typically at 
concentrations ranging from 40-400 µM compound in the presence of 20-200 µg of protein (see 
figure legends for specific assay conditions).  Samples were incubated at 25 ºC for 30-60 min, 
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then reduced with the addition of NaCNBH3 (1 mg/mL), and further incubated for at least 10 min 
at 25 ºC.  Samples were submitted to Dr. Peter Yau at the Protein Sciences Facility 
(http://www.biotech.uiuc.edu/centers/Proteomics/Proteinscience/index.html) at UIUC for protein 
preparation and mass spectrometry analysis using a Waters Q-ToF API-US mass spectrometer. 
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CHAPTER 3: SCREENING FOR INHIBITORS OF THE AIF—DNA 
INTERACTION USING PHOTONIC CRYSTAL BIOSENSORS 
 
The information and contents for this chapter were partially taken from the following article with 
permission from the publishers: Leo L. Chan, Maria Pineda, James T. Heeres, Paul J. 
Hergenrother, and Brian T. Cunningham “A General Method for Discovering Inhibitors of 
Protein—DNA Interactions Using Photonic Crystal Biosensors” ACS Chem. Biol. 2008, 3, 437-
48.  This work could not have been accomplished without the aid of Patrick Knerr, Aaron 
Knowlton, Ryan Stowe, Jason Olejniczak, and Dr. Rob Huigens who all participated in the 
synthesis of derivatives of compound 3.11 and/or the testing of derivatives. 
 
3.1 Background 
High-throughput screening (HTS) of compound collections is now a staple of modern 
drug discovery.  In the most common incarnation, in vitro enzyme inhibition screens of large 
(>100,000 members) compound libraries are conducted using substrates that provide an easily 
quantified chromogenic/fluorescent readout.  Such screens have led to the discovery of many 
novel enzyme inhibitors and drug leads.1, 2  Unfortunately, many potential drug targets are not 
enzymes, and thus for these systems high-throughput methods are needed that go beyond enzyme 
inhibition assays and directly report on small molecule—protein binding events.   
One area in which small molecule ligands for non-enzyme proteins would be useful is in 
the disruption of protein—macromolecule interactions (see Chapter 1).  The identification of 
compounds that perturb protein—protein or protein—nucleic acid interactions is extremely 
challenging,3-6 and this is partly due to the paucity of good high-throughput screens.  Successes 
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in modulating protein—protein and protein—nucleic acid interactions with small molecules fall 
into a few classes; surface receptor—ligand interactions (integrins,7-9 IL-1/2,10, 11 TNFα12), 
cytoplasmic targets (iNOS,13 HIV protease,14 Bcl-2/xL,15 XIAP16), and transcription-related 
targets with relevance to the anti-cancer field.17  This last class of compounds elicit their action 
by inhibiting transcription factor dimerization/DNA-binding (B-ZIP,18 Zn-finger proteins,19 
STAT3,20, 21 c-Myc/Max,22, 23 HIF-1,24 GLI25), by relieving inhibitory proteins (p53/MDM2),26 or 
by recruiting transcription factors or coactivators to certain DNA sequences by using 
polyamides27, 28 or small molecules.29-31  In order to further facilitate the identification of 
inhibitors of protein—nucleic acid interactions, a high-throughput screening method that would 
directly report on the inhibition of protein—nucleic acid complexes was designed. 
There are several techniques utilized to measure protein—nucleic acid binding.  Current 
methodologies include DNA microarrays,32 fluorescence polarization,33 electrophoretic mobility 
shift assays (EMSA),34 DNA/RNA footprinting,35, 36 chromatin immunoprecipitation (ChIP),37 
isothermal titration calorimetry (ITC),38 and surface plasmon resonance (SPR);38, 39 each is able 
to measure the degree and/or specificity of protein—DNA/RNA binding.  While the 
aforementioned techniques are useful in determining binding affinities, few are optimal for high-
throughput compound screening and drug discovery.  DNA microarrays and emerging SPR 
microscopy techniques may ultimately be suitable for HTS, and the technology discussed herein 
may be viewed as complementary to these assays.  However, DNA microarray and SPR 
microscopy-based screening has generally been applied to the identification of optimal promoter 
binding sites for transcription factors33, 40-42 and not in drug discovery.  Fluorescence polarization 
(FP) has been widely used for the measurement of protein—protein and protein—nucleic acid 
interactions,33 as well as the screening of compound libraries for inhibitors of these 
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interactions.43-45  Although fluorescence polarization is a popular method for such experiments, 
there are some limitations to fluorescence polarization as an HTS method.  One limitation is the 
recommended >10 fold mass excess of the non-fluorescent binding partner,46 although there are 
examples showing that fluorescence polarization can be effective below this limit.47  Another 
limitation is the potential for false positives due to fluorescent compounds, which is an inherent 
limitation of any fluorescence-based HTS method.  Given the largely unexplored 
pharmacological realm that is protein—nucleic acid interactions, HTS assays independent of 
fluorescent tags would be extremely useful, especially in those cases where fluorescence 
polarization is not possible.   In this chapter, the first use of photonic crystal technology for the 
development of an assay capable of detecting protein—DNA binding, and further applications 
towards a high-throughput screening mode for discovery of inhibitors of a protein—DNA 
interaction are discussed. 
 
3.2 Photonic Crystal Biosensors for Measuring Protein—DNA Interactions 
As stated above, fluorescence polarization has been successfully utilized in multiple high-
throughput screens, including some whose goal was the identification of inhibitors of protein—
DNA interactions.18, 23  Thus, in our search for inhibitors of the Apoptosis Inducing Factor 
(AIF)—DNA interaction, we initially attempted to develop an FP-based HTS.  Unfortunately, 
DNA sequences with two different fluorescent tags did not give a noticeable change in 
fluorescence polarization upon incubation with increasing concentrations of AIF (Chapter 2, 
Figure 2.4).48  We ascribed the failure of the FP method in this case to the low affinity of AIF for 
any DNA sequence, as demonstrated by the molar ratios required in EMSA.49, 50  In addition, the 
FP assay with AIF is complicated by the fact that AIF itself is fluorescent due to the presence of 
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its flavin cofactor.  We thus sought to develop a general and high-throughput technique for the 
identification of inhibitors of protein—DNA interactions that would be able to avoid these 
complications.   
A new class of disposable microplate-based optical biosensors based on the unique 
properties of photonic crystals (PC) has been developed of the past decade by Cunningham et 
al.51  Like other optical biosensors, including those utilized in SPR, PC biosensors detect 
biomolecular interactions on the surface of a transducer through changes in dielectric 
permittivity with respect to the liquid media.  As discussed in Chapter 1, a photonic crystal is 
composed of a periodic arrangement of dielectric material that effectively prevents propagation 
of light at specific wavelengths and directions.  When illuminated with broadband light, 
appropriately configured photonic crystals are able to reflect a narrow band of light whose 
wavelength is directly dependent on the local density of adsorbed biomolecules (Figure 3.1).  
Association of macromolecules with the sensor surface modulates the peak wavelength value 
(PWV) of the reflected light, allowing for detection of binding by a shift in the PWV.  Photonic 
crystal optical biosensors incorporated onto standard format 96-, 384-, or 1536-well microplates 
have been used to detect antibody—antigen, small molecule—protein, and whole cell—protein 
interactions on the biosensor surface without the use of fluorescent labels.51  As discussed further 
in this chapter, photonic crystal technology was applied to the detection and analysis of 
protein—DNA interactions.  To demonstrate the scope of this method, two very different 
protein—DNA interactions were chosen for study: the bacterial MazEF complex, which binds to 
its promoter DNA in a sequence-specific manner,52 and human AIF, a protein that binds non-
specifically to chromosomal DNA.49   
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The PC optical biosensors used in this work have been described previously.51  Briefly, 
the sensor contains a one-dimensional surface grating structure with a period of 550 nm (Figure 
3.1A).  It is produced via a room-temperature replica molding process using a UV-curable 
polymer on a transparent polyester sheet.  The low refractive index polymer grating structure is 
subsequently coated with a film of high refractive index TiO2 to achieve the final sensor 
structure.  The completed sensor is cut from the polyester sheet and attached to the bottom of a 
Figure 3.1.  A) Schematic of the PC biosensor.  A broadband LED illuminates the biosensor from the 
bottom, and reflected light is collected and transferred to a spectrometer where the peak wavelength value 
(PWV) is measured.  B) Image of PC biosensor films adhered to the bottom of black 384-well plates.  C) 
Diagram of protein—DNA binding experiments performed with PC biosensors.  Streptavidin coated 
biosensors are used to bind biotinylated DNA oligomers, and a distinct peak wavelength of the reflected 
light is observed.  After the addition of Starting BlockTM (Pierce Biotechnologies), a DNA-binding protein is 
added, and a shift in the wavelength of reflected light is observed. 
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standard 384-well microplate (Figure 3.1B).  The readout instrument (SRU Biosystems BIND 
Reader)51, 53, 54 illuminates microplate wells from below with a broadband light source coupled to 
8 optical fibers, each illuminating a ~2 mm diameter region of the PC surface at normal 
incidence.  Reflected light is collected by a second optical fiber, bundled next to the illuminating 
fiber, and measured by a spectrometer.  An automated motion stage enables parallel collection of 
reflectance data at timed intervals to acquire kinetic information from all 384 wells.  Figure 3.1C 
illustrates the general experimental setup of DNA-binding assays performed using PC 
biosensors. 
 
3.3 Photonic Crystal Biosensors for the Detection of MazEF Binding to the 
MazEF Promoter Sequence 
MazEF is a bacterial toxin-antitoxin system thought to be responsible for the maintenance 
of resistance-encoding plasmids in certain infectious bacteria.55-57  Originally identified on the E. 
coli chromosome, MazEF is a heterohexameric, ~77 kDa complex consisting of one MazE 
(antitoxin) dimer, and two MazF (toxin) dimmers.58  MazF is an RNase that is released from 
MazE upon plasmid loss, resulting in inhibition of bacterial growth.52  In addition to its toxic 
action, the MazEF complex also regulates its expression by binding to its own promoter 
sequence.52 
 
3.3.1 MazEF Binding is Sequence-Specific and is Inhibited by Non-Biotinylated Promoter 
Sequence 
MazEF was shown previously to bind to its own promoter sequence using an 
electrophoretic mobility shift assay (EMSA).52  MazE has some intrinsic DNA binding ability,  
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while formation of the MazEF complex dramatically increases DNA binding.52  For the 
experiments described herein, the same promoter sequence used by Zhang and co-workers52 was 
purchased with the 5’ end functionalized with biotin.  The sensor surface was incubated with 1 
µM biotinylated DNA (12 hr at 4 ºC) and blocked with Starting BlockTM (Pierce Biotechnology) 
for 2 h at 4 ºC.  MazEF was expressed and purified as previously reported,59 with modifications  
described in Section 3.8.1b then added to DNA-containing wells at the specified concentration 
(Figure 3.2A) for 1 hr at 25 ºC.  Figure 3.2A shows the association of the MazEF protein 
complex with biosensors coated with promoter DNA.  This association was inhibited by 
preincubating MazEF with increasing concentrations of free promoter DNA for 15 min (Figure 
3.2B).  
The binding of MazEF to its promoter sequence was also specific; when a control 
sequence of GC-rich DNA with the 5’ end biotinylated was complexed to the PC biosensor, 
MazEF exhibited only minimal binding (Figure 3.3).  Kinetic data of MazEF binding to the 
promoter-bound biosensor were also monitored over the course of 30 minutes (Figure 3.3). 
Figure 3.2.  A) MazEF associates with its promoter sequence bound to the PC biosensor surface in a dose-
dependent fashion.  B) Preincubation of MazEF (1.8 µM) with its non-biotinylated promoter sequence reduces 
the association of MazEF with the promoter-bound biosensor surface.  All error bars represent the calculated 
standard error (n = 3). 
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Following the demonstration that PC biosensors are able to detect sequence-dependent 
protein—DNA interactions, the sequence-independent AIF—DNA interaction was targeted next. 
 
3.4 Photonic Crystal Biosensors for the Detection of AIF—DNA Binding 
As discussed in Chapter 1, AIF is a mammalian mitochondrial NADH oxidoreductase 
that also has a key role in caspase-independent cell death.60, 61  The 67 kDa form of AIF is 
produced in the cytoplasm, where it then translocates to the mitochondria and carries out its 
oxidoreductase function as well as possible upkeep of complex I.62  Upon cellular insults (such 
as DNA damage), AIF is cleaved off the inner mitochondrial membrane and released into the 
cytoplasm as a 57 kDa protein.  Once in the cytoplasm, AIF translocates to the nucleus and binds 
Figure 3.3.  Kinetics of MazEF (6.6 µM) binding to its own promoter sequence.  A rapid increase in PWV 
shift is observed upon MazEF addition to the promoter-bound biosensor surface.  In contrast, MazEF 
showed little affinity for a biotinylated alternating GC control DNA of the same length as its promoter 
sequence, similar to its association blocked sensor surface (no DNA).  All error bars represent the calculated 
standard error (n = 3). 
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to DNA in a sequence-independent fashion, causing stage I chromatin condensation, eventually 
leading to cell death.  AIF is thought to contact DNA through electrostatic interactions, as 
mutations of surface lysine and arginine residues abrogates DNA binding in vitro and in cell 
culture.50  These surface residues are contained within the FAD-binding domain and the C-
terminal domain of AIF, and it is proposed that 12 base pairs of dsDNA can be bound in this 
stretch of AIF.50  Although the crystal structure of AIF has been solved,50, 63 no co-crystal 
structure has been obtained for AIF and DNA.  Small molecule inhibitors of the AIF—DNA 
interaction are of great interest due to the involvement of AIF in multiple disease state models 
including Parkinson’s Disease,64 ischemia/reperfusion injury,65 amyotrophic lateral sclerosis 
(ALS),66 and Huntington’s Disease;67 however, no small molecule inhibitors of the AIF—DNA 
interaction have been reported. 
 
3.4.1 AIF—DNA Binding is pH-Dependent and is Inhibited by Non-Biotinylated DNA 
Oligomers 
Analyses of the DNA-binding properties of the 57 kDa form of AIF (AIF∆1-121) have 
been performed previously using EMSA.49  AIF binds DNA in a sequence-independent fashion, 
as different sequences of DNA oligomers are able to prevent AIF binding to a DNA ladder.49  
Therefore, a biotinylated, randomized 30 bp sequence of dsDNA was chosen as the DNA target 
of AIF; it has been shown that AIF is capable of binding DNA of this length.49  Preparation of 
the biosensor surface was analogous to the MazEF experiments described above, except the 
specified concentrations of AIF were incubated with biotinylated DNA for 30 min at 25 ºC.  As  
monitored by the shift in PWV, the association of AIF with biotinylated DNA was found to be 
pH dependent (Figure 3.4), and a pH of 6.3 was found to give modest PWV shifts while  
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permitting protein stability.  This pH dependence is not surprising due to the fact that the pI of 
AIF∆1-121 is 7.8, and a pH lower than the pI would favor binding to a DNA substrate given the 
electrostatic nature of the AIF—DNA interaction.  Figure 3.5A shows the association of AIF 
with biotinylated DNA; this interaction is also inhibited by a 15 min preincubation with free 
DNA (Figure 3.5B).  AIF is thought to bind DNA in a cooperative fashion, due to the fact that a 
large molar excess of AIF is required to detect binding.49  Because MazEF binds to its promoter 
in a sequence-dependent fashion, and no known cooperative interaction has been postulated, we 
propose the difference in PWV shift values between MazEF and AIF arise from the difference in 
the relative affinities of these proteins for their DNA targets. 
 
Figure 3.4.   AIF (2 µM) associates with a randomized DNA sequence bound to the biosensor surface in a pH-
dependent fashion.  The pH chosen for further assays was 6.3, the pH at which AIF exhibits moderate PWV 
shifts and is stable over the course of the assay.  All error bars represent the calculated standard error (n = 3). 
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3.4.2 High-Throughput Screening Viability of AIF—DNA Binding Assay 
The data in Figures 3.2 and 3.5 demonstrate that the PC biosensor can be successfully 
used to detect protein—DNA interactions.  With these experiments in place, a high-throughput 
screen to identify compounds that prevent the AIF—DNA interaction was developed. 
As with previous experiments, a 1 µM solution of biotinylated DNA was immobilized on 
streptavidin coated PC biosensors, and Starting Block was then added to reduce non-specific 
interactions between AIF and the biosensor surface.  AIF (3.51 µM) and a small collection 
(~1000) of small molecules (each at 25 µM) were incubated together for 15 min at 25 ºC in a 
clear 384-well plate (Falcon); reference wells for each compound were also prepared in the same 
384-well plate.  These solutions were then transferred to the DNA-containing 384-well biosensor 
plate.  Compounds that inhibit the AIF—DNA interaction would prevent the PWV shift observed 
in the AIF—DNA binding event.  In this fashion, approximately 1000 compounds (obtained 
from an in-house compound collection)68 were screened in duplicate at a concentration of 25 
µM.  Contained within this collection of ~1000 was the previously identified inhibitor (Chapter 
Figure 3.5.  A) Increasing AIF concentration (0-51.7 µM) causes a dose-dependent increase in the PWV shift.  
B) Preincubation of AIF (7.02 µM) with a non-biotinylated randomized DNA sequence inhibits the interaction of 
AIF with the DNA-bound sensor surface.  All error bars represent the calculated standard error (n = 3). 
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2) of the AIF—DNA interaction, aurin tricarboxylic acid (ATA), also at a concentration of 25 
µM.  All experimental wells were normalized against the following two reference wells: AIF 
with no biotinylated DNA (to account for the nonspecific interactions of AIF with the 
streptavidin coated biosensor), and biotinylated DNA with compounds (to account for 
nonspecific interactions with the DNA or biosensor surface).  The quality of the screen was 
assessed via the Z’-factor (Eq. 2, Section 3.8.1g), a unitless coefficient reflective of the assay’s 
signal dynamic range and data variability.  This particular assay attained a median score of 0.65, 
regarding this as an “excellent” assay.69  Most wells showed very little variation in the PWV 
shift, implying no prevention of the AIF—DNA interaction (Figure 3.6).   
In the screen ATA displayed ~80% inhibition of AIF-DNA binding, and was the only 
compound to exhibit significant inhibition out of the ~1000 compounds screened.  
Representative PWV values are shown for a group of compounds not containing ATA (Figure 
3.6A), and the group of compounds that contains ATA (Figure 3.6B).  The PWV shifts were then 
converted to a percent inhibition of AIF, and this data is graphed for all ~1000 compounds 
(Figure 3.6C).  The PC biosensor was then used to assess the effect of a range of concentrations 
of ATA; this analysis revealed that ATA inhibits AIF—DNA binding with an IC50 of 23 µM 
(Figure 3.7A). 
To confirm the result obtained from the miniature HTS assay, EMSA was again used to 
probe the ability of ATA to inhibit the AIF—DNA interaction.  The migration of linearized 
pUC19 plasmid DNA was retarded by increasing concentrations of AIF (Figure 3.7B).  Holding 
the concentration of AIF constant and increasing the amount of ATA prevented the association 
of AIF with the plasmid DNA (Figure 3.7C).  ATA inhibited AIF—DNA binding with an IC50 of  
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approximately 50 µM, as determined by densitometry (Figure 3.7D).  A structurally related 
analogue of ATA, p-rosolic acid, was unable to inhibit AIF—DNA binding (Figure 3.7C).   
Following the demonstration of PC biosensors to measure protein—DNA interaction in 
two separate cases and a miniaturized HTS with a previously identified positive control, a true  
Figure 3.6.  A) A representative group of ~1000 compounds screened for their ability to inhibit the AIF—
DNA interaction.  () represents a control in which there is no compound present; that is, only AIF (3.51 
µM) and 1% DMSO are incubated with the blocked DNA-bound biosensor.  () represents a control in 
which AIF was preincubated with 6.25 µM of the non-biotinylated DNA oligomer prior to addition to the 
DNA-bound biosensor.  () represents all other wells that contain AIF and 25 µM compounds, none of 
which show inhibition of AIF—DNA binding.  All compounds were referenced to control wells for DMSO, 
AIF, and small molecule nonspecific binding.  B) A group of compounds where ATA was present (sample 
172).  C) Inhibition data for all compounds screened, where ATA is the only compound out of the ~1000 
screened to show significantly higher inhibition (~80%).  Dotted lines above and below the x-axis represent 
three standard deviations away from the mean.  All error bars represent the calculated standard error (n = 2). 
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HTS of ~175,000 compounds was performed in a search for novel inhibitors of the AIF—DNA 
interaction. 
 
 
 
Figure 3.7.  A) Dose-response curve of the inhibition of AIF-DNA binding by ATA as measured by PC 
biosensor technology.  ATA inhibits AIF in this assay with an IC50 of ~23 µM.  B) AIF retards the migration 
of linearized pUC19 plasmid DNA (2.7 kB) through a 1% agarose gel.  The pH dependence is lessened in this 
assay due to the greater affinity of AIF for larger pieces of DNA.  C) ATA inhibits AIF in the gel assay while 
its analogue, p-rosolic acid, does not.  “P” represents pUC19 plasmid DNA without any AIF added, while “A” 
represents pUC19 plasmid DNA incubated with 15 µM AIF.  All other wells contain increasing concentrations 
of ATA or p-Rosolic acid (1-200 µM) in addition to pUC19 and AIF.  D) Analysis of the ATA-AIF gel in 
Figure 5C by densitometry reveals that ATA inhibits AIF in this assay with an IC50 of ~50 µM.  Percent 
inhibition was calculated by using densitometry software (Image J).  All error bars represent the calculated 
standard error (n = 2). 
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3.5 High-Throughput Screen for Inhibitors of the AIF—DNA Interaction 
 
3.5.1 High-Throughput Screen 
 Initial screening efforts described above were performed in a relatively simple, medium-
throughput gel assay using a 10 compound per well format.  At the time, the screening library 
available at the High-Throughput Screening Facility (University of Illinois at Urbana-Champaign, 
http://scs.illinois.edu/htsf/) had swollen to >170,000 compounds.  A library of this size required a 
degree of multiplexing in order to make the screen experimentally and financially feasible.  As 
described in the Section 3.8.2a, the HTS was performed via the PC biosensor method essentially 
as described in Section 3.4.2, except with 10 compounds per well instead of one.  The effect of 
increasing the DMSO concentration 10-fold on AIF—DNA binding was negligible (data not 
shown), and increasing the incubation time of AIF in the presence of immobilized DNA to 12 h 
allowed for consistent detection of the positive control (ATA) amongst multiplexed library plates.  
AIF (14 µM) was incubated in the presence of 10 compounds (each at 50 µM) for 30 min at 25 
ºC, then added to biotinylated DNA (1 µM) with enough buffer (PBS + 0.005% Tween 20, pH 
6.3) such that the final concentration of AIF and library compounds was 7  µM and 25 µM 
respectively.  The raw data from the HTS is displayed in Figure 3.8, with a Z’ score of 0.8 for 
this screen.  All wells that showed greater than 70% inhibition were deconvoluted using the AIF 
gel-shift assay as described in Chapter 2. 
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3.5.2 Hit Deconvolution and Validation 
All compounds were “cherry picked” from 5 mg/mL DMSO stock solutions, resulting in 
a variable concentration (150-400 µM) of compound used in deconvolution assays.  Each 
individual compound from the indicated wells in the primary screen was selected and incubated 
with AIF for 30 min at 25 ºC prior to adding the mixture to linearized pUC19 and a second 
incubation step (15 min at 25 ºC).  All reactions were subjected to agarose gel electrophoresis 
and stained with SYBR Green I overnight at 25 ºC.  A representative deconvolution gel is shown  
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Figure 3.8.  High-throughput screen for inhibitors of the AIF—DNA interaction.  Biotinylated DNA (1 µM) 
was immobilized on streptavidin-coated PC biosensors overnight.  AIF was preincubated with library 
compounds at 10 compounds per well, and the mixture was added to the plate so that the final concentration of 
AIF and compounds was 7 µM and 25 µM respectively.  % Inhibition was determined by normalizing the 
negative controls (AIF + DMSO) and the positive controls (AIF + DMSO + 25 µM non-biotinylated DNA).  
ATA (25 µM) was included in each plate as a quality control.  Any well that displayed >70% inhibition was 
taken as a “hit” for further analysis.  Each plate contained 4 positive and 4 negative controls which were 
averaged prior to normalization, all other wells were performed without replicates. 
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in Figure 3.9A, where a “hit” is classified as a well where the pUC19 is allowed to penetrate the 
agarose gel unimpeded.  20 “hit” wells (200 individual compounds) were subjected to this 
analysis, 19 of which were identified as inhibitors of the AIF—DNA interaction in the gel assay 
(Figure 3.9B).  As an additional confirmation of activity, and to guard against potential 
aggregation-based inhibition, all 19 “hits” were once more subjected to the PC biosensor assay 
conditions, which contains 0.005% Tween 20.  11 of the 19 compounds displayed inhibition of 
the AIF—DNA interaction (Figure 3.10A, B) in both the gel-shift assay and PC biosensor assay.  
Figure 3.9.  Deconvolution of primary hits.  A) A representative gel-shift assay where a single well containing 
10 compounds is separated to identify the inhibitory compound(s).  AIF (15 µg) was preincubated with 
compounds (150-400 µM) for 30 min at 25 ºC prior to the addition of linearized pUC19 (60 ng) and another 
15 min incubation 25 ºC.  Loading dye was added and the mixture was electrophoresed for 1 h and stained 
with SYBR Green I overnight.  DNA: pUC19 + DMSO; DNA + AIF: pUC19 + AIF + DMSO.  B) Structures 
of the 19 compounds out of the 200 tested that showed inhibition in the gel-shift assay. 
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Among the compounds displayed in Figure 3.10B are familiar classes of previously identified 
inhibitors of the AIF—DNA interaction, including ATA itself (3.1); compound 3.19, a 
trihydroxy-containing compound akin to 2.6 derivatives; and compound 3.3, a compound similar 
to 2.4 as described in Chapter 2.  Additionally, multiple large anionic dyes were identified (3.16, 
3.17, 3.18), including Congo Red (3.16), a known aggregator and promiscuous inhibitor,70-72 
suggesting that these compounds were not to be pursued.  While the utility of these types of dyes 
in disease treatment may vary,73 their identification in in vitro screens is a previously described 
phenomenon and is most likely due to non-specific mechanisms of action.74, 75  Dose-dependent 
analysis of the remaining compounds revealed the most potent inhibitors of the AIF—DNA 
interaction to be 3.6 and 3.11 (Figure 3.11).  Compounds 3.5 and 3.6 were taken directly from 
the thawed library plates used in the HTS, while 3.2, 3.4, and 3.11 were reordered from 
Chembridge.  Further analysis revealed that compounds 3.5 and 3.6 required overnight storage of 
the 10 mM DMSO stock at 4 ºC, and subsequent thawing the next day, in order to show 
appreciable inhibition of AIF (Figure 3.12).  At the time, the quantity of reordered material was 
not sufficient to identify the effect of freeze-thaws or time on the chemical integrity of 3.5 or 3.6, 
and the compounds themselves were never resynthesized.  In addition, structural analogous of 
compound 3.5 and 3.6 (or their breakdown products) have been previously reported as hits in 
high-throughput screens for inhibitors of tyrosine phosphatases,76 cdc25B phosphatase,77 and 
DNA adenine methyltransferases,78 and this promiscuity was not a desirable quality for a lead 
compound.  Given the relatively low potency, and validated or suspected non-specific modes of 
action of the identified compounds in Figure 3.10, compound 3.11 was selected for derivative 
synthesis and structure-activity relationship studies.  
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Figure 3.10.  PC biosensor repeat of deconvoluted hits.  A) High-throughput screen conditions were repeated 
where AIF (14 µM) was preincubated with individual compounds (25 µM) for 30 min at 25 ºC.  The mixture 
was then added to immobilized biotinylated DNA and the PWV shift was recorded after an overnight incubation.  
An asterisk represents a compound that showed repeatable AIF inhibition.  B) Compounds that are active in both 
the gel-shift assay (Figure 3.9) and the PC biosensor assay above.   
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Figure 3.11.  Dose-dependent inhibition of the AIF—DNA interaction.  AIF gel-shift assays were performed as 
in previous experiments.  AIF (15 µg) was preincubated in the presence of increasing concentrations of 
compound for 30 min at 25 ºC.  60 ng of linearized pUC19 was then added and further incubated for 15 min at 
25 ºC.  Loading dye was then added and the mixture was electrophoresed for 1 h and stained with SYBR Green I 
overnight.  Compounds 3.5 and 3.6 were taken directly from the library plates, while 3.2, 3.4, and 3.11were 
reordered from Chembridge and diluted to 10 mM in DMSO prior to testing. 
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3.6 Investigation of the Structure-Activity Relationship and Specificity of the 
Compound 3.11 Series of AIF Inhibitors 
 
3.6.1 Synthesis of Compound 3.11 Derivatives 
 The general synthetic scheme for all derivatives is shown in Scheme 1.  As mentioned 
above, the synthesis of derivatives of compound 3.11 was accomplished by a host of chemists, 
Figure 3.12.  Freeze thawing is required for the inhibitory activity of compounds 3.5 and 3.6.  AIF gel-shift 
assays were performed as in previous experiments.  AIF (15 µg) was incubated with increasing concentrations of 
compound for 30 min at 25 ºC.  60 ng linearized pUC19 was added and further incubated for 15 min at 25 ºC.  
Loading dye was added and the mixture was electrophoresed for 1 h and stained with SYBR Green I overnight.  
Compounds 3.5 and 3.6 were reordered from Chembridge, and were subjected to a single overnight freeze thaw 
and retested after initial testing showed little inhibitory activity.  D: pUC19 + DMSO, all other wells contain 
pUC19 + AIF + increasing concentrations of compound. 
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and the detailed syntheses and all relevant spectra will be reported in future theses or 
publications. 
 
3.6.2 Compound 3.11 Derivative Testing in AIF Gel Assay 
 As described above and in Chapter 2, the standard gel-shift assay was used to analyze the 
inhibitory properties of all 3.11 derivatives.  All synthesized derivatives of 3.11 and their relative 
inhibition of the AIF—DNA interaction are shown in Table 3.1.   Throughout the synthesis of 
the 3.11 series of derivatives, some general structure-activity relationship trends emerged.  
Methylation of the carboxylic acid ablated activity of any 3.11 derivative; deletion of a single 
nitro group did not affect activity; thioether linkages were preferred on the left side of the 
molecule; and hydrophobic or aromatic side chains were preferred on the right side of the 
molecule. 
 
3.6.3 Toxicity of 3.11 Derivatives 
 As the purpose of any inhibitor the AIF—DNA interaction would ultimately be to have 
cytoprotective properties, it was important to establish that derivatives of compound 3.11 were 
not toxic at relevant concentrations for cytoprotection assays.  As described Section 3.8.3b, 
Scheme 3.1.  General synthetic scheme for compound 3.11 derivatives shown in Table 3.1.  R1, R2: various 
functionalities (see Table 3.1).  X: N, S, O, SO2. 
F F
NO2O2N
F N
NO2O2N
X N
NO2O2N
N R2R1
H
DIPEA, THF
25 °C, 1 h
DIPEA, THF
25 °C, 12 h
R1
R2
R1
R2
HO2C
X
HO2C
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Table 3.1.  Derivatives of compound 3.11.  IC50 enhancement: All compounds were tested alongside 
3.11 and normalized to the IC50 of 3.11 in the AIF gel-shift assay.  A IC50 enhancement > 1 indicates a 
more potent compound.  NA: not active.  Error values for IC50 enhancement indicate the range (n = 2) 
or standard deviation (n = 3-6).  Table 3.1 was adapted from primary data acquired by Aaron Knowlton. 
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Table 3.1. (continued) 
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Table 3.1. (continued) 
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Table 3.1. (continued) 
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Table 3.1. (continued) 
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mouse embryonic fibroblasts (MEFs) were chosen for general toxicity studies.  MEFs were 
seeded in 96-well plates and incubated for 24 hr in the presence of DMSO or compound (100 
µM).  Following compound treatment, cells were fixed with trichloroacetic acid (TCA), and the 
sulforhodamine B cytotoxicity assay was carried out as previously described.79  As shown in 
Figure 3.13, the compounds containing more hydrophobic side chains are more toxic to MEFs, 
with compound 3.74 (the methylated version of 3.11) being the only exception.  For these 
toxicity studies, 100 µM of compound 4150 was used as the “100% death” control, and all data 
was normalized to this control and the cells treated with DMSO only.  Compound 4150 is a 
novel compound discovered in the Hergenrother lab that elicits complete cell death in a more 
reliable manner than standard cytotoxins such as etoposide. 
 
3.6.4 Activity of 3.11 Derivatives in HUβ Gel Assay 
 AIF contacts DNA in a sequence-independent fashion through electrostatic interactions 
of its surface lysine residues with the phosphate backbone of DNA, as discussed above and in 
Chapter 1.  To address the possibility of promiscuous inhibition of AIF—DNA binding by 3.11 
derivatives, a DNA-binding assay involving the bacterial histone-like protein HUβ was designed 
by Aaron Knowlton in the Hergenrother lab.  HUβ is a heat-stable sequence-independent DNA-
binding protein that has functions in DNA compaction, much like histones in eukaryotic systems, 
and as a scaffolding protein for DNA replication in bacteria.80-82  Recombinantly expressed and 
purified His6-tagged HUβ displayed dose-dependent binding to the linearized pUC19 plasmid as 
used in the AIF gel-shift assay.  As shown in Table 3.2, 3.11 derivatives had a near identical 
structure-activity relationship in the AIF and HUβ gel-shift assays.  This result led to the testing 
of 3.11 derivatives in a biochemical assay that was unrelated to DNA-binding. 
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Figure 3.13.  Toxicity of PJKI.13 derivatives to MEFs.  MEFs were seeded into 96-well plates and treated with 
100 µM compound for 24 hr prior to fixation and growth inhibition quantification by SRB assay.  All compound 
structures can be found in Table 3.1.  With the exception of compound 3.69, the most toxic compounds were 
active against AIF (see Table 3.1).  All error bars represent the range (n = 2). 
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3.6.5 Activity of 3.11 Derivatives in Chymotrypsin Assay 
 Chymotrypsin, cruzain, and β-lactamase have been used recently in high-throughput 
screening efforts for aggregation-based mechanisms of inhibition, in an attempt to classify and  
eliminate structural motifs responsible for non-specific inhibition of enzymes.83  Unfortunately, 
the conclusion of those efforts was that there is no common structural motif which can be labeled  
Table 3.2.  Comparison of AIF gel-shift assay IC50 enhancement and HUβ gel-shift assay IC50.  HUβ IC50s were 
approximated by preincubating HUβ with 0, 25, 50, or 100 µM compound and testing the ability of the mixture 
to retard the migration of linearized pUC19, as in previous AIF gel-shift assays.  NT: not tested; NA: not active.  
The more active compounds against HUβ are highlighted in green and red.  Table 3.2 was adapted from primary 
data acquired by Aaron Knowlton. 
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Figure 3.14.  Derivatives of compound 3.11 inhibit chymotryspin.  Chymotrypsin (2 µg/mL) was incubated with 
100 or 200 µM compound for 30 min prior to addition to a 384-well plate containing 400 µM substrate so that 
the final concentrations of chymotrypsin, compound, and substrate were 1 µg/mL, 50 or 100 µM, and 200 µM 
respectively.  The absorbance at 405 nm was acquired over 30 min, the first 5 min were used to calculate the 
slope, and then each slope was normalized against the DMSO (substrate only) control and chymotrypsin (DMSO 
+ chymotrypsin + substrate) control to yield the % Inhibition.  The first gray bar for each compound represents 
50 µM compound, the second bar represents 100 µM.  Error bars represent the range (n = 2). 
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as an “aggregator” and while simple inclusion of detergent or bovine serum albumin to the 
screening assay buffer solves many problems, the existence of detergent-resistant “super 
aggregators” serves to cloud the situation further.  To address the possibility of an aggregation-
based mechanism of inhibition of AIF by derivatives of 3.11, a chymotrypsin assay was  
performed.  As described in previously published protocols84 and Section 3.8.3c, chymotrypsin 
was preincubated with 0, 50, or 100 µM of many different 
3.11 derivatives, and a colorimetric substrate was added to the mixture and the absorbance over 
30 min was measured at 405 nm (Figure 3.14).  Comparing the results of the chymotrypsin assay 
with the structure-activity relationship studies of AIF and HUβ reveals a similar trend for all 
three proteins (Table 3.3).  Additionally, in the presence of increasing concentrations of the 
detergent Triton-X-100, the inhibitory properties of two of the more potent 3.11 derivatives are  
Table 3.3.  Comparison of AIF gel-shift assay IC50 enhancement values and the approximate IC50s of compound 
in the HUβ gel-shift and chymotrypsin assays. 
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completely ablated (Figure 3.15).  These results strongly suggest a detergent sensitive non-
specific mechanism of action of 3.11 derivatives.  Accordingly, this class of compounds was 
abandoned. 
 
3.7 Summary and Future Directions 
Given the difficulty in identifying inhibitors of protein—nucleic acid interactions, a 
facile, general method for identifying such compounds would be of great value to the chemical 
Figure 3.15.  Inhibition of chymotrypsin by 3.47 and 3.66 is detergent sensitive.  Chymotrypsin was 
preincubated with 100 µM compound in the presence or absence of varying concentrations of Triton-X-100.  
Because of the activating effect of detergents in enzymatic assays, chymotrypsin was preincubated with DMSO 
only in the presence of varying concentrations of Triton-X-100, and this series was subtracted from the 
compound series to generate the data above.  All error bars represent the range (n = 2). 
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biology and medicinal chemistry community.  The data presented above indicate that the 
photonic crystal biosensor assay is suitable for the rapid identification of inhibitors of protein—
nucleic acid interactions.  Photonic crystal technology is analogous to SPR-based methods of 
detecting binding events, with the key advantage of full compatibility with the standard 384-well 
format, allowing for high-throughput screening of large compound libraries.  In its current 
incarnation, the biosensor readout instrument allows for the screening of >120 plates per 8 hr, 
translating to a maximum of ~22,000 individual wells per day.  As with other optical biosensors, 
detection of binding is ultimately based on differences in molecular weight; thus a decreased 
signal will be obtained if the ligand is much smaller than its protein or nucleic acid binding 
partner.  While only demonstrated herein for protein—DNA interactions, analogous experiments 
with protein—RNA and protein—protein interactions are currently underway, some of which 
will be discussed in Chapter 4.  In addition to applications in protein—DNA disruption, screens 
for compounds that enhance protein—DNA interactions would also be feasible with this 
technology. 
 Employing PC biosensor technology in a HTS for inhibitors of the AIF—DNA 
interaction was successful in identifying such inhibitors, though most of the inhibitors seemed to 
lack potency, stability, or AIF-specific mechanisms of action.  Recent results show that the 
breakdown product or multimerization of compound 3.6 is not an inhibitor of chymotrypsin, and 
the inhibition of AIF is not detergent sensitive (data not shown, acquired by Aaron Knowlton).  
HUβ inhibition is retained, though the relevance of this inhibition in a eukaryotic cell remains to 
be seen.  Future directions include the synthesis of sufficient quantities of compound 3.6 so that 
the identity of the inhibitory moiety may be determined.  
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3.8 Materials and Methods 
 
3.8.1 Protein—DNA Interaction Studies 
3.8.1a DNA Oligomers 
 DNA sequences (IDTDNA) used in PC biosensor assays are displayed in Table 3.4. 
3.8.1b Purification of MazEF 
MazEF was expressed and purified as described previously59 with the specified 
modifications.  A pET28a plasmid (Novagen) harboring the mazEF gene was transfected into E. 
coli BL21 (Invitrogen) and expressed by 1 mM IPTG induction.  MazEF was then purified by 
Ni-NTA affinity chromatography (Qiagen).  Deviating from Wang et al,59 Ni-NTA purified 
MazEF was additionally purified by Sepharose SP (GE Biosciences) cation-exchange 
chromatography.  MazEF was then dialyzed into PBS (pH 7.8).  
3.8.1c Purification of AIF and pUC19 plasmid DNA 
AIF(∆1-128) was cloned into pET28a (Novagen) and expressed in E. coli Rosetta 2 
(Invitrogen).  AIF(∆1-128) was purified by Ni-NTA affinity chromatography (Qiagen), and 
dialyzed into PBS (7.8).  pUC19 plasmid DNA was propagated in E. coli DH5α (Invitrogen) and 
isolated using a plasmid miniprep kit (Qiagen).  pUC19 plasmid DNA was then linearized using 
Table 3.4.  Biotinylated DNA sequences and their complements used in PC biosensor assays. 
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Nde I (NEB) and purified using a plasmid miniprep kit, pUC19 was stored in 10 mM Tris (pH 
8.0).   
3.8.1d Electrophoretic Mobility Shift Assays (EMSA) 
AIF—DNA binding assays were performed in 50 mM Tris (pH 8.0) 100 mM NaCl with a 
final reaction volume of 25 µL. A 60 ng amount of linearized pUC19 was incubated with AIF for 
15 min at 25 ºC.  A 5 µL volume of loading dye was then added, and 12.8 µL of the mixture was 
then loaded onto a 1% agarose gel and electrophoresed for 1 hr.  Gels were post-stained with 
SYBR Green I (Cambrex) and visualized on a BioRad gel imager.  Densitometry was performed 
using ImageJ, and analysis by TableCurve2D v 5.01.   
3.8.1e Protein—DNA Binding Assays and Screen 
Biotinylated DNA oligomers were diluted to 1 µM in 50 mM HEPES, 150 mM NaCl, pH 
7.0.  MazEF and AIF were diluted to the appropriate concentrations in PBS, pH 7.8 and 6.3, 
respectively.  
384-well microplate streptavidin-coated sensors (SRU Biosystems) were washed with 
HEPES buffer, and stabilized at room temperature.  A 1 µM solution of biotinylated DNA 
oligomers was added, the microplate covered with a thermal seal (Fisher Scientific) and 
incubated overnight at 4 ºC.  All wells were blocked for 2 hours at 4 ºC with Starting Block 
(Pierce Biotechnology).  Protein dilutions were transferred to the PC biosensor plate utilizing a 
Biomek NxP liquid handler (Beckman Coulter).  Kinetic data was measured with the biosensor 
readout instrument (SRU Biosystems BINDTM Reader) every three minutes for one hour.  Data 
was fitted utilizing GraphPad Prism (Graphpad Software).   
For measuring the inhibitory action of free promoter DNA, MazEF and AIF were diluted 
to 1.84 µM and 7.02 µM, respectively.  Non-biotinylated DNA oligomers were diluted to the 
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appropriate concentration in PBS pH 7.8 or pH 6.3, depending on their binding partner.  Non-
biotinylated DNA oligomers were incubated with MazEF or AIF for 15 min prior to addition to 
the DNA-containing sensor plate. 
Screening conditions were similar to those described above, including buffer conditions 
(with the addition of 0.005% Tween 20) and biotinylated DNA concentrations.  The final 
concentration of AIF was 3.51 µM, and the final concentration of the non-biotinylated DNA 
used as a positive control was 6.25 µM.  All compounds were stored at 4 ºC in DMSO at 2.5 
mM.  Compounds were diluted to 50 µM in PBS (pH 6.3, 0.05% Tween) and added to AIF 
giving a final concentration of 25 µM.  After a 15 min 25 ºC incubation, AIF and compounds 
were added to the DNA-containing sensor plate read for 30 min. 
3.8.1f Data analysis 
The PWV shift (shift in peak wavelength value of reflectance) of screening compounds at 
30 min was normalized for every plate via percent inhibition, Eq. 1.:   
   
where NSBP (the nonspecific binding of the protein to a blocked surface without DNA), was 
measured on wells with a blocked surface.  P represents the protein binding signal and PI is the 
signal from wells with protein preincubated with compounds.  NSBI was the nonspecific binding 
of the test compounds to a blocked surface without DNA.  The Z’ factor, Eq. 2.: 
  
was calculated to determine quality of the screening assay, with σ, standard deviation, and µ, 
mean, of positive and negative controls.69 
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3.8.2 High-Throughput Screen for Inhibitors of the AIF—DNA Interaction 
3.8.2a Library Description and Screen Set Up 
 The library used for this screen is housed at the HTSF (UIUC), and is a combination of 
synthesized, harvested, and purchased compounds.  All compound plates were stored at -20 ºC in 
DMSO at either 5 mg/mL or 10 mM depending on the source of the compound.  The ~175,000 
compound HTS was performed exactly as in Section 3.8.1f, now with 10 compounds per well 
instead of 1.  0.5 µL of each compound was transferred to 45 µL PBS (pH 6.3) and stored at 4 ºC 
for up to 2 days.  AIF was purified as described above and stored in PBS (pH 6.3) for no longer 
than 24 h.  20 µL of AIF (7 µM) was added to a 384-well plate, and 20 µL of compounds was 
added and allowed to incubate for 30 min at 25 ºC.  20 µL of this mixture was then added to the 
washed SA1 PC biosensor plate containing stabilized biotinylated DNA (1 µM) and 20 µL of 
PBS (pH 6.3), bringing the final concentration of AIF and compounds to 3.5 µM and 25 µM 
respectively.  Plates were allowed to incubate for 12 h at 4 ºC and the PWV shift was measured.  
Data was normalized to the 0% inhibition control (DMSO, AIF + biotinylated DNA) and the 
100% inhibition control (DMSO, AIF + biotinylated DNA + 6.25 µM non-biotinylated DNA).  
25 µM ATA was included as a quality control, and ~80% inhibition was observed for this 
compound throughout the screen.  All controls were performed in duplicate and averaged prior to 
normalization. 
3.8.2b Deconvolution Gel Assays 
 AIF gel-shift assays were performed as described in Chapter 2 and Section 3.8.1d.  
Individual compounds were taken from thawed library plates and 0.5 µL was added to a 384-
well plate containing 15 µL of 50 mM Tris, 100 mM NaCl, pH 8.0.  15 µg AIF was then added, 
allowed to incubate for 30 min at 25 ºC.  60 ng of linearized pUC19 was then added, and allowed 
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to incubate for 15 min at 25 ºC.  5 µL of loading dye was added, and the mixture was loaded on 
to a 1% agarose gel and electrophoresed for 1 h.  The gel was stained with SYBR Green I 
overnight at 25 ºC and visualized using a Biorad gel imager. 
 
3.8.3 Compound 3.11 Series of AIF Inhibitors 
3.8.3a Synthesis of 3.11 Derivatives 
 As stated in Section 3.6.1, complete compound syntheses will be reported in future theses 
or publications.  All compounds were stored in DMSO at 10 mM or lower depending on the 
dilution series required. 
3.8.3b Toxicity Assays 
 Mouse embryonic fibroblasts (ATCC) were cultured in DMEM supplemented with 10% 
fetal bovine serum (Benchmark) + 100 µg/mL penicillin and streptomycin.  MEFs were seeded 
in 96-well plates at 10,000 cells/mL (200 µL total volume) and allowed to incubate for 24 h in a 
CO2 incubator (ThermoFisher).  50 µL of 500 µM compounds in media (DMEM + supplements) 
was added to cells and allowed to incubate for an additional 24 hr.  Cells were fixed with 3.3% 
TCA (final concentration), at 4 ºC for 1 h.  Plates were washed gently with tap water and dried 
prior to the addition of 50 µL 0.0057% sulforhodamine B (SRB) in 1% acetic acid and 
incubation at 25 ºC for 30 min.  Plates were washed gently with tap water, and the remaining 
SRB was solubilized with 100 µL 10 mM Tris (pH 10.5) with gentle agitation for 5 min at 25 ºC.  
Cell death was quantified by reading the absorbance of each well at 510 nm. 
3.8.3c Chymotrypsin Assays 
 Chymotrypsin and its substrate, succimidyl-Ala-Ala-Pro-PNA, were purchased from 
Sigma-Aldrich (C4129, S7388).  Chymotrypsin was diluted to 4 mg/mL in assay buffer (25 mM 
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KH2PO4, 25 mM K2HPO4, pH 7.4), and the substrate was diluted and stored in DMSO protected 
from light.  While different assays required different concentrations of chymotrypsin, the assays 
reported above keep the final concentration at 1 µg/mL.  In a standard, clear bottom 384-well 
plate, 25 µL of chymotrypsin (2 µg/mL in assay buffer) was allowed to incubate with 1 µL of 
compound for 30 min at 25 ºC.  25 µL of substrate (400 µM in assay buffer, diluted from 40 mM 
stock in DMSO) was added and immediately placed on a plate reader (SpectraMax Plus 384, 
Molecular Devices) and the absorbance at 405 nm was recorded over 30 min.  % Inhibition was 
calculated by measuring the absorbance change over the first 5-10 minutes, calculating the slope, 
and normalizing to the 0% inhibition (chymotrypsin + substrate) and the 100% inhibition 
(substrate only).  Since detergents are known to nonspecifically activate some enzymes, 
chymotrypsin assays containing detergent were performed alongside a DMSO only control series 
which was subtracted from those containing compound. 
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CHAPTER 4: ADAPTATION OF PHOTONIC CRYSTAL BIOSENSORS 
TO THE DETECTION OF MODULATORS OF PROTEIN—PROTEIN 
INTERACTIONS 
 
The information and contents for this chapter were partially taken from the following article with 
permission from the publishers: James T. Heeres, Seok-Ho Kim, Benjamin J. Leslie, Erich A. 
Lidstone, Brian T. Cunningham, and Paul J. Hergenrother “Identifying Modulators of Protein—
Protein Interactions Using Photonic Crystal Biosensors” J. Am. Chem. Soc. 2009, 131, 18202-3.  
This work could not have been accomplished without the aid of Dr. Seok-Ho Kim and Dr. 
Benjamin Leslie who together performed the chemical synthesis of D-biotin-tris-NTA (BTN). 
 
4.1 Background 
 While the value of small molecules that inhibit or enhance protein—protein interactions 
is widely recognized,1, 2 the identification of such compounds remains problematic.3, 4  This is 
partly due to the wide and shallow nature of many protein—protein interfaces, but also because 
of the inherent difficulties associated with detecting protein—protein binding en masse.  Assays 
utilized for the detection of protein—protein interactions include enzyme-linked immunosorbent 
assays (ELISAs),5 fluorescence polarization (FP),6 and surface plasmon resonance (SPR).7  As 
discussed in Chapter 1, ELISAs and FP have been applied in a high-throughput screening (HTS) 
mode for the identification of small molecule inhibitors of protein—protein interactions,2, 8, 9 
while most modes of SPR can be multiplexed for low-to-medium throughput applications.10  To 
develop an assay for the high-throughput identification of modulators of protein—protein 
interactions independent of antibodies or fluorescent measurements, a strategy was devised that 
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requires only a single affinity-tagged protein and an alternately tagged or untagged version of the 
cognate partner.  The His6 tag was chosen because of its near universal application as a 
facilitator of protein purification.11, 12  Ni2+-charged nitrilotriacetic acid (NTA) bound to a 
support resin is a standard method for purification His6-tagged proteins, sometimes followed by 
either ion-exchange or size-exclusion chromatography.   
In order to link streptavidin (SA) coated photonic crystal (PC) biosensors to NTA, a D-
biotin-tris-NTA conjugate was envisioned.  Following adsorption of such a compound to the 
sensor surface and overnight stabilization, conjugated PC biosensors could be charged with Ni2+,  
allowing recognition and binding of the His6 tag with a much higher affinity than monomeric 
Ni-NTA.13  Following washing of unbound His6-tagged protein away, alternately tagged or 
untagged proteins could be added and the binding could be quantified by a shift in the peak 
wavelength value (PWV) of the sensor (Figure 4.1).  Furthermore, simple preincubation steps 
would be necessary to demonstrate the ability of small molecules or natural products that are 
capable of inhibiting or enhancing the protein—protein interaction.   
Described below is the synthesis of D-biotin-tris-NTA (BTN) at its application to 
photonic crystal (PC) biosensors.  BTN-conjugated PC biosensors represent a merging of protein 
purification and screening techniques that takes advantage of a near universal protein tag, and a 
high-throughput platform for data acquisition to generate an assay capable of quantifying binding 
or lack thereof of any protein—protein interaction. 
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4.2 Synthesis of D-Biotin-Tris-Nitriloacetic Acid (BTN) and the Detection of 
His6-Tagged Proteins 
 
4.2.1 Synthesis of D-Biotin-tris-NTA (BTN) 
 BTN was synthesized in a manner similar to analogous compounds (Scheme 4.1).13, 14  
The synthesis of BTN was performed by Dr. Seok-Ho Kim and Benjamin J. Leslie.  Compound 
1 was stirred in the presence of t-butyl bromoacetate to form compound 2.  Deprotection of the 
benzyl protecting group with H2, Pd/C afforded compound 3.  Addition of 1,4,8,11- 
Figure 4.1.  Structure of D-Biotin-tris-NTA (BTN) and a schematic of a His6-tagged protein binding 
to the BTN-conjugated PC biosensors, followed by cognate protein binding.  Each binding event 
results in a shift of the peak wavelength value of the sensors 
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Scheme 4.1.  Synthesis of BTN.  The synthesis of BTN was performed by Dr. Seok-Ho Kim and Benjamin 
J. Leslie. 
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tetraazacyclotetradecane in the presence of HBTU (N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-
1-yl)uranium) afforded compound 4.  Carbobenzyloxy (Cbz)-protected amino caproic acid was 
added to a stirred solution of compound 4 in the presence of HBTU to afford compound 5.  The 
Cbz protecting group was removed with H2, Pd/C to afford compound 6.  Biotin linkage was 
achieved by stirring D-biotin in the presence of HATU (N,N,N′,N′-Tetramethyl-O-(7-
azabenzotriazol-1-yl)uranium) and then the addition of compound 6 to afford compound 7 which 
was globally deprotected using trifluoroacetic acid (TFA) to generate D-biotin-tris-NTA (BTN). 
 
4.2.2 BTN-Conjugated PC Biosensors for the Detection of His6-Tagged Proteins 
tris-NTA conjugates have been previously reported in the literature.  Initial studies by 
Lata and coworkers13 demonstrated the increased affinity of tris-NTA for His6-tagged protein 
compared to mono-NTA conjugates.  When incubated with His6-tagged maltose binding protein 
(MBP), mono-NTA displayed an affinity of 13 ± 5 µM for MBP, while tris-NTA displayed an 
affinity of 2.1 ± 0.8 nM.  Interestingly, subnanomolar affinity (0.14 ± 0.05 nM) was achieved 
when tris-NTA was incubated with His10-tagged MBP.  Later studies showed the utility of tris-
NTA conjugates in fluorescent labeling of His6-tagged proteins in vitro and in whole cells,14 as 
well as surface plasmon resonance (SPR) studies.15  The increase in affinity from mono- to tris-
NTA is important because the micromolar affinity of mono-NTA for His6-tagged proteins is less 
compatible with the microfluidic format of SPR or the multiple wash steps required in other 
high-throughput assays such as PC biosensors (see Chapter 1).  Towards the application of tris-
NTA conjugates to high-throughput screening and protein—protein interactions, BTN was 
incubated with streptavidin (SA)-coated PC biosensors. 
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BTN was first employed in a proof-of-concept study using SA-coated PC biosensors 
where BTN was allowed to equilibrate in a 384-well plate of SA-coated sensors overnight at 4 ºC.  
As shown in Figure 4.2, a small (0.2-0.3 nm) shift is observed after BTN incubation and washing 
with assay buffer (AB, 10 mM HEPES, 150 mM NaCl, 20 µM EDTA, 0.005% Tween 20 pH  
7.4).  After charging with 500 µM NiCl2 and washing again with AB, His6-tagged proteins were 
tested on the charged BTN-conjugated PC biosensor.  Initial studies were focused upon His6-
tagged apoptosis inducing factor (AIF) as a model protein.  His6-AIF displayed BTN-, Ni2+-, 
and dose-dependent binding to the BTN-conjugated PC biosensor (Figure 4.3).  In order to show 
the general utility of BTN-conjugated PC biosensors, four different His-tagged proteins (caspase- 
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Figure 4.2. Overnight incubation of BTN with SA-functionalized PC biosensors produces a 0.2-0.3 nm 
shift.  BTN (10 µM) in AB was added to SRU SA1 plates and allowed to incubate at 4 ºC overnight, and the 
PWV shift was recorded before and after a wash step with AB.  Time course analysis displays the PWV 
shift due to equilibration (0-26 min), overnight incubation with BTN (26-30 min), and after washing with 
AB (30-33 min).  10 replicates (in duplicate) are displayed in the inset.  All error bars represent the range (n 
= 2). 
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Figure 4.3.  His6-AIF binding to BTN coupled PC biosensors.  A)  PC biosensors were treated with 5 µM BTN 
at t =26 min.  After equilibration and washing, Charging Buffer (containing 500 µM Ni2+) was added (60 min).  
After again washing, 1 mg/mL His6-AIF was added and the PWV shift was observed (72-84 min).  The PWV 
shift observed is much higher in wells that received 5 µM BTN (black squares), then those that did not (white 
squares).  B) Increasing concentrations of His6-AIF show increasing shifts in PWV.  Experiments were 
performed as in A).  The PWV shift observed from the highest concentration of AIF (1 mg/mL) was 
dramatically reduced when Ni2+ was withheld, showing that His6-AIF binding is both BTN and Ni2+ dependent.  
Error represent the standard error from the mean (n = 2). 
 
Figure 4.4. Dose-dependent binding of His6-tagged proteins (Caspase-3, Caspase-7, Caspase-9, and 
FKBP12) to BTN-functionalized PC biosensors.  Varying concentrations of His6-tagged proteins were 
added to BTN functionalized PC biosensors, and the PWV Shift was recorded for 10 min.  All error bars 
represent the range (n = 2). 
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3,-7,-9, and FK506 binding protein (FKBP12), ranging in size from 12 to 37 kDa) were shown to 
bind the BTN-functionalized PC biosensor surface in a dose-dependent manner as indicated by 
PWV shifts; this binding was not observed in the absence of NiCl2 (Figure 4.4).   
 
4.2.3 Reusability of BTN-Conjugated PC Biosensors 
As a reusable biosensor surface would substantially reduce the cost of a PC biosensor 
screen, the possibility of regenerating and reusing the BTN-conjugated PC biosensor plates was 
explored. Charged BTN-conjugated PC biosensors were incubated with 0.1 mg/mL His6-
FKBP12 for 10 min, and then washed with AB.  Treatment of the wells with 350 mM EDTA (a 
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Figure 4.5.  BTN-conjugated PC biosensors are reusable at least 5 times.  His6-FKBP12 was bound to charged 
BTN-functionalized PC biosensors, washed with AB and then with Stripping Buffer.  For experiments 1-2, 
Stripping Buffer was repeatedly added to each well until it was determined no further decrease in PWV could be 
obtained.  In experiments 3-5, Stripping Buffer was added, and the plate was incubated overnight at 4 ºC, with 
experiment 4 and 5 performed on subsequent days after experiments 1-3.  All error bars represent the range (n 
=2). 
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Ni2+ chelating agent), followed by washing, regenerated the sensor surface with minimal loss of 
binding capacity, even when binding and stripping procedures were repeated five times (Figure 
4.5).   
4.3 BTN-Conjugated PC Biosensors for the Detection of Protein—Protein 
Interaction Enhancement: FKBP12 and FRB 
 
4.3.1 Dose-Dependence of FKBP12—FRB Interaction on Rapamycin 
The interaction between FKBP12 and the FK506-rapamycin binding (FRB) domain of 
mammalian target of rapamycin (mTOR) has been well described.16-18  Briefly, FKBP12 can be 
recruited to either calcineurin via the natural product FK506, or to the FRB binding domain of 
mTOR via rapamycin.  This recruitment results in the inhibition of these two proteins, 
subsequently causing immunosuppression and the induction of autophagy.  Both effects are 
relevant to the treatment of many diseases, including autoimmune disease,19, 20 cancer,21, 22 and 
neurodegenerative diseases.23, 24 
To demonstrate the effect of rapamycin on the FKBP12—FRB interaction using PC 
biosensors, His6-tagged FKBP12 was first immobilized onto charged BTN-conjugated PC 
biosensors.  Following a brief incubation with increasing concentrations of rapamycin, GST-
FRB was added and the PWV shift was measured (Figure 4.6).  In the absence of rapamycin, 
there is no shift in the PWV even when high concentrations of His6-FKBP12 and GST-FRB are 
used (Figure 4.6A), but in the presence of as little as 500 nM rapamycin an increase in PWV can 
be observed (Figure 4.6B).  This assay was repeated five times in triplicate over the course of ten 
days employing two different protein batches, and shows consistent results (Figure 4.7).  
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Figure 4.6.  Dose-dependent enhancement of the His6-FKBP12—GST-FRB interaction by 
rapamycin.  A) GST-FRB (100 µg/mL) does not induce a shift in PWV when added to immobilized 
His6-FKBP12 (100 µg/mL). B)  In the presence of increasing concentrations of rapamycin, the 
PWV shift observed upon GST-FRB increases in a dose-dependent manner.  All error bars represent 
the range (n =2). 
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4.3.2 Demonstration of HTS Capability of the FKBP12—FRB Assay 
To demonstrate the HTS capability of the PC biosensor assay, we performed a “needle-
in-a-haystack” experiment with His6-FKBP12 and GST-FRB (Figure 4.8).  320 compounds from 
an in-house screening library were added to different wells of a 384-well SA-coated PC  
biosensor plate that had been charged with BTN, NiCl2, and His6-FKBP12.  Rapamycin was 
then spiked into a well; the final concentration of screening compounds was 50 µM, whereas 
rapamycin was at 1 µM.  As shown in Figure 4.8, after addition of GST-FRB the rapamycin-
containing well is easily identified amongst the screening compounds, demonstrating that this  
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Figure 4.7.  Repeatability of the GST-FRB-rapamycin-His6-FKBP12 interaction.  His6-FKBP12 (0.1 mg/mL) 
was added to charged BTN-conjugated PC biosensors, and allowed to incubate for 10 min at 25 ºC.  After a 
wash with AB, 1 µM rapamycin or DMSO was added, incubated for 5 min, then 0.1 mg/mL GST-FRB was 
added and allowed to incubate for 10 min at 25 ºC prior to a final was with AB.  This procedure was repeated 
5 times across 10 days in different sections of a 384-well plate (each bar represents one experiment for that 
day).  All error bars represent the standard deviation from the mean (n = 3). 
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assay is capable of being performed in an HTS mode for identifying modulators of protein—
protein interactions.   
 
4.4 BTN-Conjugated PC Biosensors for the Detection of Inhibitors of 
Protein—Protein Interactions: Caspase-9 and XIAP 
 
4.4.1 Dose-Dependence of the Caspase-9—XIAP Interaction 
X-linked inhibitor of apoptosis protein (XIAP) is a key negative regulator of classical 
apoptosis, inhibiting the enzymatic activity of initiator (caspase-9) and executioner (caspase-3, -7) 
Figure 4.8.  Enhancement of GST-FRB binding to His6-FKBP12 is detectable in an HTS.  A1 and B1 
contain no His6-FKBP12 (only DMSO and GST-FRB).  All other wells contain His6-FKBP12, GST-FRB, 
and screen compounds (50 µM) or rapamycin (1 µM in well G16). 
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caspases through two baculoviral IAP-containing repeat (BIR) domains.  The BIR2 domain is 
responsible for the inhibition of caspase-3,-7 and has a strong affinity (KD = 0.5 nM) for caspase-
7 and has a comparable inhibition constant against caspase-3.25-27  The BIR3 domain is 
responsible for the inhibition of caspase-9 and has a much weaker affinity for this protein (KD = 
0.5 µM).28, 29 
To demonstrate the detection of the interaction between XIAP and caspase family 
enzymes, His6-tagged caspase-3 was immobilized on charged BTN-conjugated PC biosensors as 
described above and in the Section 4.6.4a.  After washing with AB, GST-XIAP was added and 
the shift in PWV was observed (Figure 4.9).  This experiment was repeated with caspase-7 and -
Figure 4.9.   Dose-dependent binding of GST-XIAP to immobilized His6-caspase-3.  His6-caspase-3 (100 
µg/mL) was immobilized on charged BTN-conjugated PC biosensors, then washed with AB.  Increasing PWV 
shifts are seen when increasing concentrations of GST-XIAP are added to the His6-caspase-3 containing wells.  
All error bars represent the range (n = 2).  
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9 (Figure 4.10).  The weaker affinity of XIAP for caspase-9 is most likely the reason for the 
relatively low (0.4-0.6 nm) PWV shift observed compared to that observed for caspase-3 and -7. 
 
4.4.2 Inhibition of the Caspase-9—XIAP Interaction by SM-164 
Inhibitors of the caspase—XIAP interaction would be able to sensitize cancerous cells to 
standard chemotherapeautics, as a large percentage of cancers contain upregulated levels of 
XIAP.30-32  Multiple small molecule inhibitors of XIAP have been identified either through 
HTS33 or rational design strategies.34-36  In this study, the XIAP inhibitor SM-16435 was 
employed, as it was reported to have inhibitory activities against both the BIR2 and BIR3 
domains.   
Analogous to experiments described above, His6-caspase-7/9 was immobilized on 
charged BTN-conjugated PC biosensors.  Prior to GST-XIAP addition, SM-164 was 
preincubated with GST-XIAP for 30 min at 25 ºC, and the mixture was added to the immobilized 
caspases.  SM-164 was able to efficiently block the binding of GST-XIAP to immobilized His6-
caspase-9 (Figure 4.11), though not as efficiently against His6-caspase-7.  This discrepancy in 
inhibitory activity is most likely due to the differential affinity of XIAP for caspase-9 versus -3,-
7, that SM-164 was initially designed against the BIR3 domain of caspase-9,37 and its dual 
activity against the BIR2 and BIR3 domains arises from the dimerization of the BIR3 targeting 
module.  Furthermore, addition of SM-164 after complex formation between GST-XIAP and 
His6-caspase-9 results in complex disruption (Figure 4.12), although complete disruption is not 
achieved even in the presence of a high concentration of SM-164.  Alternative low-throughput 
methods employing a flow-cell (e.g. SPR) would be predicted to show complete disruption as 
disrupted proteins are removed from the equilibrium. 
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Figure 4.10.  Dose-dependent binding of GST-XIAP to immobilized His6-caspase-7 and -9.  A) His6-caspase-7 
(100 µg/mL) was immobilized on charged BTN-conjugated PC biosensors, then washed with AB.  Increasing 
PWV shifts are seen when increasing concentrations of GST-XIAP are added to the His6-caspase-7 containing 
wells.  B)  His6-caspase-9 experiments were performed as in A).  All error bars represent the range (n =2). 
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Figure 4.11.  Inhibition of the XIAP-caspase-7/9 interaction by SM-164.  A) His6-caspase-9 was 
immobilized on charged BTN-conjugated PC biosensors, and washed with AB prior to GST-XIAP 
addition.  GST-XIAP was incubated with 0.5 µM SM-164 or AB for 30 min at 25 ºC, then the 
mixture was added to His6-caspase-9 containing wells and the PWV shift was observed.  B)  His6-
caspase-7 experiments were performed as in A) except the SM-164 concentration was raised to 50 
µM.  All error bars represent the range (n = 2). 
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4.4.3 Demonstration of HTS Capability of the Caspase-9—XIAP Assay 
While the ability to screen for protein—protein interaction enhancers (as shown in Figure 
4.8) is desirable, screens for inhibitors of protein—protein interactions are much more common.  
Analogous to experiments described above, a “needle-in-a-haystack” experiment was devised 
using His6-caspase-9, GST-XIAP, and SM-164.  As shown in Figure 4.13, SM-164 (10 µM) is 
readily identified amongst 375 library compounds (80 µM) as the sole inhibitor of the His6-
caspase-9—GST-XIAP interaction. 
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Figure 4.12.  Dose-dependent disruption of a preformed His6-caspase-9—GST-XIAP complex by SM-164.  
GST-XIAP was allowed 10 minutes to bind to immobilized His6-caspase-9, washed with AB, and then 
incubated with increasing concentrations of SM-164.  All error bars represent the range (n = 2). 
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4.4.4 Comparison of the Inhibitory Activities of SM-164 and SM-122 
SM-164 is a relatively potent inhibitor of the caspase-9—XIAP interaction35 (Figure 
4.11), with efficacy in the sub-micromolar range.  In vitro screens for inhibitors of protein—
protein interactions typically involve the identification of compounds as “hits” in the mid- to 
high-micromolar range.  To address this, SM-122, a previously described35 analogue of SM-164, 
 
Figure 4.13.  SM-164 is detectable in a “needle-in-a-haystack” experiment.  All wells of a 384-well BTN-
conjugated PC biosensor plate were washed, charged, and washed as described above.  GST-XIAP (0.1 
mg/mL) was incubated for 30 min at 25 °C with a library plate of 375 compounds (each at 80 µM), with 
SM-164 (10 µM) added to well H11.  During this time, 0.1 mg/mL His6-caspase-9 was added to the charged 
BTN-coupled PC biosensor plate in all wells except 4 control wells, and the plate was incubated for 15 min 
at 25 °C.  After a wash step, the GST-XIAP/compound mixture was added to all wells except 4 control 
wells, and allowed to incubate for 15 min at 25 °C.  SM-164 shows robust inhibition of the GST-XIAP—
His6-caspase-9 interaction in this assay.  ∆PWV Shift (nm) represents the difference in signal observed after 
the addition of the GST-XIAP/compound mixture.  Green bars: BTN only, no protein added; blue bars: 0.1 
mg/mL GST-XIAP only, no His6-caspase-9 added; orange bars: 0.1 mg/mL His6-caspase-9 only, no GST-
XIAP added. 
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was employed.  SM-122 was reported to have a 315-fold lower potency against the caspase-9—
XIAP interaction than SM-164.38 
 GST-XIAP was preincubated with increasing concentrations of SM-164 or SM-122, and 
this mixture was then added to immobilized His6-caspase-9.  As shown in Figure 4.14, it was 
found that SM-164 inhibits the XIAP-caspase-9 interaction with an IC50 = 0.39 µM, whereas 
SM-122 has an IC50 = 2.72 µM.   
Figure 4.14.  SM-164 is a more potent inhibitor of the GST-XIAP—His6-caspase-9 interaction than SM-
122.  This assay was performed exactly the same as Figure 4.13, where GST-XIAP was preincubated with 
either SM-164 or SM-122 for 30 min at 25 °C, prior to addition to a His6-caspase-9 coated sensor.  SM-164 
inhibits the GST-XIAP interaction with an IC50 = 0.39 µM, while SM-122 has an IC50 = 2.72 µM.  IC50 
values were calculated and averaged over two separate experiments; shown here is a representative graph.  
All error bars represent the standard deviation from the mean (n = 3). 
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While these numbers do not correlate exactly with the IC50s and KDs reported in the 
literature,35 it is difficult to compare the results based upon the many experimental differences, 
most notably the use of full length GST-XIAP in the PC biosensor study, and individually 
purified BIR2 and BIR3 domains in the literature.  Nevertheless, a weaker inhibitor of the 
XIAP—caspase-9 interaction that is active in the micromolar range can be detected using BTN-
conjugated PC biosensors. 
 
4.4.5 Detection of Weaker Protein—Protein Interactions: Mutagenesis of XIAP 
Having demonstrated the detection of sub-micromolar interactions such as GST-XIAP—
His6-caspase-9 and GST-FRB—rapamycin—His6-FKBP12, the next challenge was to show that 
BTN-conjugated PC biosensors could detect weaker protein—protein interactions.  While 
upcoming screens of different protein—protein interactions will ultimately address this issue, the 
most direct route was to mutate residues implied in the inhibitory activity of XIAP.  Such 
residues have been previously reported,39 and the mutations F270K, D315A, and W310A were 
chosen, resulting in a reported increase in IC50 against caspase-9 activity of 4-, 6-, and > 180-fold 
respectively.  While no direct binding studies had been performed using these mutants (only 
enzymatic assays), the corresponding drop in inhibitory activity was assumed to be correlated 
with the affinity of WT or mutant XIAP for caspase-9, and thus these mutants would exhibit a 
lower shift in PWV in the PC biosensor assay. 
XIAP mutagenesis was performed as described in Section 4.6.3 using standard 
QuikChange™ site-directed mutagenesis techniques.  After sequence confirmation, XIAP 
mutants were expressed and purified as GST-fusions.  As shown in Figure 4.15, GST-XIAP and 
GST-XIAP-F270K express very well, while the D315A and W310A mutants express at a much  
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Figure 4.15.  Mutagenesis of XIAP.  A)  SDS-PAGE analysis of GST-XIAP purifications (S: clarified lysate 
supernatant, FT: purification flow through, W: purification wash step, 1-3: elution fractions).  B)  Increasing 
concentrations of GST-XIAP (WT and mutants) was added to immobilized His6-caspase-9 (0.1 mg/mL).  
Significant background signal was observed in the 0.1 and 0.5 mg/mL concentrations of the D315A and 
W310A mutants, so all background signal from GST-XIAP has been subtracted from those two 
concentrations.  The asterisk denotes BTN-only wells that did not receive His6-caspase-9 or GST-XIAP.  All 
error bars represent the range (n = 2). 
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lower level.  All four of these proteins were added to immobilized His6-caspase-9, and their 
shifts in PWV were recorded.  As shown in Figure 4.15, WT XIAP shows the greatest shift in 
PWV versus the different mutants.  Further studies will be needed to confirm the differential 
affinity of the XIAP mutants for caspase-9, though this initial study hints at the possibility of the 
detection of weaker affinity protein—protein interactions. 
 
4.5 Summary and Future Directions 
In this proof-of-concept study, BTN-conjugated PC biosensors were demonstrated to be 
capable of detecting protein—protein interactions, the enhancement of those interactions by a 
natural product, and the inhibition of those interactions by rationally designed small molecules.  
The primary advantage of using PC biosensors over other label-free techniques for protein—
protein interaction detection lies in the plate-based format that allows for HTS and liquid 
handling.  Prior to this study, the detection of protein—protein interactions using PC biosensors 
was limited to non-specific protein adsorption and cognate protein binding.40, 41  This strategy 
runs the risk of diminishing or ablating the immobilized proteins activity or native conformation, 
and could significantly decrease the binding of the cognate protein.  The His6 tag is one of the 
most universal tags for protein purification utilized, and thus BTN was designed for the 
adaptation of SA-coated PC biosensors to the binding of this tag.  The ability of BTN to be 
stripped of Ni2+ and reused without any significant loss in binding capacity is an important 
improvement over using biotinylated reagents, where the biosensor plate would be discarded 
after a single use, overriding a potential cost-limitation in the use of PC biosensors.  In addition 
to the cost reduction, if the BTN-conjugated biosensor plates are reused five times, then 
screening 200,000 compounds (at one compound per well in 384-well plates) would require less 
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than 20 mg of the BTN reagent.  The small concentrations of BTN required for each assay and 
the reusability of BTN-conjugated PC biosensors are key features of BTN considering the effort 
required in its synthesis.  Future directions for BTN-conjugated PC-biosensors include further 
validation with known small molecule modulators of protein—protein interactions, some of 
which have already been completed (Table 4.1), and the screening for novel inhibitors or 
enhancers of clinically relevant protein—protein interactions. 
Table 4.1.  Selected small molecule modulators of protein—protein interactions studied or to be studied using 
BTN-conjugated PC biosensors. 
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Small molecule modulators of protein—protein interactions have tremendous potential in 
biology and medicine. PC biosensors have been adapted for protein—protein interactions, in that 
their identification is general (interfacing with widely-utilized His6 fusion proteins), does not 
require antibodies or fluorescent tags, and utilizes commercially available biosensor readers and 
plates.  Applications of this technique for the high-throughput identification of novel protein—
protein modulators are on-going and will be reported in due course.  
 
4.6 Materials and Methods 
 
4.6.1 Recombinant Protein Expression 
4.6.1a His6-FKBP12   
The cDNA encoding human FKBP12 was provided in a pGEX vector by Prof. Jie Chen 
(University of Illinois at Urbana-Champaign).  pGEX-FKBP12 was digested with EcoRI and 
BamHI, and the excised  FKBP12 cDNA was cloned in to pET28a (Novagen) that had also been 
digested with EcoRI and BamHI.  Correct insertion of FKBP12 was confirmed by DNA 
sequencing.  The pET28a-FKBP12 vector was transformed into Rosetta2 E. coli (Invitrogen) and 
protein expression was induced via the addition of isopropyl β-D-thiogalactopyranoside (IPTG) 
to 1 mM at 37 ºC for 4 h.  Bacteria were harvested by centrifugation and stored at -20 ºC. 
4.6.1b GST-FRB 
The cDNA encoding the FRB domain of human mTOR was provided in a pGEX vector 
by Prof. Jie Chen.  The correct cDNA sequence was confirmed by DNA sequencing.  The 
pGEX-FRB vector was transformed into Rosetta2 E. coli and protein expression was induced via 
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the addition of IPTG to 0.3 mM at 25 ºC for 6 h.  Bacteria were harvested by centrifugation and 
stored at -20 ºC. 
4.6.1c His6-caspase-3/7   
The cDNA encoding human caspase-3 or caspase-7 was provided by Dr. Guy Salvesen 
(The Burnham Institute) in a pET23b vector.  The correct cDNA sequence was confirmed by 
DNA sequencing.  The pET23b-caspase-3/7 vector was transformed into Rosetta2 E. coli and 
protein expression was induced via the addition of IPTG to 1 mM at 37 ºC for 4 h.  Bacteria were 
harvested by centrifugation and stored at -20 ºC. 
4.6.1d His6-caspase-9   
The cDNA encoding human caspase-9 was provided by Dr. Qian Tin (Cornell University) 
in a pET28a vector.  The correct cDNA sequence was confirmed by DNA sequencing.  The 
pET28a-caspase-9 vector was transformed into Rosetta2 E. coli and protein expression was 
induced via the addition of IPTG to 1 mM at 37 ºC for 4 h.  Bacteria were harvested by 
centrifugation and stored at -20 ºC. 
4.6.1e GST-XIAP   
The cDNA encoding human XIAP was provided by Dr. Colin Duckett (University of 
Michigan) in a pGEX vector.  The correct cDNA sequence was confirmed by DNA sequencing.  
The pGEX-XIAP vector was transformed into BL21(DE3) E. coli and protein expression was 
induced via the addition of IPTG to 1 mM at 37 ºC for 4 h.  Bacteria were harvested by 
centrifugation and stored at -20 ºC. 
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4.6.2 Protein Purification   
4.6.2a His6-tagged proteins   
All pellets stored at -20 ºC were thawed at 25 ºC in 10-15 mL of modified NTA binding 
buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole pH 8.0).  Bacteria were lysed by 
continuous sonication for 60 s, centrifuged at 35,000 x g, and incubated with 1 mL Ni-NTA 
Agarose (Qiagen) slurry for 1 h at 4 ºC.  Resin was washed with an additional 30 mL of cold 
modified NTA binding buffer, then washed with 30 mL of cold modified wash buffer (50 mM 
Tris, 300 mM NaCl, 20 mM imidazole pH 8.0), followed by elution with 10 mL of elution buffer 
(50 mM Tris, 300 mM NaCl, 500 mM imidazole pH 8.0).  All proteins were dialyzed overnight 
into assay buffer (AB, 10 mM HEPES, 150 mM NaCl, 20 µM EDTA, 0.005% Tween 20 pH 7.4) 
and concentrated using a 3K MWCO spin concentrator (Amicon).  Protein concentration was 
determined by BCA assay (Pierce Biotechnologies). 
4.6.2b GST-tagged proteins   
All pellets stored at -20 ºC were thawed at 25 ºC in 10-15 mL of binding buffer (PBS + 1 
mM DTT).  Bacteria were lysed by continuous sonication for 60 s, centrifuged at 35,000 x g, and 
incubated with 1 mL glutathione sepharose 4B (GE Biosciences) slurry for 1 h at 4 ºC.  Resin 
was washed with an additional 30 mL of cold PBS + 1 mM DTT, followed by elution with 10 
mL of elution buffer (PBS + 20 mM glutathione).  All proteins were dialyzed overnight into 
assay buffer (AB, 10 mM HEPES, 150 mM NaCl, 20 µM EDTA, 0.005% Tween 20 pH 7.4) and 
concentrated using a 3K MWCO spin concentrator (Amicon).  Protein concentration was 
determined by BCA assay (Pierce). 
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4.6.3 Mutagenesis of XIAP 
The mutagenesis of pGEX-XIAP was performed using standard QuikChange™ site-
directed mutagenesis techniques with the primers shown in Table 4.2.   
All PCR reactions were performed with a 0.7/0.3 mixture of Taq DNA Polymerase (Invitrogen) 
and Pfu Turbo DNA Polymerase (Stratagene).  Parental DNA was digested using DpnI 
(Invitrogen), and portions of the reaction were transformed into electrocompetent DH5α E. coli.  
Following antibiotic selection and plasmid isolation, the correct sequence of all mutants was 
confirmed by sequencing. 
 
4.6.4 Photonic Crystal (PC) Biosensor Assays and Data Analysis 
 SRU 384-well SA1 plates were allowed to warm to 25 ºC, and were washed 5 times with 
AB to remove glycerol.  Each well was equilibrated with 40 µL of AB; this volume was kept 
consistent through subsequent steps.  Equilibration reads were performed on a Profiler BIND® 
Reader (SRU Biosystems).  After signal stabilization, the wells were aspirated of AB, and 10 µM 
of BTN in AB was added to each well and allowed to incubate at 4 ºC overnight.  Sensor plates 
were allowed to warm to 25 °C, and wells were read to confirm the PWV shift due to BTN, then 
Table 4.2.  Mutagenic primers for XIAP. 
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washed 3 times with AB, and read again; at this point there was a consistent 0.2-0.3 nm of shift 
due to BTN remaining bound to the surface.  BTN-functionalized PC biosensors were charged 
with Charging Buffer (10 mM HEPES, 150 mM NaCl, 500 µM NiCl2, 20 µM EDTA, 0.005% 
Tween 20 pH 7.4) read, washed 3 times with AB, and then read again prior to His6-tagged 
protein addition.  After the final wash of each experiment, Stripping Buffer (10 mM HEPES, 150 
mM NaCl, 350 mM EDTA, 0.005% Tween 20 pH 7.4) was added and the plate was incubated 
overnight at 4 ºC.  After the overnight incubation, wells were washed 5 times with AB, and could 
be recharged for reuse. 
4.6.4a His6-caspase-3/7/9—GST-XIAP:   
His6-caspase-9 or His6-caspase-7 (100 µg/mL) was incubated with charged BTN-
functionalized PC biosensors for 10 min, washed 3 times with AB, and then incubated with 0, 50, 
or 100 µg/mL GST-XIAP for 10 min and finally washed 3 times with AB.  GST-XIAP was also 
shown to bind His6-caspase-3 in analogous experiments.  GST-XIAP binding to His6-caspase-9 
or His6-caspase-7 was inhibited by a 30 min preincubation with SM-164.  SM-164 was also able 
to disrupt preformed GST-XIAP—His6-caspase-9 complexes. 
4.6.4b His6-FKBP12—GST-FRB:   
His6-FKBP12 (100 µg/mL) was incubated with charged BTN-functionalized PC 
biosensors for 15 min, washed 3 times with AB, and then incubated with 100 µg/mL GST-FRB 
for 15 min and finally washed 3 times with AB.  No increase in PWV was observed in the 
absence of rapamycin.  Rapamycin was added to wells containing His6-FKBP12 at 
concentrations of 0, 0.1, 0.5, and 1 µM 5 min prior to GST-FRB addition, which greatly 
enhanced the PWV shift observed due to GST-FRB binding. 
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4.6.4c HTS Assays 
To demonstrate the HTS capability of the PC biosensor assay, a whole 384-well plate 
was coated with 10 µM BTN, charged, and bound with 100 µg/mL His6-FKBP12 except for 
wells A1 and B1.  A library plate from an in-house library containing 10 mM small molecules in 
DMSO was diluted to 200 µM in AB, and rapamycin was added to well G16 at a concentration 
of 4 µM.  GST-FRB was incubated with the diluted library plate for 30 min so that the final 
concentration of GST-FRB was 200 µg/mL, library compounds were 100 µM, and rapamycin 
was 2 µM.  Finally, GST-FRB + compounds was added to the His6-FKBP12 bound plate so that 
the final concentration of GST-FRB was 100 µg/mL, library compounds were 50 µM, and 
rapamycin was 1 µM.  This “needle-in-a-haystack” assay was repeated in an analogous fashion 
for SM-164 and the GST-XIAP—caspase-9 interaction.  GST-XIAP (0.1 mg/mL) was incubated 
with 375 library compounds (80 µM) or SM-164 (10 µM) for 30 min at 25 °C.  This mixture was 
applied to wells previously coated with 0.1 mg/mL His6-caspase-9, and washed after a 15 min 
incubation. 
4.6.4d Reusability Assays 
To demonstrate the reusability of the BTN-functionalized PC biosensor, His6-FKBP12 
was repeatedly bound, stripped, and rebound.  Charged BTN-functionalized PC biosensors were 
incubated with 100 µg/mL His6-FKBP12, washed, and then incubated with Stripping Buffer.  In 
experiments 1-3, Stripping Buffer was used repeatedly until no further decrease in PWV was 
observed, while experiments 4 and 5 were performed on successive days following overnight 
incubation with Stripping Buffer. 
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Interaction Using Photonic Crystal Biosensors,” UIUC Biochemistry Fall Conference 
(September 2008), oral presentation. 
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6. Heeres, J.T.; Hergenrother, P.J. “Disruption of the Apoptosis Inducing Factor—DNA 
Interaction: Potential for Therapeutics in Parkinson’s Disease,” UIUC Biochemistry Student 
Seminar (April 2007), oral presentation. 
 
7. Heeres, J.T.; Finch, K.E.; Hergenrother, P.J. “Small Molecule Disruption of the AIF—DNA 
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• isothermal titration calorimetry 
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